0001425450-22-000107.txt : 20221101 0001425450-22-000107.hdr.sgml : 20221101 20221101164810 ACCESSION NUMBER: 0001425450-22-000107 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221101 DATE AS OF CHANGE: 20221101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORTHOPEDIATRICS CORP CENTRAL INDEX KEY: 0001425450 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261761833 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38242 FILM NUMBER: 221351127 BUSINESS ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 BUSINESS PHONE: 574-268-6379 MAIL ADDRESS: STREET 1: 2850 FRONTIER DRIVE CITY: WARSAW STATE: IN ZIP: 46582 10-Q 1 kids-20220930.htm 10-Q kids-20220930
2022Q3FALSE0001425450--12-31P18Mhttp://www.orthopediatrics.com/20220930#AssetsNoncurrentExcludingPropertyPlantAndEquipmenthttp://www.orthopediatrics.com/20220930#AssetsNoncurrentExcludingPropertyPlantAndEquipmenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent00014254502022-01-012022-09-3000014254502022-10-28xbrli:shares00014254502022-09-30iso4217:USD00014254502021-12-31iso4217:USDxbrli:shares00014254502022-07-012022-09-3000014254502021-07-012021-09-3000014254502021-01-012021-09-300001425450us-gaap:CommonStockMember2021-12-310001425450us-gaap:AdditionalPaidInCapitalMember2021-12-310001425450us-gaap:RetainedEarningsMember2021-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001425450us-gaap:RetainedEarningsMember2022-01-012022-03-3100014254502022-01-012022-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001425450us-gaap:CommonStockMember2022-01-012022-03-310001425450us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001425450us-gaap:CommonStockMember2022-03-310001425450us-gaap:AdditionalPaidInCapitalMember2022-03-310001425450us-gaap:RetainedEarningsMember2022-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100014254502022-03-310001425450us-gaap:RetainedEarningsMember2022-04-012022-06-3000014254502022-04-012022-06-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001425450us-gaap:CommonStockMember2022-04-012022-06-300001425450us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001425450us-gaap:CommonStockMember2022-06-300001425450us-gaap:AdditionalPaidInCapitalMember2022-06-300001425450us-gaap:RetainedEarningsMember2022-06-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000014254502022-06-300001425450us-gaap:RetainedEarningsMember2022-07-012022-09-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001425450us-gaap:CommonStockMember2022-07-012022-09-300001425450us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001425450us-gaap:CommonStockMember2022-09-300001425450us-gaap:AdditionalPaidInCapitalMember2022-09-300001425450us-gaap:RetainedEarningsMember2022-09-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001425450us-gaap:CommonStockMember2020-12-310001425450us-gaap:AdditionalPaidInCapitalMember2020-12-310001425450us-gaap:RetainedEarningsMember2020-12-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-3100014254502020-12-310001425450us-gaap:RetainedEarningsMember2021-01-012021-03-3100014254502021-01-012021-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001425450us-gaap:CommonStockMember2021-01-012021-03-310001425450us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001425450us-gaap:CommonStockMember2021-03-310001425450us-gaap:AdditionalPaidInCapitalMember2021-03-310001425450us-gaap:RetainedEarningsMember2021-03-310001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100014254502021-03-310001425450us-gaap:RetainedEarningsMember2021-04-012021-06-3000014254502021-04-012021-06-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001425450us-gaap:CommonStockMember2021-04-012021-06-300001425450us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001425450us-gaap:CommonStockMember2021-06-300001425450us-gaap:AdditionalPaidInCapitalMember2021-06-300001425450us-gaap:RetainedEarningsMember2021-06-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000014254502021-06-300001425450us-gaap:RetainedEarningsMember2021-07-012021-09-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001425450us-gaap:CommonStockMember2021-07-012021-09-300001425450us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001425450us-gaap:CommonStockMember2021-09-300001425450us-gaap:AdditionalPaidInCapitalMember2021-09-300001425450us-gaap:RetainedEarningsMember2021-09-300001425450us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-3000014254502021-09-300001425450kids:MDOrthopaedicsMember2022-01-012022-09-300001425450kids:MDOrthopaedicsMember2021-01-012021-09-300001425450kids:ApiFixLtdMember2022-01-012022-09-300001425450kids:ApiFixLtdMember2021-01-012021-09-30kids:children0001425450country:US2022-09-300001425450kids:PublicOfferingMemberus-gaap:CommonStockMember2022-08-152022-08-150001425450us-gaap:IPOMemberus-gaap:CommonStockMember2022-08-150001425450kids:PublicOfferingMemberus-gaap:CommonStockMember2022-08-150001425450kids:PublicOfferingMember2022-08-152022-08-150001425450kids:PublicOfferingMemberus-gaap:CommonStockMember2022-09-202022-09-20iso4217:EUR0001425450us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2022-01-012022-09-300001425450us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2022-01-012022-09-300001425450us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2022-01-012022-09-300001425450us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-01-012022-09-300001425450us-gaap:ComputerEquipmentMembersrt:MinimumMember2022-01-012022-09-300001425450us-gaap:ComputerEquipmentMembersrt:MaximumMember2022-01-012022-09-300001425450us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-01-012022-09-300001425450srt:MinimumMemberus-gaap:OfficeEquipmentMember2022-01-012022-09-300001425450us-gaap:OfficeEquipmentMembersrt:MaximumMember2022-01-012022-09-300001425450us-gaap:TechnologyEquipmentMember2022-01-012022-09-300001425450kids:SampleInventoryMember2022-01-012022-09-300001425450srt:MinimumMember2022-01-012022-09-300001425450srt:MaximumMember2022-01-012022-09-300001425450kids:New2017EquityIncentivePlanMember2022-09-300001425450us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-09-300001425450us-gaap:RestrictedStockMember2022-01-012022-09-300001425450us-gaap:RestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-01-012022-09-300001425450us-gaap:RestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2022-01-012022-09-300001425450kids:PegaMedicalMember2022-07-012022-07-010001425450kids:PegaMedicalMember2022-07-010001425450us-gaap:CommonStockMemberkids:PegaMedicalMember2022-07-012022-07-010001425450us-gaap:CommonStockMemberkids:PegaMedicalMember2022-07-010001425450kids:PegaMedicalMemberus-gaap:RestrictedStockUnitsRSUMember2022-07-010001425450kids:PegaMedicalMemberus-gaap:RestrictedStockUnitsRSUMember2022-07-012022-07-010001425450kids:PegaMedicalMemberus-gaap:TrademarksAndTradeNamesMember2022-07-012022-07-010001425450kids:PegaMedicalMemberus-gaap:PatentsMember2022-07-012022-07-010001425450kids:PegaMedicalMemberus-gaap:CustomerRelationshipsMember2022-04-012022-04-010001425450kids:MDOrthopaedicsMember2022-04-012022-04-010001425450kids:MDOrthopaedicsMember2022-04-010001425450kids:MDOrthopaedicsMemberus-gaap:TrademarksAndTradeNamesMember2022-04-012022-04-010001425450kids:MDOrthopaedicsMemberus-gaap:PatentsMember2022-04-012022-04-010001425450kids:MDOrthopaedicsMemberus-gaap:CustomerRelationshipsMember2022-04-012022-04-0100014254502022-04-012022-09-300001425450kids:PegaMedicalMember2022-01-012022-09-300001425450us-gaap:PatentsMember2022-01-012022-09-300001425450us-gaap:PatentsMember2022-09-300001425450us-gaap:LicensingAgreementsMember2022-01-012022-09-300001425450us-gaap:LicensingAgreementsMember2022-09-300001425450us-gaap:CustomerRelationshipsMember2022-01-012022-09-300001425450us-gaap:CustomerRelationshipsMember2022-09-300001425450us-gaap:IntellectualPropertyMember2022-01-012022-09-300001425450us-gaap:IntellectualPropertyMember2022-09-300001425450us-gaap:TrademarksMember2022-09-300001425450us-gaap:TrademarksMember2022-01-012022-09-300001425450us-gaap:PatentsMember2021-01-012021-12-310001425450us-gaap:PatentsMember2021-12-310001425450us-gaap:IntellectualPropertyMember2021-01-012021-12-310001425450us-gaap:IntellectualPropertyMember2021-12-310001425450us-gaap:LicensingAgreementsMember2021-01-012021-12-310001425450us-gaap:LicensingAgreementsMember2021-12-310001425450us-gaap:TrademarksMemberus-gaap:MeasurementInputDiscountRateMember2022-09-30xbrli:pure0001425450us-gaap:TrademarksMemberkids:MeasurementInputEstimatedRoyaltyRateMember2022-09-300001425450us-gaap:TrademarksMemberkids:MeasurementInputLongTermGrowthRateMember2022-09-300001425450us-gaap:TrademarksMember2021-12-310001425450us-gaap:TrademarksMemberkids:MDOrthopaedicsMember2022-01-012022-09-300001425450us-gaap:TrademarksMemberkids:PegaMedicalMember2022-01-012022-09-300001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001425450us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-09-300001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2022-09-300001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001425450us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-09-300001425450us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450kids:ExchangeTradeMutualFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2021-12-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310001425450us-gaap:FairValueInputsLevel2Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450us-gaap:OtherDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450kids:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001425450kids:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-09-300001425450kids:ContingentConsiderationLiabilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputPriceVolatilityMember2022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputPriceVolatilityMember2021-12-310001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-01-012022-09-300001425450us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-01-012021-12-310001425450us-gaap:MortgagesMember2022-09-300001425450us-gaap:MortgagesMember2021-12-310001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-120001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-130001425450us-gaap:RevolvingCreditFacilityMember2022-08-152022-08-150001425450us-gaap:RevolvingCreditFacilityMember2022-06-012022-06-300001425450us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberkids:FourthAmendedLoanAgreementMember2022-06-132022-06-130001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-06-132022-06-130001425450us-gaap:RevolvingCreditFacilityMemberkids:FourthAmendedLoanAgreementMember2022-06-132022-06-130001425450us-gaap:MortgagesMember2022-01-012022-09-300001425450us-gaap:NotesPayableOtherPayablesMember2022-07-012022-09-300001425450us-gaap:NotesPayableOtherPayablesMember2021-07-012021-09-300001425450us-gaap:NotesPayableOtherPayablesMember2022-01-012022-09-300001425450us-gaap:NotesPayableOtherPayablesMember2021-01-012021-09-300001425450kids:SquadronMember2022-07-012022-09-300001425450kids:SquadronMember2021-07-012021-09-300001425450kids:SquadronMember2022-01-012022-09-300001425450kids:SquadronMember2021-01-012021-09-300001425450us-gaap:DomesticCountryMember2021-12-310001425450us-gaap:StateAndLocalJurisdictionMember2021-12-3100014254502014-05-3000014254502018-12-110001425450us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001425450us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001425450us-gaap:EmployeeStockOptionMember2021-12-310001425450us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001425450us-gaap:EmployeeStockOptionMember2022-09-300001425450us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001425450us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001425450us-gaap:RestrictedStockMember2021-12-310001425450us-gaap:RestrictedStockMember2021-01-012021-12-310001425450us-gaap:RestrictedStockUnitsRSUMember2021-12-310001425450us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001425450us-gaap:RestrictedStockMember2022-09-300001425450us-gaap:RestrictedStockUnitsRSUMember2022-09-300001425450kids:RestrictedStockAwardsAndRestrictedStockUnitsMember2022-09-300001425450kids:RestrictedStockAwardsAndRestrictedStockUnitsMember2022-01-012022-09-300001425450kids:RestrictedStockAwardsAndRestrictedStockUnitsMember2022-07-012022-09-300001425450kids:RestrictedStockAwardsAndRestrictedStockUnitsMember2021-07-012021-09-300001425450kids:RestrictedStockAwardsAndRestrictedStockUnitsMember2021-01-012021-09-300001425450us-gaap:CommonStockMember2022-01-012022-09-300001425450kids:SquadronMember2022-09-300001425450us-gaap:RestrictedStockMember2022-01-012022-09-300001425450us-gaap:RestrictedStockMember2021-01-012021-09-300001425450us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001425450us-gaap:EmployeeStockOptionMember2021-01-012021-09-30kids:segment0001425450country:US2022-07-012022-09-300001425450country:US2021-07-012021-09-300001425450country:US2022-01-012022-09-300001425450country:US2021-01-012021-09-300001425450us-gaap:NonUsMember2022-07-012022-09-300001425450us-gaap:NonUsMember2021-07-012021-09-300001425450us-gaap:NonUsMember2022-01-012022-09-300001425450us-gaap:NonUsMember2021-01-012021-09-300001425450kids:TraumaAndDeformityMember2022-07-012022-09-300001425450kids:TraumaAndDeformityMember2021-07-012021-09-300001425450kids:TraumaAndDeformityMember2022-01-012022-09-300001425450kids:TraumaAndDeformityMember2021-01-012021-09-300001425450kids:SpineMember2022-07-012022-09-300001425450kids:SpineMember2021-07-012021-09-300001425450kids:SpineMember2022-01-012022-09-300001425450kids:SpineMember2021-01-012021-09-300001425450kids:SportsMedicineAndOtherMember2022-07-012022-09-300001425450kids:SportsMedicineAndOtherMember2021-07-012021-09-300001425450kids:SportsMedicineAndOtherMember2022-01-012022-09-300001425450kids:SportsMedicineAndOtherMember2021-01-012021-09-300001425450srt:AffiliatedEntityMember2022-01-012022-09-30kids:supplier0001425450kids:StructureMedicalLLCMembersrt:AffiliatedEntityMember2022-07-012022-09-300001425450kids:StructureMedicalLLCMembersrt:AffiliatedEntityMember2021-07-012021-09-300001425450kids:StructureMedicalLLCMembersrt:AffiliatedEntityMember2022-01-012022-09-300001425450kids:StructureMedicalLLCMembersrt:AffiliatedEntityMember2021-01-012021-09-300001425450us-gaap:DiscontinuedOperationsDisposedOfBySaleMembersrt:AffiliatedEntityMember2019-12-310001425450kids:VilexMembersrt:AffiliatedEntityMember2022-07-012022-09-300001425450kids:VilexMembersrt:AffiliatedEntityMember2022-01-012022-09-300001425450kids:VilexMembersrt:AffiliatedEntityMember2021-07-012021-09-300001425450kids:VilexMembersrt:AffiliatedEntityMember2021-01-012021-09-300001425450kids:VilexAndOrthexMember2019-06-012019-06-300001425450kids:SquadronMembersrt:AffiliatedEntityMemberkids:TeamNoteBMember2019-12-312019-12-310001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2021-07-202021-07-200001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2022-07-012022-09-300001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2022-01-012022-09-300001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2021-07-012021-09-300001425450kids:FireflyTechnologyMemberus-gaap:LicensingAgreementsMember2021-01-012021-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

☒    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number: 001-38242
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
Delaware
26-1761833
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification Number)
2850 Frontier Drive
Warsaw, IN 46582
(574) 268-6379
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market
________________________________________________________________________________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐    No ☒

As of October 28, 2022, the registrant had 22,891,500 outstanding shares of common stock, $0.00025 par value per share.




OrthoPediatrics Corp.
Form 10-Q
For the Quarterly Period Ended September 30, 2022

TABLE OF CONTENTS
Page No.
PART I. FINANCIAL INFORMATION
Item 1
Item 2
Item 3
Item 4
PART II. OTHER INFORMATION
Item 1
Item 1A
Item 2
Item 3
Item 4
Item 5
Item 6







NOTE REGARDING FORWARD-LOOKING STATEMENTS

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. You can often identify forward-looking statements by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "target," "ongoing," "plan," "potential," "predict," "project," "should," "will" or "would," or the negative of these terms or other terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of the COVID-19 pandemic, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to:

•our ability to achieve or sustain profitability in the future;

•our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations;

•our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively;

•our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability;

•our ability to comply with extensive government regulation and oversight both in the United States and abroad;

•our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and

•our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others;

We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 3, 2022 and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.
3

PART I. FINANCIAL INFORMATION

ITEM 1.        FINANCIAL STATEMENTS
ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In Thousands, Except Share Data)
September 30, 2022December 31, 2021
ASSETS
Current assets:
Cash$35,423 $7,641 
Restricted cash1,449 1,365 
Short term investments84,710 45,902 
Accounts receivable - trade, less allowance for doubtful accounts of $608 and $347, respectively
26,184 17,942 
Inventories, net74,041 57,569 
Prepaid expenses and other current assets2,751 3,229 
Total current assets224,558 133,648 
Property and equipment, net36,313 28,515 
Other assets:
Amortizable intangible assets, net66,285 55,494 
Goodwill88,044 72,349 
Other intangible assets14,854 14,268 
Total other assets169,183 142,111 
Total assets$430,054 $304,274 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade$10,881 $9,325 
Accrued compensation and benefits6,323 5,351 
Current portion of long-term debt with affiliate143 137 
Current portion of acquisition installment payable7,630 12,862 
Other current liabilities3,769 2,040 
Total current liabilities28,746 29,715 
Long-term liabilities:
Long-term debt with affiliate, net of current portion799 907 
Acquisition installment payable, net of current portion7,822 14,309 
Contingent consideration3,460 28,910 
Deferred income taxes5,457 4,771 
Other long-term liabilities440 293 
Total long-term liabilities17,978 49,190 
Total liabilities46,724 78,905 
Stockholders' equity:
Common stock, $0.00025 par value; 50,000,000 shares authorized; 22,896,031 shares and 19,677,214 shares issued as of September 30, 2022 (unaudited) and December 31, 2021, respectively
6 5 
Additional paid-in capital559,339 394,899 
Accumulated deficit(168,920)(178,026)
Accumulated other comprehensive income (loss)(7,095)8,491 
Total stockholders' equity383,330 225,369 
Total liabilities and stockholders' equity$430,054 $304,274 

See notes to condensed consolidated financial statements.
4

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In Thousands, Except Share and Per Share Data)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net revenue$34,950 $25,079 $91,295 $73,236 
Cost of revenue9,061 6,525 21,859 17,914 
Gross profit25,889 18,554 69,436 55,322 
Operating expenses:
Sales and marketing11,919 9,862 34,108 29,687 
General and administrative15,116 11,034 42,829 34,163 
Trademark impairment3,609 — 3,609 — 
Research and development2,206 1,302 5,980 3,935 
Total operating expenses32,850 22,198 86,526 67,785 
Operating loss(6,961)(3,644)(17,090)(12,463)
Other expenses (income):
Interest expense, net708 542 2,485 1,851 
Fair value adjustment of contingent consideration(23,010)(1,430)(25,450)3,710 
Other expense (income)945 (267)1,668 (802)
Total other expenses (income)(21,357)(1,155)(21,297)4,759 
Income (loss) before income taxes$14,396 $(2,489)$4,207 $(17,222)
Provision for income taxes (benefit)(4,143)(292)(4,899)(890)
Net income (loss)$18,539 $(2,197)$9,106 $(16,332)
Weighted average shares outstanding
Basic21,150,219 19,291,374 20,703,883 19,256,128 
Diluted21,295,323 19,291,374 20,958,503 19,256,128 
Net income (loss) per share
Basic$0.88 $(0.11)$0.44 $(0.85)
Diluted$0.87 $(0.11)$0.43 $(0.85)

See notes to condensed consolidated financial statements.
5

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In Thousands)
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net income (loss)$18,539 $(2,197)$9,106 $(16,332)
Other comprehensive income (loss):
Foreign currency translation adjustment(4,164)288 (15,661)(1,343)
Unrealized loss on short-term investments(452)(88)(1,130)(282)
Adjustment for realized loss on securities1,205 — 1,205 — 
Other comprehensive income (loss), net of tax(3,411)200 (15,586)(1,625)
Comprehensive income (loss)$15,128 $(1,997)$(6,480)$(17,957)

See notes to condensed consolidated financial statements.
6

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Three and Nine Months Ended September 30, 2022
Accumulated
AdditionalOtherTotal
Common StockPaid-inAccumulatedComprehensiveStockholders'
SharesValueCapitalDeficitIncome (Loss)Equity
Balance at January 1, 202219,677,214 $5 $394,899 $(178,026)$8,491 $225,369 
Net loss— — — (9,100)— (9,100)
Other comprehensive loss— — — — (2,751)(2,751)
Restricted stock144,084 — 1,526 — — 1,526 
Balance at March 31, 202219,821,298 $5 $396,425 $(187,126)$5,740 $215,044 
Net loss— — — (333)— (333)
Other comprehensive loss— — — — (9,424)(9,424)
Stock option exercise1,340 — 42 — — 42 
Restricted stock57,180 — 1,770 — — 1,770 
Consideration for MD Ortho acquisition173,241 — 9,707 — — 9,707 
Stock portion of ApiFix anniversary installment payment185,811 — 10,410 — — 10,410 
Balance at June 30, 202220,238,870 $5 $418,354 $(187,459)$(3,684)$227,216 
Net income— — — 18,539 — 18,539 
Other comprehensive loss— — — — (3,411)(3,411)
Stock option exercise670 — 21 — — 21 
Restricted stock5,342 — 1,682 — — 1,682 
Issuance of common stock, net of issuance cost2,616,250 1 139,282 — — 139,283 
Issuance of unregistered shares34,899 — — — — — 
Balance at September 30, 202222,896,031 $6 $559,339 $(168,920)$(7,095)$383,330 

7

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In Thousands, Except Share Data)
Three and Nine Months Ended September 30, 2021
Accumulated
AdditionalOtherTotal
Common StockPaid-inAccumulatedComprehensiveStockholders'
SharesValueCapitalDeficitIncome (Loss)Equity
Balance at January 1, 202119,560,291 $5 $388,622 $(161,766)$7,907 $234,768 
Net loss— — — (10,379)— (10,379)
Other comprehensive loss— — — — (3,622)(3,622)
Stock option exercise2,010 — 62 — — 62 
Restricted stock97,111 — 1,316 — — 1,316 
Balance at March 31, 202119,659,412 $5 $390,000 $(172,145)$4,285 $222,145 
Net loss— — — (3,756)— (3,756)
Other comprehensive income— — — — 1,797 1,797 
Restricted stock10,632 — 1,415 — — 1,415 
Balance at June 30, 202119,670,044 $5 $391,415 $(175,901)$6,082 $221,601 
Net loss— — — (2,197)— (2,197)
Other comprehensive income— — — — 200 200 
Stock option exercise2,412 — 75 — — 75 
Restricted stock(294)— 1,439 — — 1,439 
Balance at September 30, 202119,672,162 $5 $392,929 $(178,098)$6,282 $221,118 

See notes to condensed consolidated financial statements.
8

ORTHOPEDIATRICS CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In Thousands)
Nine Months Ended
September 30,
20222021
OPERATING ACTIVITIES
Net income (loss)$9,106 $(16,332)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization9,579 7,870 
Stock-based compensation4,978 4,170 
Trademark impairment3,609 — 
Fair value adjustment of contingent consideration(25,450)3,710 
Acquisition installment payable1,926 1,701 
Deferred income taxes(4,804)(890)
Changes in certain current assets and liabilities:
Accounts receivable - trade(5,567)(716)
Inventories(14,812)(3,244)
Prepaid expenses and other current assets696 (138)
Accounts payable - trade(389)(956)
Accrued legal settlements— (6,342)
Accrued expenses and other liabilities1,800 (168)
Other903 (493)
Net cash used in operating activities(18,425)(11,828)
INVESTING ACTIVITIES
Acquisition of MD Ortho, net of cash acquired(8,360)— 
Acquisition of Pega, net of cash acquired(31,730)— 
Sale of short-term marketable securities45,529 4,000 
Purchases of licenses— (7,908)
Purchase of short-term marketable securities(85,029)— 
Purchases of property and equipment(10,554)(6,468)
Net cash used in investing activities(90,144)(10,376)
FINANCING ACTIVITIES
Proceeds from issuance of debt with affiliate31,000 — 
Payments on debt with affiliate(31,000)— 
Installment payment for ApiFix(3,234)— 
Proceeds from issuance of common stock, net of issuance costs139,282 — 
Proceeds from exercise of stock options63 137 
Payments on mortgage notes(102)(97)
Net cash provided by financing activities136,009 40 
Effect of exchange rate changes on cash426 (266)
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH27,866 (22,430)
Cash and restricted cash, beginning of year$9,006 $30,132 
Cash and restricted cash, end of period$36,872 $7,702 
9

SUPPLEMENTAL DISCLOSURES
Cash paid for interest$512 $43 
Transfer of instruments from property and equipment to inventory$(193)$80 
Issuance of common shares to acquire MD Ortho$9,707 $— 
Issuance of common shares for ApiFix acquisition installment$10,410 $— 
See notes to condensed consolidated financial statements.
10

ORTHOPEDIATRICS CORP.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(Dollars In Thousands, Except Share and Per Share data)
NOTE 1 – BUSINESS

OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLocTM, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, Cerament® and ApiFix® Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation.

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 613,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300,000 opportunity globally, including over $1,500,000 in the United States.

Our largest investor is Squadron Capital LLC, or Squadron, a private investment firm based in Granby, Connecticut.

A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. Since then, the pandemic has presented a significant public health and economic challenge around the world and has adversely impacted our business. Specifically, we have seen surgeons and their patients deferring elective procedures in which our products would have otherwise been used. The volatility in COVID cases and hospitalizations, including the impacts of the Delta variant in the third quarter of 2021 and the current hospital support staffing shortages in certain geographies, continue to drive volatility into our business. We continue to closely monitor developments related to the pandemic and the related staffing shortages and our decisions will continue to focus on the safety and security of our employees, distributors, surgeons and their patients while maintaining operations to support our customers. The full extent of the impact of the pandemic on our business is uncertain and cannot be accurately predicted and will depend on future developments that are also uncertain and cannot be predicted.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., Orthex, LLC, Telos Partners, LLC, ApiFix, Ltd., OrthoPediatrics Iowa Holdco, Inc., MD Orthopaedics, Inc.,
11

MD International Inc., OrthoPediatrics GMbH, OrthoPediatrics GP LLC, OrthoPediatrics US L.P. and OrthoPediatrics Canada ULC doing business as Pega Medical (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $168,920 and $178,026 as of September 30, 2022 and December 31, 2021, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short term investments, at September 30, 2022 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months.

On August 15, 2022, we completed a public offering of our common stock, in which we issued 1,091,250 shares of common stock at a public offering price of $55.00 per share and 1,525,000 pre-funded warrants to Squadron. The purchase price of each warrant was equal to the price per share at which the common shares were sold to the public, minus $0.00025, which was the exercise price of each warrant. The aggregate gross proceeds for both the warrants and common shares were $143,894. The total net proceeds from the offering were $139,282, after deducting $4,318 of underwriting discounts and commissions and paying $294 in offering costs. The Company has used $31,000 of the net proceeds to pay off the outstanding debt on the line of credit with Squadron. On September 20, 2022, the Company issued an aggregate of 1,525,000 shares of common stock to Squadron upon exercise of the pre-funded warrants.

Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an
12

inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.

Foreign Currency Transactions

We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense.

Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in July 2022, we established an operating company in Germany and in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss.

Revenue from Contracts with Customers

In accordance with ASC 606, "Revenue from Contracts with Customers," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the customer for surgeries or other treatment on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement.
Revenue Recognition – International

Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns.
13

Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when title passes upon shipment. Pricing for each customer is dictated by a unique pricing agreement.

Cash, Cash Equivalents and Short Term Investments

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value.

The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations.

Restricted Cash

In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the September 30, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 13 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 200 Euro at its Netherlands entity for potential Italian tenders.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.

The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.

Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other
14

standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.   

The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 5 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis.

Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.

In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.



15

Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years

Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses (including those acquired in the Band-Lok, MD Ortho and Pega transactions), the value of internally developed software (including by Orthex), and the value of acquired customer relationships and non-competition agreements (including in the Orthex, Telos, ApiFix, MD Ortho and Pega transactions, as applicable). Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period.

Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges were recorded in any of the periods presented.

Goodwill and Other Intangible Assets

Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such
16

a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No goodwill impairment charges were recorded in any period presented.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof.

We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022. No impairment charges were recorded in any other period presented.

Acquisition Payable and Contingent Consideration

Upon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. The amount of expense related to acquisition installment payables recorded in interest expense, net for the three and nine months ended September 30, 2022 were $381 and $1,926, respectively, and $489 and $1,701, respectively, for the same periods last year. The fair value adjustments of contingent consideration for the three and nine months ended September 30, 2022 were income adjustments of $23,010 and $25,450, respectively, and for the same periods last year, were an income adjustment of $1,430 and an expense adjustment of $3,710, respectively.

Cost of Revenue

Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.
17


Advertising Costs

Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.

Research and Development Costs

Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.

Stock-Based Compensation

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan"). The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.

Litigation and Contingencies

Accruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments.
18

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, we would make an adjustment to the valuation allowance.

We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.

“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to
19

qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company.

Recent Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08 "Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04 "Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.

In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments". The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures.
20




NOTE 3 – BUSINESS COMBINATIONS

Pega Medical

On July 1, 2022, the Company, along with its newly-formed, indirect wholly-owned subsidiary OrthoPediatrics Canada ULC, purchased all of the issued and outstanding share capital of Pega Medical Inc., a corporation incorporated under the Canada Business Corporations Act (“Pega Medical”). Pega Medical has developed and sells a portfolio of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System, a well-recognized, innovative implant designed to treat bony deformities in children with osteogenesis imperfecta without disrupting their normal growth. Pega's product portfolio increases our total systems and increases the percentage of total trauma and deformity cases we can treat.

The Company acquired Pega Medical for approximately $32,045, comprised of $32,042 in cash and $3 in stock, representing the repurchase right price to be paid by the Company in the event a selling shareholder leaves employment with Pega Medical for certain reasons during the three-year period following the closing. Approximately $1,052 of the cash consideration was deposited into escrow and will be held for a period of up to eighteen (18) months to cover certain indemnification obligations of the selling shareholders of Pega Medical. Final purchase consideration is subject to certain working capital adjustments yet to be finalized. Additionally, 34,899 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $1,497 (based on the July 1, 2022 closing share price of $42.90) were issued to the selling shareholders. The common stock issued to the selling shareholders, excluding the value attributable to the repurchase right, is not considered part of the purchase consideration and is subject to a repurchase right previously mentioned. The Company will recognize expense over the three-year service period at which point the right to repurchase will expire. In the event the repurchase right is triggered, the Company will have the right to repurchase the shares of common stock issued to such selling shareholder at a price of $0.10 per share. Pursuant to the terms of the transaction, the Company also issued $499 in restricted stock units to employees of Pega Medical, which are subject to an approximate three-year vesting schedule. The restricted stock units are not considered part of the purchase consideration.

The following table summarizes the total consideration paid for Pega Medical and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

21

Fair value of estimated total acquisition consideration$32,045 
Assets
Cash312 
Accounts receivable-trade2,100 
Inventories4,876 
Prepaid expenses and other current assets360 
Property and equipment604 
Amortizable intangible assets10,362 
Other intangible assets3,040 
Total assets21,654 
Liabilities
Accounts payable and accrued liabilities2,527 
Other current liabilities160 
Deferred tax liability3,305 
Total liabilities5,992 
Less: total net assets15,662 
Goodwill$16,383 

The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:

AmountRemaining Economic Useful Life
Trademarks / Names$3,040 Indefinite
Patents3,141 10 years
Customer Relationships & Other 7,221 15 years
$13,402 

The fair value estimates and purchase price allocation included above are preliminary while the Company finalizes fair value estimates of the acquired intangible assets and related tax considerations.


MD Orthopaedics

On April 1, 2022, OrthoPediatrics Iowa Holdco, Inc., a newly-formed, wholly-owned subsidiary of the Company, merged with and into MD Orthopaedics, Inc., an Iowa corporation (“MD Ortho”). MD Ortho has developed and manufactures a portfolio of orthopedic clubfoot products. The acquisition expands our total addressable market, serving as a specialty bracing platform company within our Trauma and Deformity business.

Under the terms of the related merger agreement, the Company paid to the indirect, sole shareholder of MD Ortho consideration of (a) $8,781 in cash, after adjusting for closing net working capital, and (b) 173,241 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $9,707 (based on the April 1, 2022 closing share price of $56.03). The Company incurred approximately $381 of acquisition-related costs, that are included in general and administrative expenses on the consolidated statement of operations for the nine months ended September 30, 2022.
22


The following table summarizes the total consideration paid for MD Ortho and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

Fair value of estimated total acquisition consideration$18,487 
Assets
Cash420 
Accounts receivable-trade1,062 
Inventories1,126 
Prepaid expenses and other current assets100 
Property and equipment2,444 
Amortizable intangible assets9,120 
Other intangible assets2,410 
Total assets16,682 
Liabilities
Accounts payable and accrued liabilities45 
Other current liabilities586 
Deferred tax liability3,014 
Total liabilities3,645 
Less: total net assets13,037 
Goodwill$5,450 

The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:

AmountRemaining Economic Useful Life
Trademarks / Names$2,410 Indefinite
Patents2,660 10 years
Customer Relationships6,460 15 years
$11,530 

The fair value estimates and purchase price allocation included above are preliminary while the Company finalizes fair value estimates of the acquired intangible assets and related tax considerations. During the third quarter ended September 30, 2022, the Company increased the deferred tax liability recorded as a result of the acquisition of MD Ortho based on newly obtained prior year tax information. This resulted in an increase to goodwill.

The following table represents the pro forma net revenue and net loss assuming the acquisitions of MD Ortho and Pega Medical occurred on January 1, 2021.

From the date of acquisition through September 30, 2022, combined revenue for the acquisitions was approximately $7,006 and combined net income was approximately $1,145.
23

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net Revenue$34,950 $29,680 $98,779 $86,544 
Net income (loss)$18,539 $(1,859)$10,013 $(13,576)
NOTE 4 - GOODWILL AND INTANGIBLE ASSETS

Goodwill

Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows:
Total
Goodwill at January 1, 2022$72,349 
MD Ortho acquisition5,450 
Pega Medical acquisition16,383 
Foreign currency translation impact(6,138)
Goodwill at September 30, 2022
$88,044 

Intangible Assets

As of September 30, 2022, the balances of intangible assets were as follows:
Amortizable intangible assetsWeighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationImpairmentNet Intangible Assets
Patents12.2 years$45,763 $(7,334)$— $38,429 
License Agreements4.9 years10,697 (3,342)— 7,355 
Customer Relationships & Other13.6 years17,170 (1,271)— 15,899 
Intellectual Property10.0 years5,859 (1,257)— 4,602 
Total amortizable assets$79,489 $(13,204)$— $66,285 
Other intangible assets
Trademark assetsIndefinite$18,463 $— $(3,609)$14,854 

As of December 31, 2021, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.7 years$44,493 $(5,664)$38,829 
Intellectual Property10.1 years9,847 (1,408)8,439 
License Agreements5.5 years10,674 (2,448)8,226 
Total amortizable assets$65,014 $(9,520)$55,494 

Licenses are tied to product launches and do not begin amortizing until the product is launched to the market.

24

Trademarks are non-amortizing intangible assets and are recorded in Other intangible assets on the condensed consolidated balance sheets.

During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the trademark assets is less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. The primary reason for the impairment is the lower forecasted revenue of our ApiFix product than previously expected and the subsequent impact to the discounted cash flow model utilized to calculate the fair value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022 to reduce the carrying amount of the intangible asset to its estimated fair value. Following the impairment, the newly calculated fair value becomes the new accounting basis and carrying value of the trademark. No impairment charges were recorded in any other period presented. The following table represents the significant unobservable inputs utilized in the calculation of estimated fair value associated with the ApiFix trademark asset:

September 30, 2022
Discount rate28.0 %
Estimated royalty rate5.0 %
Long term growth rate3.0 %

Changes in the carrying amount of trademark assets for the nine months ended September 30, 2022 were as follows:
Total
Trademark assets at January 1, 2022$14,268 
MD Ortho Acquisition2,410 
Pega Medical Acquisition3,040 
Trademark impairment(3,609)
Foreign currency translation impact(1,255)
Trademark assets at September 30, 2022
$14,854 


NOTE 5 - FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021.
25

September 30, 2022
Level 1Level 2Level 3Total
Financial Assets
Cash Equivalents$— $— $— $— 
Short term investments
Exchange Trade Mutual Funds$42,634 $— $42,634 
Corporate Bonds$9,680 $— $— $9,680 
Treasury Bonds$32,396 $— $— $32,396 
Asset Backed Securities$— $— $— $— 
Other$— $— $— $— 
Financial Liabilities
Contingent Consideration$— $— $3,460 $3,460 
December 31, 2021
Level 1Level 2Level 3Total
Financial Assets
Cash Equivalents$— $— $— $— 
Short term investments
Exchange Trade Mutual Funds$— $— $— $— 
Corporate Bonds$22,476 $— $— $22,476 
Treasury Bonds$14,317 $— $— $14,317 
Asset Backed Securities$— $8,272 $— $8,272 
Other$837 $— $— $837 
Financial Liabilities
Contingent Consideration$— $— $28,910 $28,910 

The Company's level 1 assets consist of short term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months.

The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date using an option pricing model and a Monte Carlo simulation based on forecasted annual revenue, expected volatility and discount rates. The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The adjustments in the fair value of the contingent consideration payments included an income adjustment of $23,010 and $1,430 for the three month periods ended September 30, 2022 and September 30, 2021, respectively, and an income adjustment of $25,450 and an expense adjustment of $3,710 for the nine month periods ended September 30, 2022 and September 30, 2021, respectively, in other expenses on the condensed consolidated statements of operations. For both the three and nine months ended September 30, 2022, the significant factor driving the reported fair value adjustment is the reduction in forecasted revenue which subsequently reduces the final expected payment.

26

The following table summarizes the change in fair value of Level 3 instruments in 2022:
Total
Balance at January 1, 2022
$28,910 
Change in fair value of contingent consideration(25,450)
Balance at September 30, 2022
$3,460 

The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of September 30, 2022 and December 31, 2021:
September 30, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
16.2 %18.4 %
Volatility factor46.5 %50.3 %
Expected years1.6 years2.4 years

(1) The present value discount rate includes estimated risk premium.

The estimated fair value reflects assumptions made by management as of September 30, 2022; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration.


NOTE 6 - DEBT AND CREDIT ARRANGEMENTS

Long-term debt consisted of the following:
September 30, 2022December 31, 2021
Mortgage payable to affiliate$942 $1,044 
Less: current maturities143 137 
Long-term debt with affiliate, net of current maturities$799 $907 

On June 13, 2022, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Fourth Amendment increased the amount available under the revolving credit facility from $25,000 to $50,000 in anticipation of using the facility to fund the cash portion of the Company’s July 1, 2022 acquisition of Pega Medical Inc. After borrowing $31,000 under the Loan Agreement in June 2022 to fund such acquisition, the Company repaid the entire amount on August 15, 2022 with proceeds from a public offering of securities. See Note 3 – Business Combinations for information relating to the acquisition and Note 8 – Stockholders’ Equity for information relating to the public offering.

The Loan Agreement provides a revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears.

Borrowings under the revolving credit facility are made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the
27

earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions.

In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At September 30, 2022 the mortgage balance was $942 of which current principal of $143 was included in the current portion of long-term debt. As of December 31, 2021, the mortgage balance was $1,044 of which current principal due of $137 was included in the current portion of long-term debt.

The aggregate interest expense relating to the notes payable to Squadron and the mortgage note payable to Tawani was $12 and $14 for the three months ended September 30, 2022 and 2021, respectively, and $512 and $42 for the nine months ended September 30, 2022 and 2021, respectively. The unused commitment fee paid to Squadron was $44 and $32 for the three months ended September 30, 2022 and 2021, respectively, and $111 and $95 for the nine months ended September 30, 2022 and 2021, respectively.

NOTE 7 - INCOME TAXES

The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss).

For the nine months ended September 30, 2022, the income tax benefit was $4,899 compared to $890 for the nine months ended September 30, 2021. Our effective income tax (benefit) rate was (116.5)% and 5.2% for the nine months ended September 30, 2022 and 2021, respectively.

The deferred tax assets were fully offset by a valuation allowance at September 30, 2022 and December 31, 2021, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix and Pega Medical. The company has recorded a tax benefit during the period ended September 30, 2022 for losses generated in the foreign jurisdiction. As of December 31, 2021, we had available federal, state and foreign tax loss carryforwards of $114,008, $73,997 and $22,671, respectively. We had available federal tax credits of $176. Net operating losses generated prior to December 31, 2017 will begin to expire in 2028. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $23,920 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062. A second ownership change under Section 382 was deemed to occur on December 11, 2018. The estimated annual limitation is $9,736, which is increased by $22,430 annually over the first five years as a result of an unrealized built in gain. NOLs sustained prior to May 30, 2014 will still be constrained by the lower limitation.
28


Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September 30, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth.

Management has reviewed the tax implications of the MD Ortho purchase accounting and recorded approximately $3,010 of deferred tax liabilities. This resulted in a decrease to the overall net US deferred tax assets, thereby causing a remeasurement of the valuation allowance during the quarter ended September 30, 2022, such that an approximately $3,010 of tax benefit was recorded for the reversal of the valuation allowance.

NOTE 8 - STOCKHOLDERS’ EQUITY

Stock Options

The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.

Our stock option activity and related information are summarized as follows:
Weighted-AverageContractual Terms
OptionsExercise Pricein Years
Outstanding at January 1, 20226,638 $30.97 1.3
Exercised(2,010)30.97 
Forfeited or expired(1,072)— 
Outstanding at September 30, 2022
3,556 $30.97 0.9

Options generally include a time-based vesting schedule permitting the options to vest ratably over three years. At September 30, 2022 and December 31, 2021, all options were fully vested.

There was no stock-based compensation expense on stock options for the three and nine months ended September 30, 2022 and 2021, respectively.

Restricted Stock Awards & Restricted Stock Units

Our restricted stock activity and related information are summarized as follows:
Weighted-AverageWeighted-Average
RemainingRemaining
RestrictedContractual TermsRestrictedContractual Terms
Stock Awardsin YearsStock Unitsin Years
Outstanding at January 1, 2022368,446 1.1— —
Granted216,631 11,634 
Forfeited(10,025)— 
Vested(150,067)— 
Outstanding at September 30, 2022
424,985 1.711,634 2.8
Restricted stock exercisable at September 30, 2022
— — 

29

At September 30, 2022, there was $12,374 of unrecognized compensation expense remaining related to our service-based restricted stock awards and stock units. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 1.7 years or earlier upon an elimination of the restriction period as a result of a change in control event.

Stock-based compensation expense on restricted stock amounted to $1,682 and $1,440 for the three months ended September 30, 2022 and 2021, respectively, and $4,978 and $4,170 for the nine months ended September 30, 2022 and 2021, respectively. The increase in the stock compensation for the three and nine months ended September 30, 2022 is primarily due to increase in plan participants from acquired businesses and newly hired employees to support the continued expansion of our business.

During the three months ended September 30, 2022 the Company purchased all of the issued and outstanding share capital of Pega Medical Inc. See Note 3 - Business Combinations for additional detail. As a component of that acquisition, the Company issued 34,899 shares of unregistered common stock. The Company determined that these shares were not part of the purchase consideration and would recognize expense over three years. During the three months ended September 30, 2022 the Company recognized expense of $133 associated with these shares.

During the three months ended September 30, 2022 the Company completed a following-on offering in which we issued 1,525,000 of pre-funded warrants to Squadron. The warrants had an exercise price of $0.00025. All warrants issued in the quarter were exercised and included in our outstanding common stock as of and during the three months ended September 30, 2022. As of September 30, 2022 and 2021 the Company had no warrants outstanding.

NOTE 9 – NET LOSS PER SHARE

The following is a reconciliation of basic and diluted net loss per share:
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Net income (loss)$18,539 $(2,197)$9,106 $(16,332)
Less: Earnings allocated to participating securities353 — 174 — 
Net income available to common shareholders18,186 (2,197)8,932 (16,332)
Denominator for basic and diluted net income (loss) per share:
Weighted average shares outstanding for basic21,150,219 19,291,374 20,703,883 19,256,128 
Weighted average shares outstanding for diluted21,295,323 19,291,374 20,958,503 19,256,128 
Earnings (loss) per share:
Basic $0.88 $(0.11)$0.44 $(0.85)
Diluted$0.87 $(0.11)$0.43 $(0.85)

Our basic and diluted net loss per share is computed using the two-class method.  For purposes of our equity disclosures and calculation of weighted average shares for basic earnings per share calculations, the two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. For the periods presented with a net loss the weighted average shares outstanding remains consistent between basic and diluted as the effect would have been anti-dilutive.

30

The following table shows the contingently issuable and convertible equity shares that were excluded from the calculation of diluted net earnings (loss) per share because their effect would have been anti-dilutive:
Nine Months Ended September 30,
20222021
Restricted stock— 375,915 
Stock options— 6,638 
Total shares— 382,553 

NOTE 10 – BUSINESS SEGMENT

Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No customers accounted for more than 10% of total product sales for the three and nine months ended September 30, 2022 or 2021. No customer accounted for more than 10% of consolidated accounts receivable as of September 30, 2022 and December 31, 2021.

Product sales by source were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by geographic location:2022202120222021
U.S.$26,539 $19,354 $69,687 $57,930 
International8,411 5,725 21,608 15,306 
Total$34,950 $25,079 $91,295 $73,236 
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by category:2022202120222021
Trauma and deformity$23,892 $16,817 $62,976 $49,302 
Scoliosis9,979 7,266 25,383 20,874 
Sports medicine/other1,079 996 2,936 3,060 
Total$34,950 $25,079 $91,295 $73,236 

No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three and nine months ended September 30, 2022 and 2021.


31



NOTE 11 - RELATED PARTY TRANSACTIONS
In addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $218 and $173 for the three months ended September 30, 2022 and 2021, respectively, and $768 and $441 for the nine months ended September 30, 2022 and 2021, respectively.
On December 31, 2019, the Company divested Vilex for $25,000 to an affiliate of Squadron. In conjunction with the divestiture, the Company also entered into an exclusive perpetual license agreement to permit the purchasers of Vilex the ability to access intellectual property and sell products using the external fixation technology of Orthex, LLC to non-pediatric accounts. We had sales and payments related to inventory purchases to Squadron's affiliate, now known as Vilex, LLC, of $51 and $7, respectively, for the three months ended September 30, 2022, and sales and payments of $111 and $39, respectively, for the nine months ended September 30, 2022. We had sales and payments related to inventory purchases to Vilex, LLC of $45 and $150, respectively, for the three months ended September 30, 2021, and sales and payments of $200 and $675, respectively, for the nine months ended September 30, 2021.

NOTE 12 - EMPLOYEE BENEFIT PLAN

We have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. Additionally, employees of MD Ortho receive contribution matches up to 3% of their salary.

NOTE 13 – COMMITMENTS AND CONTINGENCIES

Leases

As of September 30, 2022, the Company has recorded a lease liability of $303 and corresponding right-of-use-asset of $304 on its condensed consolidated balance sheet.

Legal Proceedings

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

IMED Surgical - Software Ownership Dispute

On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron Capital, LLC (“Squadron”), and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company (the “Plaintiff”), in Broward County, Florida Circuit Court. In the lawsuit, the Plaintiff claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic
32

surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).

In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point & Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent. According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with the Plaintiff.

The Plaintiff, among other things, requests that the defendants be ordered to convey and assign to Plaintiff all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants.

On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent the Plaintiff desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, the Plaintiff initiated an arbitration proceeding; however, the Plaintiff failed to pay the fees it was required to pay for the arbitration to continue, resulting in the arbitration panel terminating the arbitration proceedings in mid-October 2022. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to the Plaintiff before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order.

Although we believe the IMED lawsuit is without merit and will vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.


Wishbone Medical, Inc. – Patent Infringement Litigation

On October 30, 2020, OrthoPediatrics, along with its wholly-owned subsidiary, Orthex, LLC, filed a lawsuit in federal district court (N.D. Indiana, South Bend Division, Case No. 3:20-cv-00929) against Wishbone Medical, Inc. and Nick A. Deeter (collectively “Wishbone”), claiming infringement of ’377 Patent, unfair competition, false advertising, breach of contract, defamation per se, tortious interference with contractual relationships, and tortious interference with prospective contractual relationships. In early January 2021, OrthoPediatrics amended its lawsuit by adding a declaratory judgment claim of infringement of the ‘377 Patent against Wishbone.

Thereafter, in January 2021, Wishbone filed a motion to dismiss all OrthoPediatrics’ causes of action. In late August 2021, the Court denied Wishbone's motion to dismiss with respect to OrthoPediatrics’ infringement and breach of contract claims and dismissed OrthoPediatrics' remaining causes of action. In late September 2021, Wishbone filed its answer and counterclaims, in part, seeking declaratory judgment of non-infringement and invalidity of the ‘377 Patent, and alleging OrthoPediatrics patent infringement claim(s) against Wishbone was made in bad faith. In mid-October 2021, OrthoPediatrics filed its answer to Wishbone’s counterclaims, denying all of them. Although we believe Wishbone’s counterclaims are
33

without merit and will vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have an adverse effect on our business, operating results and financial condition.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

Purchase Obligations and Performance Requirements

As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASHTM Navigation platform, the Company has agreed to a minimum purchase commitment for the first twelve months of that agreement. As of September 30, 2022, the remaining purchase commitment under the agreement was $0.

On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three and nine months ended September 30, 2022, the Company recorded an expense of $101 and $442, respectively. No expense was recorded for either the three or nine months ended September 30, 2021.

Royalties

As of September 30, 2022, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales.

We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of September 30, 2022, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.



ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the condensed consolidated financial statements and related notes thereto contained elsewhere in this quarterly report, as well as the information under "Note Regarding Forward-Looking Statements."

The description of our business included in this quarterly report is summary in nature and only includes material developments that have occurred since the latest full description. The full description of the history and general development of our business is included in "Item 1. Description of Business" section of the Company's Annual Report on Form 10-K filed with the SEC on March 3, 2022, which section is incorporated herein by reference.

Overview
34


We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3.3 billion opportunity globally, including over $1.5 billion in the United States.

We sell implants, instruments and braces to our customers for use by pediatric orthopedic surgeons to treat orthopedic conditions in children. We provide our implants in sets that consist of a range of implant sizes and include the instruments necessary to perform the surgical procedure. In the United States and a few selected international markets, our customers typically expect us to have full sets of implants and instruments on site at each hospital but do not purchase the implants until they are used in surgery. Accordingly, we must make an up-front investment in inventory of consigned implants and instruments before we can generate revenue from a particular hospital and we maintain substantial levels of inventory at any given time. In the international markets, we also sell to stocking distributors, where we transfer control of our products to the distributor when title passes upon shipment.

We currently market 46 surgical systems that serve three of the largest categories within the pediatric orthopedic market: (i) trauma and deformity, (ii) scoliosis and (iii) sports medicine/other. We primarily rely on a broad network of third parties to manufacture the components of our products, which we then inspect and package. We believe our innovative products promote improved surgical accuracy, increase consistency of outcomes and enhance surgeon confidence in achieving high standards of care. In the future, we expect to expand our product offering within these categories, as well as to address additional categories of the pediatric orthopedic market.

The majority of our revenue has been generated in the United States, where we sell our products through a network of 41 independent sales agencies employing more than 201 sales representatives specifically focused on pediatrics. These independent sales agents are trained by us, distribute our products and are compensated through sales-based commissions and performance bonuses. We do not sell our products through or participate in physician-owned distributorships, or PODs.

We market and sell our products internationally in over 70 countries, through independent stocking distributors and sales agencies. Our independent distributors manage the billing relationship with each hospital in their respective territories and are responsible for servicing the product needs of their surgeon customers. In 2017, we began to supplement our international stocking distributors with sales agencies using direct sales programs in the United Kingdom, Ireland, Australia and New Zealand where we sell directly to the hospitals. We began selling direct to Canada in September 2018, Belgium and the Netherlands in January 2019, Italy in March 2020 and Germany, Switzerland and Austria in January 2021. Additionally, in July 2022, we established an operating company in Germany and in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. In these markets, we work through sales agencies that are paid a commission, similar to our U.S. sales model. We expect these arrangements to generate an increase in revenue and gross margin.

We believe there are significant opportunities for us to strengthen our position in U.S. and international markets by increasing investments in consigned implant and instrument sets, strengthening our global sales and distribution infrastructure and expanding our product offering. For example, on April 1, 2022, the Company acquired MD Orthopaedics, Inc., a developer and manufacturer of a portfolio of orthopedic clubfoot products. Also, on July 1, 2022, the Company, along with its newly-formed, indirect wholly-owned subsidiary OrthoPediatrics Canada ULC, purchased all of the issued and outstanding share capital of Pega Medical Inc., which has developed and sells a portfolio of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System, a well-recognized, innovative
35

implant designed to treat bony deformities in children with osteogenesis imperfecta without disrupting their normal growth.

Environmental, Social and Governance ("ESG") Activities

OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 613,000 children, including MD Ortho. We believe we should continue to expand our social efforts while minimizing our impact to the environment and ensuring corporate governance. In 2021, we created an internal ESG team, which reports directly to our Board’s Governance and Nominating Committee, to identify ESG topics for disclosure by assessing both the impact on our business and the importance to our stakeholders.

We encourage you to review our ESG page under the "About" section of our corporate website for more detailed information regarding our ESG efforts and current initiatives. On our website, among other information, are the following highlights:

•OrthoPediatrics cares about our environmental impact while working in a highly regulated industry and we are certified according to ISO 13485. Our team in Warsaw recently implemented an enhanced recycling program.

•The Company and its associates regularly participate in philanthropic causes important to our local communities. We also partner with charitable organizations that provide pediatric orthopedic care around the world. In 2020 we were named as "Corporate Partner of the Year" by the World Pediatric Project - with whom we work to provide access to medical care for children in developing countries.

•We are committed to fostering an environment that is respectful, compassionate, and inclusive of everyone in our community.

•The Board of Directors understands the value of diversity and will increase the diversity of the Board over the next 12 months. The Governance and Nominating Committee engaged a global recruiting firm to assist in adding two diverse Board candidates.

We believe effectively managing our priorities, as well as increasing our transparency related to ESG programs, will help create long-term value for our stakeholders. We expect to increase our disclosures and communicate our ESG efforts in future SEC filings.

Nothing on our website shall be deemed part of or incorporated by reference into this Quarterly Report on Form 10-Q.

Impact of COVID-19 on our Business

As a result of the COVID-19 pandemic (“COVID-19” or the “pandemic”), we have experienced significant business disruption. Elective procedures are delayed in some cases as hospitals continue to struggle with adequate staffing levels. As a majority of our products are utilized in elective surgeries or procedures, the deferrals of such surgeries and procedures have had, and may continue to have, a significant negative impact on our business and results of operations. Throughout the pandemic, we have taken a variety of steps to address the impact. We continue to monitor the impact of the pandemic on our employees and customers and the markets in which we operate and will take further actions that are considered prudent to address the pandemic. We cannot accurately predict with certainty the full extent to which the pandemic will impact demand for our products in the future. Accordingly, the COVID-19 pandemic could have a material adverse impact on our results of operations, financial condition and capital resources. We encourage the readers of this document to read our risk factors in their entirety contained in Item 1A “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the
36

"SEC") on March 3, 2022 and in other reports filed with the SEC that discuss the risks and factors that may affect our business.

Despite the impact COVID-19 has had on our business, we continue to invest in research and development, invest in our people, and take steps to position ourselves for long-term success.

Other Trends and Uncertainties

From time to time we acquire, make investments in or license other technologies, products and business that may enhance our capabilities, complement our current products or expand the breadth of our markets or customer base. As a result of these transactions, we may record certain intangible assets, including goodwill and trademarks, which are subject to annual impairment testing. Fair value is based on our current assessment of the expected future cash flows based on recent results and other specific market factors. During the third quarter ended September 30, 2022, we determined that a triggering event had occurred indicating it was more likely than not the fair value of an acquired trademark was less than the associated carrying value. Subsequently, the company completed a quantitative analysis and concluded that the fair value was in fact less than the carrying value and an impairment loss was recorded in the period. We believe that the expected future cash flows in the most recent calculations represent management’s best estimate; however, if actual results differ materially from these estimates, we could record an additional impairment charge which could be material to our consolidated financial statements and have an adverse impact on our results of operations.

In the three-month period ended September 30, 2022, there has been a significant and unprecedented increase in cases of respiratory syncytial virus, or RSV, and other respiratory illnesses. RSV is a common respiratory virus that follows a seasonal pattern. The typical season shows an increase in mid-September, peaks in late December and drops around mid-April; however, in 2022 the United States has experienced a significant increase during the summer months. The volume of elective procedures utilizing our products were negatively impacted as a significant percent of hospital capacity was absorbed to cover the increase in RSV-related hospitalizations. This has had a negative impact on our sales volume and may continue to do so into the future. We are unable to accurately determine exactly how this will impact us in the future, but we will continue to monitor this dynamic as we get closer to the traditional peak of RSV season.

Emerging Growth Company and Smaller Reporting Company Status

We will qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”) until December 31, 2022. For as long as a company is deemed to be an emerging growth company, it may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. The JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.


Summary of Statements of Operations for the Three and Nine Months Ended September 30, 2022 and 2021

37

The following table sets forth our results of operations for the three and nine months ended September 30, 2022 and 2021:
Three Months Ended September 30,Nine Months Ended September 30,
20222021Increase
(Decrease)		%20222021Increase (Decrease)%
Net revenue$34,950 $25,079 $9,871 39 %$91,295 $73,236 $18,059 25 %
Cost of revenue9,061 6,525 2,536 39 %21,859 17,914 3,945 22 %
Sales and marketing expenses11,919 9,862 2,057 21 %34,108 29,687 4,421 15 %
General and administrative expenses15,116 11,034 4,082 37 %42,829 34,163 8,666 25 %
Trademark impairment3,609 — 3,609 100 %3,609 — 3,609 100 %
Research and development expenses2,206 1,302 904 69 %5,980 3,935 2,045 52 %
Total other expenses (income)(21,357)(1,155)(20,202)1749 %(21,297)4,759 (26,056)(548)%
Provision for income taxes (benefit)(4,143)(292)(3,851)(1319)%(4,899)(890)(4,009)(450)%
Net income (loss)$18,539 $(2,197)$(20,736)(944)%$9,106 $(16,332)$(25,438)(156)%

Net Revenue

The following tables set forth our net revenue by geography and product category for the three and nine months ended September 30, 2022 and 2021:
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by geographic location:2022202120222021
U.S.$26,539 $19,354 $69,687 $57,930 
International8,411 5,725 21,608 15,306 
Total$34,950 $25,079 $91,295 $73,236 
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by category:2022202120222021
Trauma and deformity$23,892 $16,817 $62,976 $49,302 
Scoliosis9,979 7,266 25,383 20,874 
Sports medicine/other1,079 996 2,936 3,060 
Total$34,950 $25,079 $91,295 $73,236 

Net revenue increased $9.9 million, or 39%, from $25.1 million for the three months ended September 30, 2021 to $35.0 million for the three months ended September 30, 2022 and increased $18.1 million, or 25%, from $73.2 million for the nine months ended September 30, 2021 to $91.3 million for the nine months ended September 30, 2022. The increase during the three and nine months ended September 30, 2022 was driven primarily by increased usage of Orthex Ex-Fix, RESPONSE and ApiFix Scoliosis, PNP Femur as well as cannulated screw systems. Additionally, growth from acquisitions for the three and nine months ended September 30, 2022 was $4.4 million and $7.0 million, respectively.

Trauma and deformity sales, which include the non-organic growth from acquisitions, increased $7.1 million, or 42%, during the three months ended September 30, 2022, and increased $13.7 million, or 28%, during the nine months ended September 30, 2022. In each case, the increase was primarily driven by strong trauma and deformity growth across numerous product lines, specifically external fixation, the PNP Femur system, and cannulated screws as well as the sales generated from acquired businesses. Scoliosis sales increased $2.7 million, or 37%, during the three months ended September 30, 2022, and increased $4.5 million, or 22%, during the nine months ended September 30, 2022. In each case, the growth was primarily driven by increased sales of our RESPONSE fusion systems and ApiFix non-fusion
38

system as well as set sales to international stocking distributors. Sports medicine / other increased $0.1 million, or 8%, during the three months ended September 30, 2022, and decreased $0.1 million, or 4%, during the nine months ended September 30, 2022. Nearly all the change in each category was due to an increase or decrease in the unit volume sold and not a result of price changes.

Cost of Revenue and Gross Margin

Cost of revenue increased $2.5 million, or 39%, from $6.5 million for the three months ended September 30, 2021 to $9.1 million for the three months ended September 30, 2022. Cost of revenue increased $3.9 million, or 22%, from $17.9 million for the nine months ended September 30, 2021 to $21.9 million for the nine months ended September 30, 2022. In both cases, the increase was due primarily to an increase in volumes sold. Gross margin was 74% for the three months ended September 30, 2021 and 74% for the three months ended September 30, 2022. Gross margin was 76% for the nine months ended September 30, 2022 and 76% for the nine months ended September 30, 2021.

Sales and Marketing Expenses

Sales and marketing expenses increased $2.1 million, or 21%, to $11.9 million for the three months ended September 30, 2022 from $9.9 million for the three months ended September 30, 2021. Sales and marketing expenses increased $4.4 million, or 15%, to $34.1 million for the nine months ended September 30, 2022 from $29.7 million for the nine months ended September 30, 2021. The changes in the three and nine month periods ended September 30, 2022 were due primarily to increased sales commission expenses, driven by increased unit volumes sold. This is partially offset by lower commission rates associated with the acquired businesses. Additionally, the Company has experienced higher expense of approximately $0.6 million related to the businesses acquired in the current year, which were not present in the prior year.

General and Administrative Expenses

General and administrative expenses increased $4.1 million, or 37%, from $11.0 million for the three months ended September 30, 2021 to $15.1 million for the three months ended September 30, 2022. General and administrative expenses increased $8.7 million, or 25%, to $42.8 million for the nine months ended September 30, 2022 from the $34.2 million for the nine months ended September 30, 2021.The increases for the three and nine month periods ended September 30, 2022 were due primarily to the addition of personnel and resources to support the continued expansion of our business and an increase in legal expenses, driven by two recent acquisitions, and other professional service expenses. Additionally, the Company has experienced higher expense of approximately $3.0 million related to the businesses acquired in the current year, which were not present in the prior year.

Depreciation and amortization expenses increased $0.7 million, or 27%, from $2.7 million for the three months ended September 30, 2021 to $3.4 million for the three months ended September 30, 2022. Depreciation and amortization expenses increased $1.7 million, or 22%, to $9.6 million for the nine months ended September 30, 2022 from $7.9 million for the nine months ended September 30, 2021.The increases for the three and nine month periods ended September 30, 2022 were primarily due to increases in depreciation from higher set deployments and the amortization of intangible assets, primarily those acquired with MD Ortho and Pega.

Additionally, the Company recorded an impairment charge associated with the ApiFix trademark. See Note 4 - Goodwill and Intangible Assets for further details.

Research and Development Expenses

Research and development expenses increased $0.9 million, or 69%, from $1.3 million for the three months ended September 30, 2021 to $2.2 million for the three months ended September 30, 2022.
39

Research and development expenses increased $2.0 million, or 52%, to $6.0 million for the nine months ended September 30, 2022 from the $3.9 million for the nine months ended September 30, 2021. The increases for the three and nine month periods ended September 30, 2022 were primarily due to incremental product development and the addition of personnel to support the future growth of the business. Additionally, the Company has experienced higher expense of approximately $0.1 million related to the businesses acquired in the current year, which were not present in the prior year.

Total Other (Income) Expense

Total other income reflects income of $21.4 million and $1.2 million for the three months ended September 30, 2022 and 2021, respectively, an increase of $20.2 million or 1,749%. Other expenses fluctuated $26.1 million, or 548%, to income of $21.3 million for the nine months ended September 30, 2022 from the $4.8 million of expense for the nine months ended September 30, 2021. The change in total other income for the three and nine months ended September 30, 2022 was primarily due to the fair value adjustments of contingent consideration, which was driven by the valuation inputs, specifically a significant reduction in the forecasted ApiFix product sales. This was offset by additional interest expense of approximately $0.7 million as the result of the finalization of the ApiFix installment paid in the second quarter and the accreted interest expense associated with the acquisition installment payables. The increased interest expense from the ApiFix installment payment was driven by the variance in our closing stock price on the payment date compared to the 30 day average used to calculate the number of shares paid, which increase was non-cash in nature.

Liquidity and Capital Resources

We have incurred operating losses since inception which resulted in negative cash flows for continuing operations from operating activities of $18.4 million and $11.8 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $168.9 million. We anticipate that our losses will continue in the near term as we continue to expand our product portfolio and invest in additional consigned implant and instrument sets to support our expansion into existing and new markets. Since inception, we have funded our operations primarily with proceeds from the sales of our common and preferred stock, convertible securities and debt, as well as through sales of our products. At September 30, 2022, we had cash, restricted cash and short term investments of $121.6 million. We also currently have $50 million available on our line of credit.

During the quarter ended September 30, 2022, we raised net proceeds of approximately $139.3 million from a public offering of (a) 1,091,250 shares our common stock, and (b) pre-funded warrants exercisable for an aggregate of up to 1,525,000 shares of common stock to Squadron Capital LLC (“Squadron”), our largest investor. The net proceeds reflect the Company’s payment of $4.3 million in underwriting discounts and commissions and $0.3 million in other offering costs. A portion of the net proceeds were used to repay $31 million of borrowings previously outstanding under the Company’s revolving credit facility with Squadron. On September 20, 2022, the Company issued an aggregate of 1,525,000 shares of common stock to Squadron upon exercise of the pre-funded warrants.

Cash Flows

40

The following table sets forth our cash flows from operating, investing and financing activities for the periods indicated:
Nine Months Ended September 30,
20222021
Net cash used in operating activities$(18,425)$(11,828)
Net cash used in investing activities(90,144)(10,376)
Net cash provided financing activities136,009 40 
Effect of exchange rate changes on cash426 (266)
Net increase (decrease) in cash$27,866 $(22,430)

Cash Used in Operating Activities

Net cash used in operating activities from continuing operations was $18.4 million and $11.8 million for the nine months ended September 30, 2022 and 2021, respectively. The primary use of this cash was to fund our operations related to the development and commercialization of our products in each of these periods. Net cash used for working capital was $17.4 million for the nine months ended September 30, 2022 compared to a use of $12.1 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2022, the primary driver of working capital cash usage was the increase in inventory of $14.8 million and trade receivables of $5.6 million, offset by trade payables of $0.4 million to support future sales growth. We also saw an increase in the sourcing of cash from other accrued expenses of $1.8 million.

Cash Used in Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2022 was $90.1 million compared to $10.4 million for the nine months ended September 30, 2021. Net cash used in investing activities for the nine months ended September 30, 2022 consisted primarily of the sale of short-term marketable securities used to fund the acquisition of MD Ortho, acquisition of Pega and cash planning in association with the public offering. This was offset by the purchases of instrument sets of $10.6 million, the cash consideration paid for acquisitions and the purchase of short-term marketable securities from the excess cash after the follow-on offering.

Cash Provided By Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2022 was $136.0 million. Net cash used in financing activities for the nine months ended September 30, 2021 was not material to the results of our operations. Net cash provided by financing activities for the nine months ended September 30, 2022 consisted primarily of the proceeds from the $31 million of debt incurred in connection with the acquisition of Pega Medical Inc., which was offset by an equal payment after the follow-on offering completed in August. The proceeds from issuance of common stock, net of issuance costs provided a source of cash in financing activities of $139.3 million for the three and nine months ended September 30, 2022.

Indebtedness

Loan Agreement

On June 13, 2022, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to its Fourth Amended and Restated Loan and Security Agreement with Squadron (as so amended, the “Loan Agreement”). The Fourth Amendment increased the amount available under the revolving credit facility from $25 million to $50 million in anticipation of using the facility to fund the cash portion of the Company’s July 1, 2022 acquisition of Pega Medical Inc. After borrowing $31 million under the Loan
41

Agreement in June 2022 to fund such acquisition, the Company repaid the entire amount on August 15, 2022 with proceeds from a public offering of securities.

The Loan Agreement provides a revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears.

Borrowings under the revolving credit facility are made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions as further detailed in the Loan Agreement.

The Loan Agreement includes events of default, the occurrence and continuation of any of which provides Squadron with the right to exercise remedies against us and the collateral securing the loans, including cash. These events of default include, among other things, the failure to pay amounts due under the credit facilities, insolvency, the occurrence of a material adverse event, which includes a material adverse change in our business, operations or properties (financial or otherwise) or a material impairment of the prospect of repayment of any portion of the obligations, the occurrence of any default under certain other indebtedness and a final judgment against us in an amount greater than $250 thousand. The occurrence of a material adverse change could result in the acceleration of payment of the debt.

As of September 30, 2022 and December 31, 2021 there was no outstanding debt on the line of credit. As a result, $50 million is currently available for future borrowing.

Mortgage Note

In August 2013, pursuant to the purchase of our office and warehouse space, we entered into a mortgage note payable to Tawani Enterprises Inc., the owner of which is a member of Squadron’s management committee. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $15 thousand, with interest compounded at 5% until maturity in August 2028, at which time a final payment of remaining principal and interest will become due. The mortgage is secured by the related real estate and building. The mortgage balance was $0.9 million and $1.0 million at September 30, 2022 and December 31, 2021, respectively.

Pediatric Orthopedic Business Seasonality

42

Our revenue is typically higher in the summer months and holiday periods, driven by higher sales of our trauma and deformity and scoliosis products, which is influenced by the higher incidence of pediatric surgeries during these periods due to recovery time provided by breaks in the school year. Additionally, our scoliosis patients tend to have additional health challenges that make scheduling their procedures variable in nature.

Critical Accounting Policies and Significant Judgments and Estimates

This management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue and expenses during the reporting periods. We monitor and analyze these items for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ materially from these estimates under different assumptions or conditions. See additional detail regarding our Critical Accounting Policies in our Annual Report on Form 10-K filed with the SEC on March 3, 2022. There have been no material changes to these policies since the filing of our Annual Report on Form 10-K.

ITEM 3.        QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a "smaller reporting company," we are not required to provide the information required by this item.

ITEM 4.        CONTROLS AND PROCEDURES

a.Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) at the end of the period covered by this quarterly report.

Based on this evaluation, we concluded that, as of such date, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives, and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

b. Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the period covered by this quarterly report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act).
43


In April 2022, we completed the acquisition of MD Ortho and in July 2022 we completed the acquisition of Pega Medical. We are currently integrating the acquired companies into our operations. The internal control over financial reporting of the acquired companies was excluded from the evaluation of the effectiveness of our internal controls. This exclusion is in accordance with the general guidance issued by the Staff of the SEC that an assessment of a recent business combination may be omitted from management's report on internal control over financial reporting during the first year following an acquisition while integrating the acquired company. The acquired companies constituted approximately 6.8% of our total assets as of September 30, 2022, including goodwill and intangible assets recorded as a part of our purchase price allocation, and approximately 7.7% of our net revenue for the nine months ended September 30, 2022.
44

PART II. OTHER INFORMATION

ITEM 1.        LEGAL PROCEEDINGS

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

A discussion of certain of those legal proceedings is contained in Note 13 – Commitments and Contingencies (under the heading “Legal Proceedings”) of the notes to the condensed consolidated financial statements included in Item 1. Financial Statements of Part I of this quarterly report on Form 10-Q, which discussion is incorporated herein by reference.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position, results of operations or cash flows.

ITEM 1A.        RISK FACTORS

In addition to the other information set forth in this quarterly report, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 3, 2022. There have been no material changes to these Risk Factors since the filing of our Annual Report on Form 10-K.

ITEM 2.        UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

a. Sale of Unregistered Securities.

On July 1, 2022, the Company issued 34,899 shares of its common stock, $0.00025 par value per share, in connection with the purchase of all of the issued and outstanding shares of Pega Medical Inc. The purchase price also included $32.0 million in cash. The shares were valued at $42.90 per share on the date of issuance. The issuance of the common stock was made in reliance upon an exemption provided under Section 4(a)(2) of the Securities Act of 1933, as amended.

b. Use of Proceeds.

None.

c. Issuer Purchases of Equity Securities.

None.

ITEM 3.        DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.        MINE SAFETY DISCLOSURES

None.

ITEM 5.        OTHER INFORMATION

a. Failure to file under Form 8-K.
45


None.

b. Modifications to nomination process.

None.

ITEM 6.        EXHIBITS

The following exhibits are included within this Report or incorporated herein by reference.




46

Exhibit
Number
Description
+
+
++
47

++
101.INS+Inline XBRL Instance Document (The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.)
101.SCH+Inline XBRL Taxonomy Extension Schema Document
101.CAL+Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE+Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)

w The schedules to the applicable agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish a copy of any schedule omitted from such agreement to the SEC upon request.

*    Exhibits that describe or evidence management contracts or compensatory plans or arrangements required to be filed as Exhibits to this Report.

+ Filed herewith.

++ Furnished herewith.

48

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 1, 2022By:/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer


November 1, 2022
By:
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer

49
 EX-31.1 2 exhibit311-ceocertificatio.htm EX-31.1 Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Bailey, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)

Date:     November 1, 2022


 EX-31.2 3 exhibit312-cfocertificatio.htm EX-31.2 Document

CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Fred L. Hite, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of OrthoPediatrics Corp.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with general accepted accounting principles;

c.    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial Officer)

Date:     November 1, 2022


 EX-32.1 4 exhibit321-ceocertificatio.htm EX-32.1 Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David R. Bailey, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.
/s/ David R. Bailey
David R. Bailey
President and Chief Executive Officer
(Principal Executive Officer)

Date:     November 1, 2022


 EX-32.2 5 exhibit322-cfocertificatio.htm EX-32.2 Document

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of OrthoPediatrics Corp. (the “Company”) for the quarterly period ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Fred L. Hite, Chief Financial Officer and Chief Operating Officer of the Company, hereby certifies, pursuant to 18 Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1.the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of the Company.

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the Report.
/s/ Fred L. Hite
Fred L. Hite
Chief Financial Officer and Chief Operating Officer
(Principal Financial Officer)

Date:     November 1, 2022


 EX-101.SCH 6 kids-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - DEBT AND CREDIT ARRANGEMENTS link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - BUSINESS SEGMENT link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - BUSINESS COMBINATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - BUSINESS SEGMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - BUSINESS COMBINATIONS - Pega Medical and MD Orthopaedics (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - BUSINESS COMBINATIONS - Assets acquired and liabilities assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - BUSINESS COMBINATIONS - Estimated fair value and useful life of identifiable intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - BUSINESS COMBINATIONS - Schedule of pro forma net revenue and net loss (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Estimated Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Trademark Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - BUSINESS SEGMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 kids-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 kids-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 kids-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Related Party Transactions [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Adjustment for realized loss on securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Discounted cash flow, Monte Carlo Valuation Technique, Discounted Cash Flow [Member] Short term investments Investments, Fair Value Disclosure Acquisition Payable and Contingent Consideration Business Combinations Policy [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Revolving credit facility Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Business software Software and Software Development Costs [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Additional paid-in capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Debt instrument, basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Accrued legal settlements Increase (Decrease) In Settlement Liabilities, Current Increase (Decrease) In Settlement Liabilities, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Stock option exercise (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Scoliosis Spine [Member] Spine [Member] Restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Schedule of Product Sales by Geographic Location Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Share-Based Payment Arrangement [Abstract] Consideration for MD Ortho and Pega Medical acquisition (in shares) Stock issued (in shares) Stock Issued During Period, Shares, Acquisitions Federal and State Domestic Tax Authority [Member] Estimated royalty rate Measurement Input, Estimated Royalty Rate [Member] Measurement Input, Estimated Royalty Rate Net income (loss) Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Equity Component [Domain] Equity Component [Domain] Discount rate Present Value Discount Rate Measurement Input, Discount Rate [Member] Payments on debt with affiliate Payments on note with affiliate Repayments of Related Party Debt Acquired Finite-Lived Intangible Assets Acquired Finite-Lived Intangible Assets [Line Items] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Related Party [Domain] Related Party [Domain] Plan Name [Axis] Plan Name [Axis] Common stock (in dollars per share) Business Acquisition, Share Price SUPPLEMENTAL DISCLOSURES Supplemental Cash Flow Elements [Abstract] Finite-Lived Intangible Assets Finite-Lived Intangible Assets, Net [Abstract] Number of operating segments Number of Operating Segments Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Total long-term liabilities Liabilities, Noncurrent Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Contractual terms (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Actual revenue from acquired entities Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual Estimated market portion opportunities Estimated Market Portion Opportunities Estimated Market Portion Opportunities Schedule of Restricted Stock Awards & Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Accounts receivable-trade Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Liability Class [Axis] Liability Class [Axis] Long-term debt with affiliate, net of current maturities Long-Term Debt, Excluding Current Maturities Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Geographical [Axis] Geographical [Axis] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Issuance of common stock, net of issuance cost Stock Issued During Period, Value, New Issues Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Schedule of Property and Equipment, Depreciable Lives Property, Plant and Equipment [Table Text Block] Revenue Recognition - United States and International Revenue from Contract with Customer [Policy Text Block] Document Type Document Type Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Depreciable lives (in years) Property, Plant and Equipment, Useful Life Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Acquisition of Pega, net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] DEBT AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] Asset Acquisition [Axis] Asset Acquisition [Axis] Products and Services [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Consideration for acquisition (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares ApiFix Ltd ApiFix Ltd. [Member] ApiFix Ltd. Financial Instrument [Axis] Financial Instrument [Axis] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Affiliated Entity Affiliated Entity [Member] Long term growth rate Measurement Input, Long Term Growth Rate [Member] Measurement Input, Long Term Growth Rate Document Period End Date Document Period End Date Vesting Period One Share-Based Payment Arrangement, Tranche One [Member] Income Tax Examination [Table] Income Tax Examination [Table] Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combinations Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Warrants exercise price (in dollars per share) Class Of Warrant Or Right, Discount On Exercise Price Of Warrants Or Rights Class Of Warrant Or Right, Discount On Exercise Price Of Warrants Or Rights Less: total net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Total assets Assets Debt Disclosure [Abstract] Net income (loss) per share Earnings Per Share [Abstract] Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Less: current maturities Current portion of long-term debt with affiliate Long-Term Debt, Current Maturities Exercised, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Finite-lived intangible assets acquired Finite-Lived Intangible Assets Acquired Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accrued compensation and benefits Employee-related Liabilities, Current Asset Backed Securities Asset-Backed Securities [Member] Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Contingent consideration, measurement input Contingent Consideration, Measurement Input Contingent Consideration, Measurement Input NET LOSS PER SHARE Earnings Per Share [Text Block] Issuance of common stock Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Cash and Cash Equivalents and Short Term Investments Cash and Cash Equivalents, Policy [Policy Text Block] Related Party Transaction Related Party Transaction [Line Items] Equity Award [Domain] Award Type [Domain] Unrecognized compensation expense, weighted average period of recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Computer equipment Computer Equipment [Member] Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Issuance of common stock, net of issuance cost (in shares) Stock Issued During Period, Shares, New Issues Mortgage payable to affiliate Mortgages [Member] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Foreign currency translation impact Goodwill, Foreign Currency Translation Gain (Loss) Patents Patents [Member] Customer Relationships Customer Relationships & Other Customer Relationships [Member] Entity Address, City or Town Entity Address, City or Town EMPLOYEE BENEFIT PLAN Retirement Benefits [Text Block] Unrealized loss on short-term investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Operating expenses: Operating Expenses [Abstract] Restricted stock Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Number of related party suppliers Number Of Related Party Entities Suppliers Number Of Related Party Entities Suppliers Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract] Minimum Minimum [Member] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Income Tax Examination Income Tax Examination [Line Items] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] FAIR VALUE OF FINANCIAL INSTRUMENTS Fair Value Disclosures [Text Block] Loss carryforwards Operating Loss Carryforwards Trading Symbol(s) Trading Symbol Entity File Number Entity File Number Contingent repurchase price, per share (in dollars per share) Business Combination, Contingent Repurchase Price, Per Share Business Combination, Contingent Repurchase Price, Per Share Research and development Research and Development Expense Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units Restricted Stock Units (RSUs) [Member] Effective income tax rate (as a percent) Effective Income Tax Rate Reconciliation, Percent Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure BUSINESS COMBINATIONS Business Combination Disclosure [Text Block] Other expenses (income): Other Nonoperating Income (Expense) [Abstract] Contingent consideration liability term Business Combination, Contingent Consideration, Liability, Term Business Combination, Contingent Consideration, Liability, Term Accounts payable - trade Increase (Decrease) in Accounts Payable Estimated annual limitation of losses Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Annual Limit Three Month LIBOR London Interbank Offered Rate (LIBOR) [Member] SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Contingent consideration, beginning balance Contingent consideration, ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Pro forma net income (loss) Business Acquisition, Pro Forma Net Income (Loss) INCOME TAXES Income Tax Disclosure [Text Block] Sales to related party Revenue from Related Parties Monthly interest and principal installments Debt Instrument, Periodic Payment Credit Facility [Domain] Credit Facility [Domain] Warrants exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Schedule of Goodwill Schedule of Goodwill [Table Text Block] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Basic (in dollars per share) Earnings Per Share, Basic Revenues from External Customers and Long-Lived Assets Revenues from External Customers and Long-Lived Assets [Line Items] Inventories, net Inventory, Policy [Policy Text Block] Structure Medical, LLC Structure Medical, LLC [Member] Structure Medical, LLC Counterparty Name [Domain] Counterparty Name [Domain] Sales and marketing Selling and Marketing Expense Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total stockholders' equity Balance Balance Stockholders' Equity Attributable to Parent Tax credit carryforward Tax Credit Carryforward, Amount Vesting [Domain] Vesting [Domain] Entity Interactive Data Current Entity Interactive Data Current Common stock issued and sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in certain current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Sale of short-term marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Accumulated Deficit Retained Earnings [Member] Segment Reporting Information Segment Reporting Information [Line Items] Common Stock Common Stock [Member] Other comprehensive income (loss), net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Number of reportable segments Number of Reportable Segments Contingent Consideration Liability Contingent Consideration Liability [Member] Contingent Consideration Liability Contingent Consideration Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Income Taxes Income Tax, Policy [Policy Text Block] Statement [Table] Statement [Table] Consideration for MD Ortho acquisition Stock Issued During Period, Value, Acquisitions Document Quarterly Report Document Quarterly Report Total assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Restricted Stock Awards And Restricted Stock Units Restricted Stock Awards And Restricted Stock Units [Member] Restricted Stock Awards And Restricted Stock Units Other intangible assets Non-amortizing intangible assets Beginning balance Ending balance Indefinite-Lived Intangible Assets (Excluding Goodwill) Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Retained Earnings (Accumulated Deficit) Accounts receivable - trade, less allowance for doubtful accounts of $608 and $347, respectively Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Purchase of short-term marketable securities Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Trademarks Assets Trademarks Trademarks [Member] Fair Value, Recurring Fair Value, Recurring [Member] RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] 2017 Plan New 2017 Equity Incentive Plan [Member] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Schedule of Pro Forma Net Revenue and Net Loss Business Acquisition, Pro Forma Information [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Divestiture purchase price Disposal Group, Including Discontinued Operation, Consideration Outstanding at period start (in shares) Outstanding at period end (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Schedule of Finite-Lived Intangible Assets Indefinite-Lived Intangible Assets Indefinite-Lived Intangible Assets [Line Items] Total other expenses (income) Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Gross Intangible Assets Finite-Lived Intangible Assets, Gross Vilex and Orthex Vilex and Orthex [Member] Vilex and Orthex Fair value adjustment of contingent consideration Fair value adjustment of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Indefinite-Lived Intangible Assets Indefinite-Lived Intangible Assets [Roll Forward] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Operating loss Operating Income (Loss) Inventories Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Increase of estimated annual limitation of first five years Operating Loss Carryforwards Limitations On Use Estimated Amount Subject to Limitation Annual Limit Increase Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets State State and Local Jurisdiction [Member] Common stock, shares outstanding (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Outstanding Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Gross Intangible Assets Indefinite-Lived Intangible Assets (Excluding Goodwill), Gross Indefinite-Lived Intangible Assets (Excluding Goodwill), Gross Foreign currency translation impact Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Indefinite-lived intangible assets acquired Indefinite-Lived Intangible Assets Acquired Expected years Contingent Consideration, Measurement Input, Period Contingent Consideration, Measurement Input, Period Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Provision for income taxes (benefit) Income tax benefit Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Property and Equipment, net Property, Plant and Equipment, Policy [Policy Text Block] Deferred income taxes Deferred Income Tax Liabilities, Net Income Statement [Abstract] Options granted (in shares) Options, granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Additional Paid-in Capital Additional Paid-in Capital [Member] License Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of revenue Cost of Goods and Services Sold Diluted (in shares) Weighted average shares outstanding for diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Acquisition installment payable, net of current portion Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent Building and building improvements Building and Building Improvements [Member] Royalty agreement percentage (as a percent) Research and Development Arrangement Contract to Perform for Others Royalty Agreement Percent Common stock, $0.00025 par value; 50,000,000 shares authorized; 22,896,031 shares and 19,677,214 shares issued as of September 30, 2022 (unaudited) and December 31, 2021, respectively Common Stock, Value, Issued Accounts payable and accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Litigation and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Impairment Impairment of Intangible Assets, Finite-Lived Public Offering Public Offering [Member] Public Offering Cash and restricted cash, beginning of year Cash and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from issuance of debt with affiliate Proceeds from Issuance of Long-Term Debt Common stock, shares issued (in shares) Common Stock, Shares, Issued Employer contribution as a percentage of employees' salary (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Warrants and rights outstanding Warrants and Rights Outstanding Acquisition related costs Business Combination, Acquisition Related Costs Weighted-average remaining contractual terms (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Defined Benefit Plan, Plan Assets, Allocation [Table] Defined Benefit Plan, Plan Assets, Allocation [Table] Amendment Flag Amendment Flag Intangible asset, useful life (in years) Finite-Lived Intangible Asset, Useful Life Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Weighted-Average Amortization Period Finite-Lived Intangible Assets, Remaining Amortization Period Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Goodwill acquired Goodwill, Acquired During Period Pro forma net revenue Business Acquisition, Pro Forma Revenue Total liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Schedule of Product Sales by Category Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Stock portion of ApiFix anniversary installment payment (in shares) Stock Issued During Period, Shares, Anniversary Installment Payment Stock Issued During Period, Shares, Anniversary Installment Payment Goodwill and Intangible Assets Disclosure [Abstract] Other current liabilities Other Liabilities, Current Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Transfer of instruments from property and equipment to inventory Transfer Of Property And Equipment To Inventory MD Orthopaedics MD Orthopaedics [Member] MD Orthopaedics Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Payments to related party Related Party Transaction, Purchases from Related Party Current portion of acquisition installment payable Business Combination, Contingent Consideration, Acquisition Installment Payable, Current Business Combination, Contingent Consideration, Acquisition Installment Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization Payments on mortgage notes Repayments of Notes Payable Exchange Trade Mutual Funds Exchange Trade Mutual Funds [Member] Exchange Trade Mutual Funds Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Outstanding at period start (in shares) Outstanding at period end (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Amortizable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Instruments Technology Equipment [Member] IPO IPO [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Property, Plant and Equipment, Net Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Office and other equipment Office Equipment [Member] Stock Option Stock options Share-Based Payment Arrangement, Option [Member] Note payable to Squadron Notes Payable, Other Payables [Member] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Stock option exercise Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Total debt Long-term debt Long-Term Debt Other expense (income) Other Nonoperating Income (Expense) Public offering price (in dollars per share) Sale of Stock, Price Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Amortizable Intangible Assets, net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Benefit Plan, Plan Defined Benefit Plan, Plan Assets, Allocation [Line Items] Firefly Technology Firefly Technology [Member] Firefly Technology Statement of Comprehensive Income [Abstract] Total operating expenses Operating Expenses Maximum Maximum [Member] Business acquisition share price trading period Business Acquisition Share Price Trading Period Business Acquisition Share Price Trading Period Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Earning allocated to participation securities, diluted Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted Fourth Amended Loan Agreement Fourth Amended Loan Agreement [Member] Fourth Amended Loan Agreement Long-term debt with affiliate, net of current portion Notes and Loans, Noncurrent Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Total current assets Assets, Current Sports medicine/other Sports Medicine And Other [Member] Sports Medicine And Other [Member] Other intangible assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Indefinite lived intangible asset, measurement input (percent) Indefinite Lived Intangible Asset, Measurement Input Indefinite Lived Intangible Asset, Measurement Input Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Business Acquisition Business Acquisition [Line Items] Entity Small Business Entity Small Business Sample inventory Sample Inventory [Member] "Emerging Growth Company" and "Smaller Reporting Company" Reporting Requirements Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy [Policy Text Block] Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy Measurement Frequency [Domain] Measurement Frequency [Domain] Amortizable intangible assets, net Net Intangible Assets Finite-Lived Intangible Assets, Net Other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other Other intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Cost of Revenue Cost of Goods and Service [Policy Text Block] Impacted children Cumulative Children Impacted, Count Cumulative Children Impacted, Count Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Acquisition installment payable Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Title of Each Class Title of 12(b) Security Short term investments Short-Term Investments Restricted stock exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercisable Number Debt Instrument Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Operating lease liability Operating Lease, Liability BUSINESS SEGMENT Segment Reporting Disclosure [Text Block] Volatility factor Measurement Input, Price Volatility [Member] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Deferred tax liabilities Deferred Tax Liabilities, Net LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Treasury Bonds US Treasury Securities [Member] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Purchases of licenses Payments to Acquire Intangible Assets Forfeited or expired, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average shares outstanding Denominator for basic and diluted net income (loss) per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Fair value of identifiable intangible assets Intangible Assets Acquired Intangible Assets Acquired Net proceeds Sale of Stock, Consideration Received on Transaction Inventories, net Inventory, Net Accounts payable - trade Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] BUSINESS Nature of Operations [Text Block] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Basic (in shares) Weighted average shares outstanding for basic (in shares) Weighted Average Number of Shares Outstanding, Basic U.S. UNITED STATES Actual net income from acquired entities Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual Stock-based compensation expense Share-Based Payment Arrangement, Expense Sale of stock, consideration received on transaction, gross Sale Of Stock, Consideration Received On Transaction, Gross Sale Of Stock, Consideration Received On Transaction, Gross Name of each exchange on which registered Security Exchange Name Outstanding at period start, weighted-average exercise price (in dollars per share) Outstanding at period end, weighted-average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Remaining economic useful life (in years) Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Issuance of common shares in acquisition Stock Issued Restricted cash Restricted Cash, Current Restricted stock Restricted Stock Awards Restricted Stock [Member] Property, Plant and Equipment Property, Plant and Equipment [Line Items] Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Finite lived intangible asset useful life extension period (in years) Finite-Lived Intangible Asset, Useful Life Extension Period Finite-Lived Intangible Asset, Useful Life Extension Period Amount of Stock as consideration (in shares) Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Equity issuance cost Equity Issuance Cost Equity Issuance Cost Installment payment for ApiFix Repayments of Other Debt Long-term liabilities: Liabilities, Noncurrent [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases Lessee, Leases [Policy Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] STOCKHOLDERS' EQUITY Share-Based Payment Arrangement [Text Block] Deferred income taxes Increase (Decrease) in Deferred Income Taxes Segment Reporting [Abstract] Trauma and deformity Trauma And Deformity [Member] Interest expense, net Interest Income (Expense), Net Total liabilities and stockholders' equity Liabilities and Equity Accounts receivable - trade Increase (Decrease) in Accounts and Notes Receivable Team Note B Team Note B [Member] Team Note B Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Goodwill Goodwill [Roll Forward] Extinguishment of debt, amount Extinguishment of Debt, Amount Cash Cash International Non-US [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Acquisition of MD Ortho, net of cash acquired Cash paid to acquire Payments to Acquire Businesses, Net of Cash Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Total other assets Assets, Noncurrent, Excluding Property, Plant and Equipment Assets, Noncurrent, Excluding Property, Plant and Equipment Net income available to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Vesting [Axis] Vesting [Axis] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Diluted (in dollars per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Vesting Period Two Share-Based Payment Arrangement, Tranche Two [Member] Trademarks / Names Trademarks and Trade Names [Member] Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Payments of stock issuance costs Payments of Stock Issuance Costs Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Total current liabilities Liabilities, Current Intellectual Property Intellectual Property [Member] Entity Ex Transition Period Entity Ex Transition Period Corporate Bonds Corporate Debt Securities [Member] Earning allocated to participation securities, basic Participating Securities, Distributed and Undistributed Earnings (Loss), Basic Unused commitment fee percentage (as a percent) Line of Credit Facility, Commitment Fee Percentage Stock portion of ApiFix anniversary installment payment Stock Issued During Period, Value, Anniversary Installment Payment Stock Issued During Period, Value, Anniversary Installment Payment Entity Address, Address Line One Entity Address, Address Line One Long-term Purchase Commitment [Table] Long-Term Purchase Commitment [Table] Income Tax Authority [Domain] Income Tax Authority [Domain] Other assets: Other Assets, Noncurrent [Abstract] Products and Services [Axis] Product and Service [Axis] Impairment of indefinitely-lived tradename assets Impairment Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Class of Stock [Domain] Class of Stock [Domain] Reversal of valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Fair Value Disclosures [Abstract] Credit Facility [Axis] Credit Facility [Axis] Long-term Purchase Commitment Long-Term Purchase Commitment [Line Items] Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Shares available for award (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Other comprehensive income (loss): Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Vilex Vilex [Member] Vilex Issuance of unregistered shares (in shares) Stock Issued During Period, Shares, Other Trademark impairment Litigation Settlement, Expense Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Commitment fee Line of Credit Facility, Commitment Fee Amount Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Fair value of estimated total acquisition consideration Business Combination, Consideration Transferred Measurement Input Type [Axis] Measurement Input Type [Axis] Squadron Squadron [Member] Squadron City Area Code City Area Code General and administrative General and Administrative Expense ASSETS Assets [Abstract] Sales and Marketing Expenses Sales And Marketing Expense Policy [Policy Text Block] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Trademark impairment Impairment of Intangible Assets (Excluding Goodwill) Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Other Other Debt Obligations [Member] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Advertising Costs Advertising Cost [Policy Text Block] Estimated limitation on losses generated prior to ownership change date Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Variable Rate [Axis] Variable Rate [Axis] Other long-term liabilities Other Liabilities, Noncurrent Disposal Group Classification [Domain] Disposal Group Classification [Domain] Pega Medical Pega Medical [Member] Pega Medical Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Current portion of long-term debt with affiliate Long-term Debt, Current Maturities, Related Party Long-term Debt, Current Maturities, Related Party Escrow Escrow Deposit Purchase commitment, remaining minimum amount committed Purchase Commitment, Remaining Minimum Amount Committed Schedule of Reconciliation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] EX-101.PRE 10 kids-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - shares
 9 Months Ended
Sep. 30, 2022
Oct. 28, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-38242  
Entity Registrant Name OrthoPediatrics Corp  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-1761833  
Entity Address, Address Line One 2850 Frontier Drive  
Entity Address, City or Town Warsaw  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46582  
City Area Code 574  
Local Phone Number 268-6379  
Title of Each Class Common Stock, $0.00025 par value per share  
Trading Symbol(s) KIDS  
Name of each exchange on which registered NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   22,891,500
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Central Index Key 0001425450  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS
€ in Thousands, $ in Thousands
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Current assets:    
Cash $ 35,423 $ 7,641
Restricted cash 1,449 1,365
Short term investments 84,710 45,902
Accounts receivable - trade, less allowance for doubtful accounts of $608 and $347, respectively 26,184 17,942
Inventories, net 74,041 57,569
Prepaid expenses and other current assets 2,751 3,229
Total current assets 224,558 133,648
Property and equipment, net 36,313 28,515
Other assets:    
Amortizable intangible assets, net 66,285 55,494
Goodwill 88,044 72,349
Other intangible assets 14,854 14,268
Total other assets 169,183 142,111
Total assets 430,054 304,274
Current liabilities:    
Accounts payable - trade 10,881 9,325
Accrued compensation and benefits 6,323 5,351
Current portion of long-term debt with affiliate 143 137
Current portion of acquisition installment payable 7,630 12,862
Other current liabilities 3,769 2,040
Total current liabilities 28,746 29,715
Long-term liabilities:    
Long-term debt with affiliate, net of current portion 799 907
Acquisition installment payable, net of current portion 7,822 14,309
Contingent consideration 3,460 28,910
Deferred income taxes 5,457 4,771
Other long-term liabilities 440 293
Total long-term liabilities 17,978 49,190
Total liabilities 46,724 78,905
Stockholders' equity:    
Common stock, $0.00025 par value; 50,000,000 shares authorized; 22,896,031 shares and 19,677,214 shares issued as of September 30, 2022 (unaudited) and December 31, 2021, respectively 6 5
Additional paid-in capital 559,339 394,899
Accumulated deficit (168,920) (178,026)
Accumulated other comprehensive income (loss) (7,095) 8,491
Total stockholders' equity 383,330 225,369
Total liabilities and stockholders' equity $ 430,054 $ 304,274
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 608 $ 347
Common stock, par value (in dollars per share) $ 0.00025 $ 0.00025
Common stock, shares authorized (in shares) 50,000,000 50,000,000
Common stock, shares issued (in shares) 22,896,031 19,677,214
Common stock, shares outstanding (in shares) 22,896,031 19,677,214
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net revenue $ 34,950 $ 25,079 $ 91,295 $ 73,236
Cost of revenue 9,061 6,525 21,859 17,914
Gross profit 25,889 18,554 69,436 55,322
Operating expenses:        
Sales and marketing 11,919 9,862 34,108 29,687
General and administrative 15,116 11,034 42,829 34,163
Trademark impairment 3,609 0 3,609 0
Research and development 2,206 1,302 5,980 3,935
Total operating expenses 32,850 22,198 86,526 67,785
Operating loss (6,961) (3,644) (17,090) (12,463)
Other expenses (income):        
Interest expense, net 708 542 2,485 1,851
Fair value adjustment of contingent consideration (23,010) (1,430) (25,450) 3,710
Other expense (income) 945 (267) 1,668 (802)
Total other expenses (income) (21,357) (1,155) (21,297) 4,759
Income (loss) before income taxes 14,396 (2,489) 4,207 (17,222)
Provision for income taxes (benefit) (4,143) (292) (4,899) (890)
Net income (loss) $ 18,539 $ (2,197) $ 9,106 $ (16,332)
Weighted average shares outstanding        
Basic (in shares) 21,150,219 19,291,374 20,703,883 19,256,128
Diluted (in shares) 21,295,323 19,291,374 20,958,503 19,256,128
Net income (loss) per share        
Basic (in dollars per share) $ 0.88 $ (0.11) $ 0.44 $ (0.85)
Diluted (in dollars per share) $ 0.87 $ (0.11) $ 0.43 $ (0.85)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 18,539 $ (2,197) $ 9,106 $ (16,332)
Other comprehensive income (loss):        
Foreign currency translation adjustment (4,164) 288 (15,661) (1,343)
Unrealized loss on short-term investments (452) (88) (1,130) (282)
Adjustment for realized loss on securities 1,205 0 1,205 0
Other comprehensive income (loss), net of tax (3,411) 200 (15,586) (1,625)
Comprehensive income (loss) $ 15,128 $ (1,997) $ (6,480) $ (17,957)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2020 $ 234,768 $ 5 $ 388,622 $ (161,766) $ 7,907
Balance (in shares) at Dec. 31, 2020   19,560,291      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) (10,379)     (10,379)  
Other comprehensive income (loss) (3,622)       (3,622)
Stock option exercise 62   62    
Stock option exercise (in shares)   2,010      
Restricted stock 1,316   1,316    
Restricted stock (in shares)   97,111      
Balance at Mar. 31, 2021 222,145 $ 5 390,000 (172,145) 4,285
Balance (in shares) at Mar. 31, 2021   19,659,412      
Balance at Dec. 31, 2020 234,768 $ 5 388,622 (161,766) 7,907
Balance (in shares) at Dec. 31, 2020   19,560,291      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) (16,332)        
Other comprehensive income (loss) (1,625)        
Balance at Sep. 30, 2021 221,118 $ 5 392,929 (178,098) 6,282
Balance (in shares) at Sep. 30, 2021   19,672,162      
Balance at Mar. 31, 2021 222,145 $ 5 390,000 (172,145) 4,285
Balance (in shares) at Mar. 31, 2021   19,659,412      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) (3,756)     (3,756)  
Other comprehensive income (loss) 1,797       1,797
Restricted stock 1,415   1,415    
Restricted stock (in shares)   10,632      
Balance at Jun. 30, 2021 221,601 $ 5 391,415 (175,901) 6,082
Balance (in shares) at Jun. 30, 2021   19,670,044      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) (2,197)     (2,197)  
Other comprehensive income (loss) 200       200
Stock option exercise 75   75    
Stock option exercise (in shares)   2,412      
Restricted stock 1,439   1,439    
Restricted stock (in shares)   (294)      
Balance at Sep. 30, 2021 221,118 $ 5 392,929 (178,098) 6,282
Balance (in shares) at Sep. 30, 2021   19,672,162      
Balance at Dec. 31, 2021 $ 225,369 $ 5 394,899 (178,026) 8,491
Balance (in shares) at Dec. 31, 2021 19,677,214 19,677,214      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) $ (9,100)     (9,100)  
Other comprehensive income (loss) (2,751)       (2,751)
Restricted stock 1,526   1,526    
Restricted stock (in shares)   144,084      
Balance at Mar. 31, 2022 215,044 $ 5 396,425 (187,126) 5,740
Balance (in shares) at Mar. 31, 2022   19,821,298      
Balance at Dec. 31, 2021 $ 225,369 $ 5 394,899 (178,026) 8,491
Balance (in shares) at Dec. 31, 2021 19,677,214 19,677,214      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) $ 9,106        
Other comprehensive income (loss) (15,586)        
Consideration for MD Ortho and Pega Medical acquisition (in shares)   34,899,000      
Balance at Sep. 30, 2022 $ 383,330 $ 6 559,339 (168,920) (7,095)
Balance (in shares) at Sep. 30, 2022 22,896,031 22,896,031      
Balance at Mar. 31, 2022 $ 215,044 $ 5 396,425 (187,126) 5,740
Balance (in shares) at Mar. 31, 2022   19,821,298      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) (333)     (333)  
Other comprehensive income (loss) (9,424)       (9,424)
Stock option exercise 42   42    
Stock option exercise (in shares)   1,340      
Restricted stock 1,770   1,770    
Restricted stock (in shares)   57,180      
Consideration for MD Ortho acquisition 9,707   9,707    
Consideration for MD Ortho and Pega Medical acquisition (in shares)   173,241      
Stock portion of ApiFix anniversary installment payment 10,410   10,410    
Stock portion of ApiFix anniversary installment payment (in shares)   185,811      
Balance at Jun. 30, 2022 227,216 $ 5 418,354 (187,459) (3,684)
Balance (in shares) at Jun. 30, 2022   20,238,870      
Increase (Decrease) in Stockholders' Equity          
Net income (loss) 18,539     18,539  
Other comprehensive income (loss) (3,411)       (3,411)
Stock option exercise 21   21    
Stock option exercise (in shares)   670      
Restricted stock 1,682   1,682    
Restricted stock (in shares)   5,342      
Issuance of common stock, net of issuance cost 139,283 $ 1 139,282    
Issuance of common stock, net of issuance cost (in shares)   2,616,250      
Issuance of unregistered shares (in shares)   34,899      
Balance at Sep. 30, 2022 $ 383,330 $ 6 $ 559,339 $ (168,920) $ (7,095)
Balance (in shares) at Sep. 30, 2022 22,896,031 22,896,031      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
OPERATING ACTIVITIES    
Net income (loss) $ 9,106 $ (16,332)
Adjustments to reconcile net income (loss) to net cash used in operating activities:    
Depreciation and amortization 9,579 7,870
Stock-based compensation 4,978 4,170
Trademark impairment 3,609 0
Fair value adjustment of contingent consideration (25,450) 3,710
Acquisition installment payable 1,926 1,701
Deferred income taxes (4,804) (890)
Changes in certain current assets and liabilities:    
Accounts receivable - trade (5,567) (716)
Inventories (14,812) (3,244)
Prepaid expenses and other current assets 696 (138)
Accounts payable - trade (389) (956)
Accrued legal settlements 0 (6,342)
Accrued expenses and other liabilities 1,800 (168)
Other 903 (493)
Net cash used in operating activities (18,425) (11,828)
INVESTING ACTIVITIES    
Acquisition of MD Ortho, net of cash acquired (8,360) 0
Acquisition of Pega, net of cash acquired (31,730) 0
Sale of short-term marketable securities 45,529 4,000
Purchases of licenses 0 (7,908)
Purchase of short-term marketable securities (85,029) 0
Purchases of property and equipment (10,554) (6,468)
Net cash used in investing activities (90,144) (10,376)
FINANCING ACTIVITIES    
Proceeds from issuance of debt with affiliate 31,000 0
Payments on debt with affiliate (31,000) 0
Installment payment for ApiFix (3,234) 0
Proceeds from issuance of common stock, net of issuance costs 139,282 0
Proceeds from exercise of stock options 63 137
Payments on mortgage notes (102) (97)
Net cash provided by financing activities 136,009 40
Effect of exchange rate changes on cash 426 (266)
NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH 27,866 (22,430)
Cash and restricted cash, beginning of year 9,006 30,132
Cash and restricted cash, end of period 36,872 7,702
SUPPLEMENTAL DISCLOSURES    
Cash paid for interest 512 43
Transfer of instruments from property and equipment to inventory (193) 80
MD Orthopaedics    
SUPPLEMENTAL DISCLOSURES    
Issuance of common shares in acquisition 9,707 0
ApiFix Ltd    
SUPPLEMENTAL DISCLOSURES    
Issuance of common shares in acquisition $ 10,410 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BUSINESS BUSINESS
OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc®, PediPlates®, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc® Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSETM Spine, BandLocTM, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, Cerament® and ApiFix® Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation.

We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 613,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300,000 opportunity globally, including over $1,500,000 in the United States.

Our largest investor is Squadron Capital LLC, or Squadron, a private investment firm based in Granby, Connecticut.
A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. Since then, the pandemic has presented a significant public health and economic challenge around the world and has adversely impacted our business. Specifically, we have seen surgeons and their patients deferring elective procedures in which our products would have otherwise been used. The volatility in COVID cases and hospitalizations, including the impacts of the Delta variant in the third quarter of 2021 and the current hospital support staffing shortages in certain geographies, continue to drive volatility into our business. We continue to closely monitor developments related to the pandemic and the related staffing shortages and our decisions will continue to focus on the safety and security of our employees, distributors, surgeons and their patients while maintaining operations to support our customers. The full extent of the impact of the pandemic on our business is uncertain and cannot be accurately predicted and will depend on future developments that are also uncertain and cannot be predicted.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., Orthex, LLC, Telos Partners, LLC, ApiFix, Ltd., OrthoPediatrics Iowa Holdco, Inc., MD Orthopaedics, Inc.,
MD International Inc., OrthoPediatrics GMbH, OrthoPediatrics GP LLC, OrthoPediatrics US L.P. and OrthoPediatrics Canada ULC doing business as Pega Medical (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.

The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $168,920 and $178,026 as of September 30, 2022 and December 31, 2021, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short term investments, at September 30, 2022 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months.

On August 15, 2022, we completed a public offering of our common stock, in which we issued 1,091,250 shares of common stock at a public offering price of $55.00 per share and 1,525,000 pre-funded warrants to Squadron. The purchase price of each warrant was equal to the price per share at which the common shares were sold to the public, minus $0.00025, which was the exercise price of each warrant. The aggregate gross proceeds for both the warrants and common shares were $143,894. The total net proceeds from the offering were $139,282, after deducting $4,318 of underwriting discounts and commissions and paying $294 in offering costs. The Company has used $31,000 of the net proceeds to pay off the outstanding debt on the line of credit with Squadron. On September 20, 2022, the Company issued an aggregate of 1,525,000 shares of common stock to Squadron upon exercise of the pre-funded warrants.

Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an
inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.

Foreign Currency Transactions

We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense.

Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in July 2022, we established an operating company in Germany and in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss.

Revenue from Contracts with Customers

In accordance with ASC 606, "Revenue from Contracts with Customers," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the customer for surgeries or other treatment on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement.
Revenue Recognition – International

Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns.
Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when title passes upon shipment. Pricing for each customer is dictated by a unique pricing agreement.

Cash, Cash Equivalents and Short Term Investments

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value.

The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations.

Restricted Cash

In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the September 30, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 13 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 200 Euro at its Netherlands entity for potential Italian tenders.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.

The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.

Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other
standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.   

The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 5 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis.

Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.

In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.
Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years

Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses (including those acquired in the Band-Lok, MD Ortho and Pega transactions), the value of internally developed software (including by Orthex), and the value of acquired customer relationships and non-competition agreements (including in the Orthex, Telos, ApiFix, MD Ortho and Pega transactions, as applicable). Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period.

Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges were recorded in any of the periods presented.

Goodwill and Other Intangible Assets

Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such
a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No goodwill impairment charges were recorded in any period presented.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof.

We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022. No impairment charges were recorded in any other period presented.

Acquisition Payable and Contingent Consideration

Upon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. The amount of expense related to acquisition installment payables recorded in interest expense, net for the three and nine months ended September 30, 2022 were $381 and $1,926, respectively, and $489 and $1,701, respectively, for the same periods last year. The fair value adjustments of contingent consideration for the three and nine months ended September 30, 2022 were income adjustments of $23,010 and $25,450, respectively, and for the same periods last year, were an income adjustment of $1,430 and an expense adjustment of $3,710, respectively.

Cost of Revenue

Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.
Advertising Costs

Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.

Research and Development Costs

Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.

Stock-Based Compensation

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan"). The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.

Litigation and Contingencies

Accruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period.

Comprehensive Income (Loss)

Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments.
Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, we would make an adjustment to the valuation allowance.

We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.

“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to
qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company.

Recent Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08 "Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04 "Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments". The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS COMBINATIONS
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
BUSINESS COMBINATIONS BUSINESS COMBINATIONS
Pega Medical

On July 1, 2022, the Company, along with its newly-formed, indirect wholly-owned subsidiary OrthoPediatrics Canada ULC, purchased all of the issued and outstanding share capital of Pega Medical Inc., a corporation incorporated under the Canada Business Corporations Act (“Pega Medical”). Pega Medical has developed and sells a portfolio of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System, a well-recognized, innovative implant designed to treat bony deformities in children with osteogenesis imperfecta without disrupting their normal growth. Pega's product portfolio increases our total systems and increases the percentage of total trauma and deformity cases we can treat.

The Company acquired Pega Medical for approximately $32,045, comprised of $32,042 in cash and $3 in stock, representing the repurchase right price to be paid by the Company in the event a selling shareholder leaves employment with Pega Medical for certain reasons during the three-year period following the closing. Approximately $1,052 of the cash consideration was deposited into escrow and will be held for a period of up to eighteen (18) months to cover certain indemnification obligations of the selling shareholders of Pega Medical. Final purchase consideration is subject to certain working capital adjustments yet to be finalized. Additionally, 34,899 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $1,497 (based on the July 1, 2022 closing share price of $42.90) were issued to the selling shareholders. The common stock issued to the selling shareholders, excluding the value attributable to the repurchase right, is not considered part of the purchase consideration and is subject to a repurchase right previously mentioned. The Company will recognize expense over the three-year service period at which point the right to repurchase will expire. In the event the repurchase right is triggered, the Company will have the right to repurchase the shares of common stock issued to such selling shareholder at a price of $0.10 per share. Pursuant to the terms of the transaction, the Company also issued $499 in restricted stock units to employees of Pega Medical, which are subject to an approximate three-year vesting schedule. The restricted stock units are not considered part of the purchase consideration.

The following table summarizes the total consideration paid for Pega Medical and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:
Fair value of estimated total acquisition consideration$32,045 
Assets
Cash312 
Accounts receivable-trade2,100 
Inventories4,876 
Prepaid expenses and other current assets360 
Property and equipment604 
Amortizable intangible assets10,362 
Other intangible assets3,040 
Total assets21,654 
Liabilities
Accounts payable and accrued liabilities2,527 
Other current liabilities160 
Deferred tax liability3,305 
Total liabilities5,992 
Less: total net assets15,662 
Goodwill$16,383 

The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:

AmountRemaining Economic Useful Life
Trademarks / Names$3,040 Indefinite
Patents3,141 10 years
Customer Relationships & Other 7,221 15 years
$13,402 

The fair value estimates and purchase price allocation included above are preliminary while the Company finalizes fair value estimates of the acquired intangible assets and related tax considerations.


MD Orthopaedics

On April 1, 2022, OrthoPediatrics Iowa Holdco, Inc., a newly-formed, wholly-owned subsidiary of the Company, merged with and into MD Orthopaedics, Inc., an Iowa corporation (“MD Ortho”). MD Ortho has developed and manufactures a portfolio of orthopedic clubfoot products. The acquisition expands our total addressable market, serving as a specialty bracing platform company within our Trauma and Deformity business.

Under the terms of the related merger agreement, the Company paid to the indirect, sole shareholder of MD Ortho consideration of (a) $8,781 in cash, after adjusting for closing net working capital, and (b) 173,241 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $9,707 (based on the April 1, 2022 closing share price of $56.03). The Company incurred approximately $381 of acquisition-related costs, that are included in general and administrative expenses on the consolidated statement of operations for the nine months ended September 30, 2022.
The following table summarizes the total consideration paid for MD Ortho and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

Fair value of estimated total acquisition consideration$18,487 
Assets
Cash420 
Accounts receivable-trade1,062 
Inventories1,126 
Prepaid expenses and other current assets100 
Property and equipment2,444 
Amortizable intangible assets9,120 
Other intangible assets2,410 
Total assets16,682 
Liabilities
Accounts payable and accrued liabilities45 
Other current liabilities586 
Deferred tax liability3,014 
Total liabilities3,645 
Less: total net assets13,037 
Goodwill$5,450 

The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:

AmountRemaining Economic Useful Life
Trademarks / Names$2,410 Indefinite
Patents2,660 10 years
Customer Relationships6,460 15 years
$11,530 

The fair value estimates and purchase price allocation included above are preliminary while the Company finalizes fair value estimates of the acquired intangible assets and related tax considerations. During the third quarter ended September 30, 2022, the Company increased the deferred tax liability recorded as a result of the acquisition of MD Ortho based on newly obtained prior year tax information. This resulted in an increase to goodwill.

The following table represents the pro forma net revenue and net loss assuming the acquisitions of MD Ortho and Pega Medical occurred on January 1, 2021.

From the date of acquisition through September 30, 2022, combined revenue for the acquisitions was approximately $7,006 and combined net income was approximately $1,145.
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net Revenue$34,950 $29,680 $98,779 $86,544 
Net income (loss)$18,539 $(1,859)$10,013 $(13,576)
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
Goodwill

Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows:
Total
Goodwill at January 1, 2022$72,349 
MD Ortho acquisition5,450 
Pega Medical acquisition16,383 
Foreign currency translation impact(6,138)
Goodwill at September 30, 2022
$88,044 

Intangible Assets

As of September 30, 2022, the balances of intangible assets were as follows:
Amortizable intangible assetsWeighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationImpairmentNet Intangible Assets
Patents12.2 years$45,763 $(7,334)$— $38,429 
License Agreements4.9 years10,697 (3,342)— 7,355 
Customer Relationships & Other13.6 years17,170 (1,271)— 15,899 
Intellectual Property10.0 years5,859 (1,257)— 4,602 
Total amortizable assets$79,489 $(13,204)$— $66,285 
Other intangible assets
Trademark assetsIndefinite$18,463 $— $(3,609)$14,854 

As of December 31, 2021, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.7 years$44,493 $(5,664)$38,829 
Intellectual Property10.1 years9,847 (1,408)8,439 
License Agreements5.5 years10,674 (2,448)8,226 
Total amortizable assets$65,014 $(9,520)$55,494 

Licenses are tied to product launches and do not begin amortizing until the product is launched to the market.
Trademarks are non-amortizing intangible assets and are recorded in Other intangible assets on the condensed consolidated balance sheets.

During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the trademark assets is less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. The primary reason for the impairment is the lower forecasted revenue of our ApiFix product than previously expected and the subsequent impact to the discounted cash flow model utilized to calculate the fair value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022 to reduce the carrying amount of the intangible asset to its estimated fair value. Following the impairment, the newly calculated fair value becomes the new accounting basis and carrying value of the trademark. No impairment charges were recorded in any other period presented. The following table represents the significant unobservable inputs utilized in the calculation of estimated fair value associated with the ApiFix trademark asset:

September 30, 2022
Discount rate28.0 %
Estimated royalty rate5.0 %
Long term growth rate3.0 %

Changes in the carrying amount of trademark assets for the nine months ended September 30, 2022 were as follows:
Total
Trademark assets at January 1, 2022$14,268 
MD Ortho Acquisition2,410 
Pega Medical Acquisition3,040 
Trademark impairment(3,609)
Foreign currency translation impact(1,255)
Trademark assets at September 30, 2022
$14,854 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE OF FINANCIAL INSTRUMENTS
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE OF FINANCIAL INSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021.
September 30, 2022
Level 1Level 2Level 3Total
Financial Assets
Cash Equivalents$— $— $— $— 
Short term investments
Exchange Trade Mutual Funds$42,634 $— $42,634 
Corporate Bonds$9,680 $— $— $9,680 
Treasury Bonds$32,396 $— $— $32,396 
Asset Backed Securities$— $— $— $— 
Other$— $— $— $— 
Financial Liabilities
Contingent Consideration$— $— $3,460 $3,460 
December 31, 2021
Level 1Level 2Level 3Total
Financial Assets
Cash Equivalents$— $— $— $— 
Short term investments
Exchange Trade Mutual Funds$— $— $— $— 
Corporate Bonds$22,476 $— $— $22,476 
Treasury Bonds$14,317 $— $— $14,317 
Asset Backed Securities$— $8,272 $— $8,272 
Other$837 $— $— $837 
Financial Liabilities
Contingent Consideration$— $— $28,910 $28,910 

The Company's level 1 assets consist of short term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months.

The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date using an option pricing model and a Monte Carlo simulation based on forecasted annual revenue, expected volatility and discount rates. The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The adjustments in the fair value of the contingent consideration payments included an income adjustment of $23,010 and $1,430 for the three month periods ended September 30, 2022 and September 30, 2021, respectively, and an income adjustment of $25,450 and an expense adjustment of $3,710 for the nine month periods ended September 30, 2022 and September 30, 2021, respectively, in other expenses on the condensed consolidated statements of operations. For both the three and nine months ended September 30, 2022, the significant factor driving the reported fair value adjustment is the reduction in forecasted revenue which subsequently reduces the final expected payment.
The following table summarizes the change in fair value of Level 3 instruments in 2022:
Total
Balance at January 1, 2022
$28,910 
Change in fair value of contingent consideration(25,450)
Balance at September 30, 2022
$3,460 

The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of September 30, 2022 and December 31, 2021:
September 30, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
16.2 %18.4 %
Volatility factor46.5 %50.3 %
Expected years1.6 years2.4 years

(1) The present value discount rate includes estimated risk premium.
The estimated fair value reflects assumptions made by management as of September 30, 2022; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEBT AND CREDIT ARRANGEMENTS
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
DEBT AND CREDIT ARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS
Long-term debt consisted of the following:
September 30, 2022December 31, 2021
Mortgage payable to affiliate$942 $1,044 
Less: current maturities143 137 
Long-term debt with affiliate, net of current maturities$799 $907 

On June 13, 2022, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Fourth Amendment increased the amount available under the revolving credit facility from $25,000 to $50,000 in anticipation of using the facility to fund the cash portion of the Company’s July 1, 2022 acquisition of Pega Medical Inc. After borrowing $31,000 under the Loan Agreement in June 2022 to fund such acquisition, the Company repaid the entire amount on August 15, 2022 with proceeds from a public offering of securities. See Note 3 – Business Combinations for information relating to the acquisition and Note 8 – Stockholders’ Equity for information relating to the public offering.

The Loan Agreement provides a revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears.

Borrowings under the revolving credit facility are made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the
earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024.

Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions.

In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At September 30, 2022 the mortgage balance was $942 of which current principal of $143 was included in the current portion of long-term debt. As of December 31, 2021, the mortgage balance was $1,044 of which current principal due of $137 was included in the current portion of long-term debt.
The aggregate interest expense relating to the notes payable to Squadron and the mortgage note payable to Tawani was $12 and $14 for the three months ended September 30, 2022 and 2021, respectively, and $512 and $42 for the nine months ended September 30, 2022 and 2021, respectively. The unused commitment fee paid to Squadron was $44 and $32 for the three months ended September 30, 2022 and 2021, respectively, and $111 and $95 for the nine months ended September 30, 2022 and 2021, respectively.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss).

For the nine months ended September 30, 2022, the income tax benefit was $4,899 compared to $890 for the nine months ended September 30, 2021. Our effective income tax (benefit) rate was (116.5)% and 5.2% for the nine months ended September 30, 2022 and 2021, respectively.

The deferred tax assets were fully offset by a valuation allowance at September 30, 2022 and December 31, 2021, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix and Pega Medical. The company has recorded a tax benefit during the period ended September 30, 2022 for losses generated in the foreign jurisdiction. As of December 31, 2021, we had available federal, state and foreign tax loss carryforwards of $114,008, $73,997 and $22,671, respectively. We had available federal tax credits of $176. Net operating losses generated prior to December 31, 2017 will begin to expire in 2028. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $23,920 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062. A second ownership change under Section 382 was deemed to occur on December 11, 2018. The estimated annual limitation is $9,736, which is increased by $22,430 annually over the first five years as a result of an unrealized built in gain. NOLs sustained prior to May 30, 2014 will still be constrained by the lower limitation.
Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September 30, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. Management has reviewed the tax implications of the MD Ortho purchase accounting and recorded approximately $3,010 of deferred tax liabilities. This resulted in a decrease to the overall net US deferred tax assets, thereby causing a remeasurement of the valuation allowance during the quarter ended September 30, 2022, such that an approximately $3,010 of tax benefit was recorded for the reversal of the valuation allowance.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
Stock Options

The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.

Our stock option activity and related information are summarized as follows:
Weighted-AverageContractual Terms
OptionsExercise Pricein Years
Outstanding at January 1, 20226,638 $30.97 1.3
Exercised(2,010)30.97 
Forfeited or expired(1,072)— 
Outstanding at September 30, 2022
3,556 $30.97 0.9

Options generally include a time-based vesting schedule permitting the options to vest ratably over three years. At September 30, 2022 and December 31, 2021, all options were fully vested.

There was no stock-based compensation expense on stock options for the three and nine months ended September 30, 2022 and 2021, respectively.

Restricted Stock Awards & Restricted Stock Units

Our restricted stock activity and related information are summarized as follows:
Weighted-AverageWeighted-Average
RemainingRemaining
RestrictedContractual TermsRestrictedContractual Terms
Stock Awardsin YearsStock Unitsin Years
Outstanding at January 1, 2022368,446 1.1— —
Granted216,631 11,634 
Forfeited(10,025)— 
Vested(150,067)— 
Outstanding at September 30, 2022
424,985 1.711,634 2.8
Restricted stock exercisable at September 30, 2022
— — 
At September 30, 2022, there was $12,374 of unrecognized compensation expense remaining related to our service-based restricted stock awards and stock units. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 1.7 years or earlier upon an elimination of the restriction period as a result of a change in control event.

Stock-based compensation expense on restricted stock amounted to $1,682 and $1,440 for the three months ended September 30, 2022 and 2021, respectively, and $4,978 and $4,170 for the nine months ended September 30, 2022 and 2021, respectively. The increase in the stock compensation for the three and nine months ended September 30, 2022 is primarily due to increase in plan participants from acquired businesses and newly hired employees to support the continued expansion of our business.

During the three months ended September 30, 2022 the Company purchased all of the issued and outstanding share capital of Pega Medical Inc. See Note 3 - Business Combinations for additional detail. As a component of that acquisition, the Company issued 34,899 shares of unregistered common stock. The Company determined that these shares were not part of the purchase consideration and would recognize expense over three years. During the three months ended September 30, 2022 the Company recognized expense of $133 associated with these shares.
During the three months ended September 30, 2022 the Company completed a following-on offering in which we issued 1,525,000 of pre-funded warrants to Squadron. The warrants had an exercise price of $0.00025. All warrants issued in the quarter were exercised and included in our outstanding common stock as of and during the three months ended September 30, 2022. As of September 30, 2022 and 2021 the Company had no warrants outstanding.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER SHARE
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
The following is a reconciliation of basic and diluted net loss per share:
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Net income (loss)$18,539 $(2,197)$9,106 $(16,332)
Less: Earnings allocated to participating securities353 — 174 — 
Net income available to common shareholders18,186 (2,197)8,932 (16,332)
Denominator for basic and diluted net income (loss) per share:
Weighted average shares outstanding for basic21,150,219 19,291,374 20,703,883 19,256,128 
Weighted average shares outstanding for diluted21,295,323 19,291,374 20,958,503 19,256,128 
Earnings (loss) per share:
Basic $0.88 $(0.11)$0.44 $(0.85)
Diluted$0.87 $(0.11)$0.43 $(0.85)

Our basic and diluted net loss per share is computed using the two-class method.  For purposes of our equity disclosures and calculation of weighted average shares for basic earnings per share calculations, the two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. For the periods presented with a net loss the weighted average shares outstanding remains consistent between basic and diluted as the effect would have been anti-dilutive.
The following table shows the contingently issuable and convertible equity shares that were excluded from the calculation of diluted net earnings (loss) per share because their effect would have been anti-dilutive:
Nine Months Ended September 30,
20222021
Restricted stock— 375,915 
Stock options— 6,638 
Total shares— 382,553 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS SEGMENT
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
BUSINESS SEGMENT BUSINESS SEGMENT
Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography.

Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No customers accounted for more than 10% of total product sales for the three and nine months ended September 30, 2022 or 2021. No customer accounted for more than 10% of consolidated accounts receivable as of September 30, 2022 and December 31, 2021.

Product sales by source were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by geographic location:2022202120222021
U.S.$26,539 $19,354 $69,687 $57,930 
International8,411 5,725 21,608 15,306 
Total$34,950 $25,079 $91,295 $73,236 
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by category:2022202120222021
Trauma and deformity$23,892 $16,817 $62,976 $49,302 
Scoliosis9,979 7,266 25,383 20,874 
Sports medicine/other1,079 996 2,936 3,060 
Total$34,950 $25,079 $91,295 $73,236 
No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three and nine months ended September 30, 2022 and 2021.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS
In addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $218 and $173 for the three months ended September 30, 2022 and 2021, respectively, and $768 and $441 for the nine months ended September 30, 2022 and 2021, respectively.
On December 31, 2019, the Company divested Vilex for $25,000 to an affiliate of Squadron. In conjunction with the divestiture, the Company also entered into an exclusive perpetual license agreement to permit the purchasers of Vilex the ability to access intellectual property and sell products using the external fixation technology of Orthex, LLC to non-pediatric accounts. We had sales and payments related to inventory purchases to Squadron's affiliate, now known as Vilex, LLC, of $51 and $7, respectively, for the three months ended September 30, 2022, and sales and payments of $111 and $39, respectively, for the nine months ended September 30, 2022. We had sales and payments related to inventory purchases to Vilex, LLC of $45 and $150, respectively, for the three months ended September 30, 2021, and sales and payments of $200 and $675, respectively, for the nine months ended September 30, 2021.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
EMPLOYEE BENEFIT PLAN
 9 Months Ended
Sep. 30, 2022
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. Additionally, employees of MD Ortho receive contribution matches up to 3% of their salary.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Leases

As of September 30, 2022, the Company has recorded a lease liability of $303 and corresponding right-of-use-asset of $304 on its condensed consolidated balance sheet.

Legal Proceedings

From time to time, we are involved in various legal proceedings arising in the ordinary course of our business.

IMED Surgical - Software Ownership Dispute

On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron Capital, LLC (“Squadron”), and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company (the “Plaintiff”), in Broward County, Florida Circuit Court. In the lawsuit, the Plaintiff claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic
surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).

In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point & Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent. According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with the Plaintiff.

The Plaintiff, among other things, requests that the defendants be ordered to convey and assign to Plaintiff all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants.

On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent the Plaintiff desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, the Plaintiff initiated an arbitration proceeding; however, the Plaintiff failed to pay the fees it was required to pay for the arbitration to continue, resulting in the arbitration panel terminating the arbitration proceedings in mid-October 2022. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to the Plaintiff before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order.

Although we believe the IMED lawsuit is without merit and will vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.


Wishbone Medical, Inc. – Patent Infringement Litigation

On October 30, 2020, OrthoPediatrics, along with its wholly-owned subsidiary, Orthex, LLC, filed a lawsuit in federal district court (N.D. Indiana, South Bend Division, Case No. 3:20-cv-00929) against Wishbone Medical, Inc. and Nick A. Deeter (collectively “Wishbone”), claiming infringement of ’377 Patent, unfair competition, false advertising, breach of contract, defamation per se, tortious interference with contractual relationships, and tortious interference with prospective contractual relationships. In early January 2021, OrthoPediatrics amended its lawsuit by adding a declaratory judgment claim of infringement of the ‘377 Patent against Wishbone.

Thereafter, in January 2021, Wishbone filed a motion to dismiss all OrthoPediatrics’ causes of action. In late August 2021, the Court denied Wishbone's motion to dismiss with respect to OrthoPediatrics’ infringement and breach of contract claims and dismissed OrthoPediatrics' remaining causes of action. In late September 2021, Wishbone filed its answer and counterclaims, in part, seeking declaratory judgment of non-infringement and invalidity of the ‘377 Patent, and alleging OrthoPediatrics patent infringement claim(s) against Wishbone was made in bad faith. In mid-October 2021, OrthoPediatrics filed its answer to Wishbone’s counterclaims, denying all of them. Although we believe Wishbone’s counterclaims are
without merit and will vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have an adverse effect on our business, operating results and financial condition.

We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.

Purchase Obligations and Performance Requirements

As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASHTM Navigation platform, the Company has agreed to a minimum purchase commitment for the first twelve months of that agreement. As of September 30, 2022, the remaining purchase commitment under the agreement was $0.

On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three and nine months ended September 30, 2022, the Company recorded an expense of $101 and $442, respectively. No expense was recorded for either the three or nine months ended September 30, 2021.

Royalties

As of September 30, 2022, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales.
We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of September 30, 2022, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements
Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., Orthex, LLC, Telos Partners, LLC, ApiFix, Ltd., OrthoPediatrics Iowa Holdco, Inc., MD Orthopaedics, Inc.,
MD International Inc., OrthoPediatrics GMbH, OrthoPediatrics GP LLC, OrthoPediatrics US L.P. and OrthoPediatrics Canada ULC doing business as Pega Medical (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated.

Unaudited Interim Condensed Consolidated Financial Statements

We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder.

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period.
The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern.
Use of Estimates
Use of Estimates

Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an
inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements.
Foreign Currency Transactions
Foreign Currency Transactions

We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense.
Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in July 2022, we established an operating company in Germany and in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss.
Revenue Recognition - United States and International
Revenue from Contracts with Customers

In accordance with ASC 606, "Revenue from Contracts with Customers," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities.

Revenue Recognition – United States

Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the customer for surgeries or other treatment on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement.
Revenue Recognition – International

Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns.
Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally.
Cash and Cash Equivalents and Short Term Investments
Cash, Cash Equivalents and Short Term Investments

We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value.

The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations.

Restricted Cash
In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the September 30, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 13 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 200 Euro at its Netherlands entity for potential Italian tenders.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.
The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts.
Fair Value of Financial Instruments
Fair Value of Financial Instruments

The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other
standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and

Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.   
The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 5 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis.
Inventories, net
Inventories, net

Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods.

We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.

The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.
In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future.
Property and Equipment, net
Property and Equipment, net

Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred.

Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.

Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation.

Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years
Amortizable Intangible Assets, net
Amortizable Intangible Assets, net

Amortizable intangible assets include fees necessary to secure various patents and licenses (including those acquired in the Band-Lok, MD Ortho and Pega transactions), the value of internally developed software (including by Orthex), and the value of acquired customer relationships and non-competition agreements (including in the Orthex, Telos, ApiFix, MD Ortho and Pega transactions, as applicable). Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period.
Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets.
Goodwill and Other Intangible Assets
Goodwill and Other Intangible Assets

Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such
a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No goodwill impairment charges were recorded in any period presented.

The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof.
We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022. No impairment charges were recorded in any other period presented.
Acquisition Payable and Contingent Consideration Acquisition Payable and Contingent ConsiderationUpon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations.
Cost of Revenue Cost of RevenueCost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States.
Sales and Marketing Expenses Sales and Marketing ExpensesSales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors.
Advertising Costs Advertising Costs Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense.
Research and Development Costs Research and Development CostsResearch and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense.
Stock-Based Compensation
Stock-Based Compensation

Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan"). The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award.

Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.

Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures.

We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.
Litigation and Contingencies Litigation and ContingenciesAccruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period.
Comprehensive Income (Loss) Comprehensive Income (Loss)Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments.
Income Taxes ncome Taxes
We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, we would make an adjustment to the valuation allowance.
We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.
Leases
Leases

At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease.

The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.
"Emerging Growth Company" and "Smaller Reporting Company" Reporting Requirements
“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements

We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.

Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to
qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

In October 2021, the FASB issued ASU No. 2021-08 "Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers". The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.

In May 2021, the FASB issued ASU No. 2021-04 "Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13 "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments". The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Property and Equipment, Depreciable Lives Sample inventory is carried at cost less accumulated depreciation. Depreciable lives are generally as follows:
Building and building improvements
25 to 30 years
Furniture and fixtures
5 to 7 years
Computer equipment
3 to 5 years
Business software
3 years
Office and other equipment
5 to 7 years
Instruments
5 years
Sample inventory
2 years
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS COMBINATIONS (Tables)
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The following table summarizes the total consideration paid for Pega Medical and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:
Fair value of estimated total acquisition consideration$32,045 
Assets
Cash312 
Accounts receivable-trade2,100 
Inventories4,876 
Prepaid expenses and other current assets360 
Property and equipment604 
Amortizable intangible assets10,362 
Other intangible assets3,040 
Total assets21,654 
Liabilities
Accounts payable and accrued liabilities2,527 
Other current liabilities160 
Deferred tax liability3,305 
Total liabilities5,992 
Less: total net assets15,662 
Goodwill$16,383 
The following table summarizes the total consideration paid for MD Ortho and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:

Fair value of estimated total acquisition consideration$18,487 
Assets
Cash420 
Accounts receivable-trade1,062 
Inventories1,126 
Prepaid expenses and other current assets100 
Property and equipment2,444 
Amortizable intangible assets9,120 
Other intangible assets2,410 
Total assets16,682 
Liabilities
Accounts payable and accrued liabilities45 
Other current liabilities586 
Deferred tax liability3,014 
Total liabilities3,645 
Less: total net assets13,037 
Goodwill$5,450 
Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combinations
The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:

AmountRemaining Economic Useful Life
Trademarks / Names$3,040 Indefinite
Patents3,141 10 years
Customer Relationships & Other 7,221 15 years
$13,402 
The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows:

AmountRemaining Economic Useful Life
Trademarks / Names$2,410 Indefinite
Patents2,660 10 years
Customer Relationships6,460 15 years
$11,530 
Schedule of Pro Forma Net Revenue and Net Loss
The following table represents the pro forma net revenue and net loss assuming the acquisitions of MD Ortho and Pega Medical occurred on January 1, 2021.

From the date of acquisition through September 30, 2022, combined revenue for the acquisitions was approximately $7,006 and combined net income was approximately $1,145.
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Net Revenue$34,950 $29,680 $98,779 $86,544 
Net income (loss)$18,539 $(1,859)$10,013 $(13,576)
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS (Tables)
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows:
Total
Goodwill at January 1, 2022$72,349 
MD Ortho acquisition5,450 
Pega Medical acquisition16,383 
Foreign currency translation impact(6,138)
Goodwill at September 30, 2022
$88,044 
Schedule of Fair Value Measurement Inputs and Valuation Techniques The following table represents the significant unobservable inputs utilized in the calculation of estimated fair value associated with the ApiFix trademark asset:
September 30, 2022
Discount rate28.0 %
Estimated royalty rate5.0 %
Long term growth rate3.0 %
The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of September 30, 2022 and December 31, 2021:
September 30, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
16.2 %18.4 %
Volatility factor46.5 %50.3 %
Expected years1.6 years2.4 years

(1) The present value discount rate includes estimated risk premium.
Schedule of Finite-Lived Intangible Assets
As of September 30, 2022, the balances of intangible assets were as follows:
Amortizable intangible assetsWeighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationImpairmentNet Intangible Assets
Patents12.2 years$45,763 $(7,334)$— $38,429 
License Agreements4.9 years10,697 (3,342)— 7,355 
Customer Relationships & Other13.6 years17,170 (1,271)— 15,899 
Intellectual Property10.0 years5,859 (1,257)— 4,602 
Total amortizable assets$79,489 $(13,204)$— $66,285 
Other intangible assets
Trademark assetsIndefinite$18,463 $— $(3,609)$14,854 

As of December 31, 2021, the balances of amortizable intangible assets were as follows:
Weighted-Average Amortization PeriodGross Intangible AssetsAccumulated AmortizationNet Intangible Assets
Patents13.7 years$44,493 $(5,664)$38,829 
Intellectual Property10.1 years9,847 (1,408)8,439 
License Agreements5.5 years10,674 (2,448)8,226 
Total amortizable assets$65,014 $(9,520)$55,494 
Changes in the carrying amount of trademark assets for the nine months ended September 30, 2022 were as follows:
Total
Trademark assets at January 1, 2022$14,268 
MD Ortho Acquisition2,410 
Pega Medical Acquisition3,040 
Trademark impairment(3,609)
Foreign currency translation impact(1,255)
Trademark assets at September 30, 2022
$14,854 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021.
September 30, 2022
Level 1Level 2Level 3Total
Financial Assets
Cash Equivalents$— $— $— $— 
Short term investments
Exchange Trade Mutual Funds$42,634 $— $42,634 
Corporate Bonds$9,680 $— $— $9,680 
Treasury Bonds$32,396 $— $— $32,396 
Asset Backed Securities$— $— $— $— 
Other$— $— $— $— 
Financial Liabilities
Contingent Consideration$— $— $3,460 $3,460 
December 31, 2021
Level 1Level 2Level 3Total
Financial Assets
Cash Equivalents$— $— $— $— 
Short term investments
Exchange Trade Mutual Funds$— $— $— $— 
Corporate Bonds$22,476 $— $— $22,476 
Treasury Bonds$14,317 $— $— $14,317 
Asset Backed Securities$— $8,272 $— $8,272 
Other$837 $— $— $837 
Financial Liabilities
Contingent Consideration$— $— $28,910 $28,910 
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation The following table summarizes the change in fair value of Level 3 instruments in 2022:
Total
Balance at January 1, 2022
$28,910 
Change in fair value of contingent consideration(25,450)
Balance at September 30, 2022
$3,460 
Schedule of Fair Value Measurement Inputs and Valuation Techniques The following table represents the significant unobservable inputs utilized in the calculation of estimated fair value associated with the ApiFix trademark asset:
September 30, 2022
Discount rate28.0 %
Estimated royalty rate5.0 %
Long term growth rate3.0 %
The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of September 30, 2022 and December 31, 2021:
September 30, 2022December 31, 2021
Valuation techniquesDiscounted cash flow, Monte Carlo
Present value discount rate(1)
16.2 %18.4 %
Volatility factor46.5 %50.3 %
Expected years1.6 years2.4 years

(1) The present value discount rate includes estimated risk premium.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEBT AND CREDIT ARRANGEMENTS (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Long-term debt consisted of the following:
September 30, 2022December 31, 2021
Mortgage payable to affiliate$942 $1,044 
Less: current maturities143 137 
Long-term debt with affiliate, net of current maturities$799 $907 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity Our stock option activity and related information are summarized as follows:
Weighted-AverageContractual Terms
OptionsExercise Pricein Years
Outstanding at January 1, 20226,638 $30.97 1.3
Exercised(2,010)30.97 
Forfeited or expired(1,072)— 
Outstanding at September 30, 2022
3,556 $30.97 0.9
Schedule of Restricted Stock Awards & Restricted Stock Units Our restricted stock activity and related information are summarized as follows:
Weighted-AverageWeighted-Average
RemainingRemaining
RestrictedContractual TermsRestrictedContractual Terms
Stock Awardsin YearsStock Unitsin Years
Outstanding at January 1, 2022368,446 1.1— —
Granted216,631 11,634 
Forfeited(10,025)— 
Vested(150,067)— 
Outstanding at September 30, 2022
424,985 1.711,634 2.8
Restricted stock exercisable at September 30, 2022
— — 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER SHARE (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Reconciliation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders The following is a reconciliation of basic and diluted net loss per share:
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Net income (loss)$18,539 $(2,197)$9,106 $(16,332)
Less: Earnings allocated to participating securities353 — 174 — 
Net income available to common shareholders18,186 (2,197)8,932 (16,332)
Denominator for basic and diluted net income (loss) per share:
Weighted average shares outstanding for basic21,150,219 19,291,374 20,703,883 19,256,128 
Weighted average shares outstanding for diluted21,295,323 19,291,374 20,958,503 19,256,128 
Earnings (loss) per share:
Basic $0.88 $(0.11)$0.44 $(0.85)
Diluted$0.87 $(0.11)$0.43 $(0.85)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share The following table shows the contingently issuable and convertible equity shares that were excluded from the calculation of diluted net earnings (loss) per share because their effect would have been anti-dilutive:
Nine Months Ended September 30,
20222021
Restricted stock— 375,915 
Stock options— 6,638 
Total shares— 382,553 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS SEGMENT (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Product Sales by Geographic Location Product sales by source were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by geographic location:2022202120222021
U.S.$26,539 $19,354 $69,687 $57,930 
International8,411 5,725 21,608 15,306 
Total$34,950 $25,079 $91,295 $73,236 
Schedule of Product Sales by Category
Three Months Ended September 30,Nine Months Ended September 30,
Product sales by category:2022202120222021
Trauma and deformity$23,892 $16,817 $62,976 $49,302 
Scoliosis9,979 7,266 25,383 20,874 
Sports medicine/other1,079 996 2,936 3,060 
Total$34,950 $25,079 $91,295 $73,236 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS (Details)
children in Thousands, $ in Thousands
Sep. 30, 2022
USD ($)
children
Business Acquisition  
Impacted children | children 613
Estimated market portion opportunities $ 3,300
U.S.  
Business Acquisition  
Estimated market portion opportunities $ 1,500
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) - USD ($)
 3 Months Ended
Sep. 20, 2022
Aug. 15, 2022
Sep. 30, 2022
Dec. 31, 2021
Class of Stock [Line Items]        
Accumulated deficit     $ (168,920,000) $ (178,026,000)
Common Stock        
Class of Stock [Line Items]        
Equity issuance cost     $ 133,000  
Public Offering        
Class of Stock [Line Items]        
Sale of stock, consideration received on transaction, gross   $ 143,894,000    
Net proceeds   $ 139,282,000    
Public Offering | Common Stock        
Class of Stock [Line Items]        
Common stock issued and sold (in shares) 1,525,000 1,091,250    
Warrants and rights outstanding   $ 1,525,000    
Warrants exercise price (in dollars per share)   $ 0.00025    
Equity issuance cost   $ 4,318,000    
Payments of stock issuance costs   294,000    
Extinguishment of debt, amount   $ 31,000,000    
IPO | Common Stock        
Class of Stock [Line Items]        
Public offering price (in dollars per share)   $ 55    
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)
€ in Thousands, $ in Thousands
Sep. 30, 2022
USD ($)
Sep. 30, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Accounting Policies [Abstract]      
Escrow $ 1,250   $ 1,250
Restricted cash $ 1,449 € 200 $ 1,365
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)
 9 Months Ended
Sep. 30, 2022
Building and building improvements | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 25 years
Building and building improvements | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 30 years
Furniture and fixtures | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Furniture and fixtures | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 7 years
Computer equipment | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 3 years
Computer equipment | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Business software  
Property, Plant and Equipment  
Depreciable lives (in years) 3 years
Office and other equipment | Minimum  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Office and other equipment | Maximum  
Property, Plant and Equipment  
Depreciable lives (in years) 7 years
Instruments  
Property, Plant and Equipment  
Depreciable lives (in years) 5 years
Sample inventory  
Property, Plant and Equipment  
Depreciable lives (in years) 2 years
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Finite-Lived Intangible Assets        
Impairment $ 0 $ 0 $ 0 $ 0
Minimum        
Finite-Lived Intangible Assets        
Intangible asset, useful life (in years)     3 years  
Maximum        
Finite-Lived Intangible Assets        
Intangible asset, useful life (in years)     20 years  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accounting Policies [Abstract]        
Impairment of indefinitely-lived tradename assets $ 3,609,000 $ 0 $ 0 $ 0
Trademark impairment $ 3,609,000 $ 0 $ 3,609,000 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accounting Policies [Abstract]        
Acquisition installment payable $ 381 $ 489 $ 1,926 $ 1,701
Fair value adjustment of contingent consideration $ (23,010) $ (1,430) $ (25,450) $ 3,710
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award        
Options granted (in shares) 0 0 0 0
Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award        
Vesting period (in years)     3 years  
Options granted (in shares)     0 0
Restricted stock        
Share-based Compensation Arrangement by Share-based Payment Award        
Vesting period (in years)     3 years  
Restricted stock | Vesting Period One        
Share-based Compensation Arrangement by Share-based Payment Award        
Vesting period (in years)     6 years  
Restricted stock | Vesting Period Two        
Share-based Compensation Arrangement by Share-based Payment Award        
Vesting period (in years)     6 months  
Maximum | Stock Option        
Share-based Compensation Arrangement by Share-based Payment Award        
Vesting period (in years)     3 years  
2017 Plan        
Share-based Compensation Arrangement by Share-based Payment Award        
Shares available for award (in shares) 1,832,460   1,832,460  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS COMBINATIONS - Pega Medical and MD Orthopaedics (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 9 Months Ended
Jul. 01, 2022
Apr. 01, 2022
Sep. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Business Acquisition            
Cash paid to acquire       $ 8,360 $ 0  
Common stock, par value (in dollars per share)     $ 0.00025 $ 0.00025   $ 0.00025
Actual revenue from acquired entities     $ 7,006      
Actual net income from acquired entities     $ 1,145      
Pega Medical            
Business Acquisition            
Fair value of estimated total acquisition consideration $ 32,045          
Cash paid to acquire 32,042          
Amount of Stock as consideration (in shares) $ 3          
Business acquisition share price trading period 3 years          
Contingent Consideration $ 1,052          
Contingent consideration liability term 18 months          
Contingent repurchase price, per share (in dollars per share) $ 0.1          
Pega Medical | Common Stock            
Business Acquisition            
Consideration for acquisition (in shares) 34,899,000          
Common stock, par value (in dollars per share) $ 0.00025          
Issuance of common stock $ 1,497          
Common stock (in dollars per share) $ 42.9          
Pega Medical | Restricted Stock Units (RSUs)            
Business Acquisition            
Issuance of common stock $ 499          
Vesting period (in years) 3 years          
MD Orthopaedics            
Business Acquisition            
Fair value of estimated total acquisition consideration   $ 18,487        
Cash paid to acquire   $ 8,781        
Consideration for acquisition (in shares)   173,241        
Common stock, par value (in dollars per share)   $ 0.00025        
Issuance of common stock   $ 9,707        
Common stock (in dollars per share)   $ 56.03        
Acquisition related costs   $ 381        
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS COMBINATIONS - Assets acquired and liabilities assumed (Details) - USD ($)
$ in Thousands
Jul. 01, 2022
Apr. 01, 2022
Sep. 30, 2022
Dec. 31, 2021
Liabilities        
Goodwill     $ 88,044 $ 72,349
Pega Medical        
Business Acquisition        
Fair value of estimated total acquisition consideration $ 32,045      
Assets        
Cash 312      
Accounts receivable-trade 2,100      
Inventories 4,876      
Prepaid expenses and other current assets 360      
Property and equipment 604      
Amortizable intangible assets 10,362      
Other intangible assets 3,040      
Total assets 21,654      
Liabilities        
Accounts payable and accrued liabilities 2,527      
Other current liabilities 160      
Deferred tax liability 3,305      
Total liabilities 5,992      
Less: total net assets 15,662      
Goodwill $ 16,383      
MD Orthopaedics        
Business Acquisition        
Fair value of estimated total acquisition consideration   $ 18,487    
Assets        
Cash   420    
Accounts receivable-trade   1,062    
Inventories   1,126    
Prepaid expenses and other current assets   100    
Property and equipment   2,444    
Amortizable intangible assets   9,120    
Other intangible assets   2,410    
Total assets   16,682    
Liabilities        
Accounts payable and accrued liabilities   45    
Other current liabilities   586    
Deferred tax liability   3,014    
Total liabilities   3,645    
Less: total net assets   13,037    
Goodwill   $ 5,450    
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS COMBINATIONS - Estimated fair value and useful life of identifiable intangible assets (Details) - USD ($)
$ in Thousands
Jul. 01, 2022
Apr. 01, 2022
MD Orthopaedics    
Business Acquisition    
Fair value of identifiable intangible assets   $ 11,530
MD Orthopaedics | Patents    
Business Acquisition    
Finite-lived intangible assets acquired   $ 2,660
Remaining economic useful life (in years)   10 years
MD Orthopaedics | Customer Relationships    
Business Acquisition    
Finite-lived intangible assets acquired   $ 6,460
Remaining economic useful life (in years)   15 years
MD Orthopaedics | Trademarks / Names    
Business Acquisition    
Indefinite-lived intangible assets acquired   $ 2,410
Pega Medical    
Business Acquisition    
Fair value of identifiable intangible assets $ 13,402  
Pega Medical | Patents    
Business Acquisition    
Finite-lived intangible assets acquired $ 3,141  
Remaining economic useful life (in years) 10 years  
Pega Medical | Customer Relationships    
Business Acquisition    
Finite-lived intangible assets acquired   $ 7,221
Remaining economic useful life (in years)   15 years
Pega Medical | Trademarks / Names    
Business Acquisition    
Indefinite-lived intangible assets acquired $ 3,040  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS COMBINATIONS - Schedule of pro forma net revenue and net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]        
Pro forma net revenue $ 34,950 $ 29,680 $ 98,779 $ 86,544
Pro forma net income (loss) $ 18,539 $ (1,859) $ 10,013 $ (13,576)
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
USD ($)
Goodwill  
Goodwill, beginning balance $ 72,349
Foreign currency translation impact (6,138)
Goodwill, ending balance 88,044
MD Orthopaedics  
Goodwill  
Goodwill acquired 5,450
Pega Medical  
Goodwill  
Goodwill acquired $ 16,383
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Finite-Lived Intangible Assets          
Gross Intangible Assets $ 79,489,000   $ 79,489,000   $ 65,014,000
Accumulated Amortization (13,204,000)   (13,204,000)   (9,520,000)
Impairment 0 $ 0 0 $ 0  
Net Intangible Assets 66,285,000   66,285,000   55,494,000
Other intangible assets          
Impairment (3,609,000) $ 0 0 $ 0  
Non-amortizing intangible assets 14,854,000   14,854,000   14,268,000
Trademarks Assets          
Other intangible assets          
Gross Intangible Assets 18,463,000   18,463,000    
Impairment     (3,609,000)    
Non-amortizing intangible assets 14,854,000   $ 14,854,000   $ 14,268,000
Patents          
Finite-Lived Intangible Assets          
Weighted-Average Amortization Period     12 years 2 months 12 days   13 years 8 months 12 days
Gross Intangible Assets 45,763,000   $ 45,763,000   $ 44,493,000
Accumulated Amortization (7,334,000)   (7,334,000)   (5,664,000)
Impairment     0    
Net Intangible Assets 38,429,000   $ 38,429,000   $ 38,829,000
License Agreements          
Finite-Lived Intangible Assets          
Weighted-Average Amortization Period     4 years 10 months 24 days   5 years 6 months
Gross Intangible Assets 10,697,000   $ 10,697,000   $ 10,674,000
Accumulated Amortization (3,342,000)   (3,342,000)   (2,448,000)
Impairment     0    
Net Intangible Assets 7,355,000   $ 7,355,000   $ 8,226,000
Customer Relationships & Other          
Finite-Lived Intangible Assets          
Weighted-Average Amortization Period     13 years 7 months 6 days    
Gross Intangible Assets 17,170,000   $ 17,170,000    
Accumulated Amortization (1,271,000)   (1,271,000)    
Impairment     0    
Net Intangible Assets 15,899,000   $ 15,899,000    
Intellectual Property          
Finite-Lived Intangible Assets          
Weighted-Average Amortization Period     10 years   10 years 1 month 6 days
Gross Intangible Assets 5,859,000   $ 5,859,000   $ 9,847,000
Accumulated Amortization (1,257,000)   (1,257,000)   (1,408,000)
Impairment     0    
Net Intangible Assets $ 4,602,000   $ 4,602,000   $ 8,439,000
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS - Estimated Fair Value (Details) - Trademarks
Sep. 30, 2022
USD ($)
Discount rate  
Schedule of Finite-Lived Intangible Assets  
Indefinite lived intangible asset, measurement input (percent) 0.280
Estimated royalty rate  
Schedule of Finite-Lived Intangible Assets  
Indefinite lived intangible asset, measurement input (percent) 0.050
Long term growth rate  
Schedule of Finite-Lived Intangible Assets  
Indefinite lived intangible asset, measurement input (percent) 0.030
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]          
Other intangible assets $ 14,854,000   $ 14,854,000   $ 14,268,000
Impairment of indefinitely-lived tradename assets $ 3,609,000 $ 0 $ 0 $ 0  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
GOODWILL AND INTANGIBLE ASSETS - Trademark Assets (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Indefinite-Lived Intangible Assets        
Beginning balance     $ 14,268,000  
Impairment $ (3,609,000) $ 0 0 $ 0
Ending balance 14,854,000   14,854,000  
Trademarks        
Indefinite-Lived Intangible Assets        
Beginning balance     14,268,000  
Impairment     (3,609,000)  
Foreign currency translation impact     (1,255,000)  
Ending balance $ 14,854,000   14,854,000  
Trademarks | MD Orthopaedics        
Indefinite-Lived Intangible Assets        
Indefinite-lived intangible assets acquired     2,410,000  
Trademarks | Pega Medical        
Indefinite-Lived Intangible Assets        
Indefinite-lived intangible assets acquired     $ 3,040,000  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash Equivalents $ 0 $ 0
Contingent Consideration 3,460 28,910
Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 42,634 0
Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 9,680 22,476
Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 32,396 14,317
Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 8,272
Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 837
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash Equivalents 0 0
Contingent Consideration 0 0
Level 1 | Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 42,634 0
Level 1 | Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 9,680 22,476
Level 1 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 32,396 14,317
Level 1 | Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 1 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 837
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash Equivalents 0 0
Contingent Consideration 0 0
Level 2 | Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0
Level 2 | Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 2 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 2 | Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 8,272
Level 2 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Cash Equivalents 0 0
Contingent Consideration 3,460 28,910
Level 3 | Exchange Trade Mutual Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Corporate Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Treasury Bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Asset Backed Securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments 0 0
Level 3 | Other    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Short term investments $ 0 $ 0
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Fair Value Disclosures [Abstract]        
Fair value adjustment of contingent consideration $ (23,010) $ (1,430) $ (25,450) $ 3,710
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) - Level 3 - Contingent Consideration Liability
$ in Thousands
 9 Months Ended
Sep. 30, 2022
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation  
Change in fair value of contingent consideration $ (25,450)
Fair Value, Recurring  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation  
Contingent consideration, beginning balance 28,910
Contingent consideration, ending balance $ 3,460
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) - Level 3 - Fair Value, Recurring - Discounted cash flow, Monte Carlo
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Expected years 1 year 7 months 6 days 2 years 4 months 24 days
Present Value Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent consideration, measurement input 16.20% 18.40%
Volatility factor    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Contingent consideration, measurement input 46.50% 50.30%
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) - Mortgage payable to affiliate - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument    
Total debt $ 942 $ 1,044
Less: current maturities 143 137
Long-term debt with affiliate, net of current maturities $ 799 $ 907
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 15, 2022
Jun. 13, 2022
Jun. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jun. 12, 2022
Dec. 31, 2021
Debt Instrument                  
Proceeds from issuance of debt with affiliate           $ 31,000,000 $ 0    
Payments on note with affiliate           31,000,000 0    
Interest expense, net       $ 708,000 $ 542,000 2,485,000 1,851,000    
Squadron                  
Debt Instrument                  
Commitment fee       $ 44,000 32,000 $ 111,000 95,000    
Mortgage payable to affiliate                  
Debt Instrument                  
Interest rate (as a percent)       5.00%   5.00%      
Monthly interest and principal installments           $ 16,000      
Long-term debt       $ 942,000   942,000     $ 1,044,000
Current portion of long-term debt with affiliate       143,000   143,000     $ 137,000
Note payable to Squadron                  
Debt Instrument                  
Interest expense, net       $ 12,000 $ 14,000 $ 512,000 $ 42,000    
Revolving Credit Facility                  
Debt Instrument                  
Proceeds from issuance of debt with affiliate     $ 31,000,000            
Payments on note with affiliate $ 31,000,000                
Revolving Credit Facility | Fourth Amended Loan Agreement                  
Debt Instrument                  
Revolving credit facility   $ 50,000,000           $ 25,000,000  
Interest rate (as a percent)   10.00%              
Unused commitment fee percentage (as a percent)   0.50%              
Revolving Credit Facility | Fourth Amended Loan Agreement | Three Month LIBOR                  
Debt Instrument                  
Debt instrument, basis spread on variable rate (as a percent)   8.61%              
Revolving Credit Facility | Fourth Amended Loan Agreement | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate                  
Debt Instrument                  
Debt instrument, basis spread on variable rate (as a percent)   8.69%              
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Dec. 11, 2018
May 30, 2014
Income Tax Examination              
Income tax benefit $ 4,143 $ 292 $ 4,899 $ 890      
Effective income tax rate (as a percent)     (116.50%) 5.20%      
Loss carryforwards         $ 22,671    
Tax credit carryforward         176    
Estimated limitation on losses generated prior to ownership change date             $ 23,920
Estimated annual limitation of losses           $ 9,736 $ 1,062
Increase of estimated annual limitation of first five years           $ 22,430  
Deferred tax liabilities 3,010   $ 3,010        
Reversal of valuation allowance $ 3,010            
Federal and State              
Income Tax Examination              
Loss carryforwards         114,008    
State              
Income Tax Examination              
Loss carryforwards         $ 73,997    
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Stock Options (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award          
Options, granted (in shares) 0 0 0 0  
Options          
Forfeited or expired (in shares)     (1,072)    
Weighted-Average Exercise Price          
Forfeited or expired, weighted-average exercise price (in dollars per share)     $ 0    
Stock Option          
Share-based Compensation Arrangement by Share-based Payment Award          
Options, granted (in shares)     0 0  
Options          
Outstanding at period start (in shares)     6,638    
Exercised (in shares)     (2,010)    
Outstanding at period end (in shares) 3,556   3,556   6,638
Weighted-Average Exercise Price          
Outstanding at period start, weighted-average exercise price (in dollars per share)     $ 30.97    
Exercised, weighted-average exercise price (in dollars per share)     30.97    
Outstanding at period end, weighted-average exercise price (in dollars per share) $ 30.97   $ 30.97   $ 30.97
Contractual terms (in years)     10 months 24 days   1 year 3 months 18 days
Vesting period (in years)     3 years    
Stock-based compensation expense $ 0 $ 0 $ 0 $ 0  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Restricted Stock (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized            
Stock-based compensation       $ 4,978,000 $ 4,170,000  
Common Stock            
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized            
Stock issued (in shares)   173,241   34,899,000    
Equity issuance cost $ 133,000          
Squadron            
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized            
Warrants and rights outstanding $ 1,525,000     $ 1,525,000    
Warrants exercise price (in dollars per share) $ 0.00025     $ 0.00025    
Restricted Stock Awards            
Restricted Stock            
Outstanding at period start (in shares)       368,446    
Granted (in shares)       216,631    
Forfeited (in shares)       (10,025)    
Vested (in shares)       (150,067)    
Outstanding at period end (in shares) 424,985     424,985   368,446
Weighted-average remaining contractual terms (in years)       1 year 8 months 12 days   1 year 1 month 6 days
Restricted stock exercisable (in shares) 0     0    
Restricted Stock Units            
Restricted Stock            
Outstanding at period start (in shares)       0    
Granted (in shares)       11,634    
Forfeited (in shares)       0    
Vested (in shares)       0    
Outstanding at period end (in shares) 11,634     11,634   0
Weighted-average remaining contractual terms (in years)       2 years 9 months 18 days    
Restricted stock exercisable (in shares) 0     0    
Restricted Stock Awards And Restricted Stock Units            
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized            
Unrecognized compensation expense $ 12,374,000     $ 12,374,000    
Unrecognized compensation expense, weighted average period of recognition (in years)       1 year 8 months 12 days    
Stock-based compensation $ 1,682,000   $ 1,440,000 $ 4,978,000 $ 4,170,000  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]                
Net income (loss) $ 18,539 $ (333) $ (9,100) $ (2,197) $ (3,756) $ (10,379) $ 9,106 $ (16,332)
Earning allocated to participation securities, basic 353     0     174 0
Earning allocated to participation securities, diluted 353     0     174 0
Net income (loss) 18,186     (2,197)     8,932 (16,332)
Net income available to common stockholders, diluted $ 18,186     $ (2,197)     $ 8,932 $ (16,332)
Denominator for basic and diluted net income (loss) per share:                
Weighted average shares outstanding for basic (in shares) 21,150,219     19,291,374     20,703,883 19,256,128
Weighted average shares outstanding for diluted (in shares) 21,295,323     19,291,374     20,958,503 19,256,128
Basic (in dollars per share) $ 0.88     $ (0.11)     $ 0.44 $ (0.85)
Diluted (in dollars per share) $ 0.87     $ (0.11)     $ 0.43 $ (0.85)
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER SHARE - Antidilutive Securities (Details) - shares
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 382,553
Restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 375,915
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0 6,638
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS SEGMENT - Narrative (Details)
 9 Months Ended
Sep. 30, 2022
segment
Segment Reporting [Abstract]  
Number of operating segments 1
Number of reportable segments 1
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues from External Customers and Long-Lived Assets        
Net revenue $ 34,950 $ 25,079 $ 91,295 $ 73,236
U.S.        
Revenues from External Customers and Long-Lived Assets        
Net revenue 26,539 19,354 69,687 57,930
International        
Revenues from External Customers and Long-Lived Assets        
Net revenue $ 8,411 $ 5,725 $ 21,608 $ 15,306
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
BUSINESS SEGMENT - Schedule of Revenue by Category (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information        
Net revenue $ 34,950 $ 25,079 $ 91,295 $ 73,236
Trauma and deformity        
Segment Reporting Information        
Net revenue 23,892 16,817 62,976 49,302
Scoliosis        
Segment Reporting Information        
Net revenue 9,979 7,266 25,383 20,874
Sports medicine/other        
Segment Reporting Information        
Net revenue $ 1,079 $ 996 $ 2,936 $ 3,060
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTY TRANSACTIONS (Details) - Affiliated Entity
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
supplier
Sep. 30, 2021
USD ($)
Dec. 31, 2019
USD ($)
Related Party Transaction          
Number of related party suppliers | supplier     1    
Discontinued Operations, Disposed of by Sale          
Related Party Transaction          
Divestiture purchase price         $ 25,000
Structure Medical, LLC          
Related Party Transaction          
Payments to related party $ 218 $ 173 $ 768 $ 441  
Vilex          
Related Party Transaction          
Payments to related party 7 150 39 675  
Sales to related party $ 51 $ 45 $ 111 $ 200  
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
EMPLOYEE BENEFIT PLAN - Narrative (Details)
 9 Months Ended
Sep. 30, 2022
Benefit Plan, Plan  
Employer contribution as a percentage of employees' salary (as a percent) 4.00%
MD Orthopaedics  
Benefit Plan, Plan  
Employer contribution as a percentage of employees' salary (as a percent) 3.00%
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 20, 2021
Dec. 31, 2019
Jun. 30, 2019
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Long-term Purchase Commitment                
Operating lease liability       $ 303,000   $ 303,000    
Operating lease right-of-use asset       $ 304,000   $ 304,000    
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]               Other long-term liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]       Assets, Noncurrent, Excluding Property, Plant and Equipment   Assets, Noncurrent, Excluding Property, Plant and Equipment    
Payments on note with affiliate           $ 31,000,000 $ 0  
Purchase commitment, remaining minimum amount committed       $ 0   0    
Cost of revenue       9,061,000 $ 6,525,000 $ 21,859,000 17,914,000  
Minimum                
Long-term Purchase Commitment                
Royalty agreement percentage (as a percent)           0.50%    
Maximum                
Long-term Purchase Commitment                
Royalty agreement percentage (as a percent)           20.00%    
License Agreements | Firefly Technology                
Long-term Purchase Commitment                
Finite lived intangible asset useful life extension period (in years) 5 years              
Cost of revenue       $ 101,000   $ 442,000    
Trademark impairment         $ 0   $ 0  
Squadron | Team Note B | Affiliated Entity                
Long-term Purchase Commitment                
Payments on note with affiliate   $ 25,000,000            
Vilex and Orthex                
Long-term Purchase Commitment                
Fair value of estimated total acquisition consideration     $ 60,000,000          
XML 74 kids-20220930_htm.xml IDEA: XBRL DOCUMENT 0001425450 2022-01-01 2022-09-30 0001425450 2022-10-28 0001425450 2022-09-30 0001425450 2021-12-31 0001425450 2022-07-01 2022-09-30 0001425450 2021-07-01 2021-09-30 0001425450 2021-01-01 2021-09-30 0001425450 us-gaap:CommonStockMember 2021-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001425450 us-gaap:RetainedEarningsMember 2021-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001425450 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001425450 2022-01-01 2022-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001425450 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001425450 us-gaap:CommonStockMember 2022-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001425450 us-gaap:RetainedEarningsMember 2022-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001425450 2022-03-31 0001425450 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001425450 2022-04-01 2022-06-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001425450 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001425450 us-gaap:CommonStockMember 2022-06-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001425450 us-gaap:RetainedEarningsMember 2022-06-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001425450 2022-06-30 0001425450 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001425450 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001425450 us-gaap:CommonStockMember 2022-09-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001425450 us-gaap:RetainedEarningsMember 2022-09-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001425450 us-gaap:CommonStockMember 2020-12-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001425450 us-gaap:RetainedEarningsMember 2020-12-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001425450 2020-12-31 0001425450 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001425450 2021-01-01 2021-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001425450 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001425450 us-gaap:CommonStockMember 2021-03-31 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001425450 us-gaap:RetainedEarningsMember 2021-03-31 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001425450 2021-03-31 0001425450 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001425450 2021-04-01 2021-06-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001425450 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001425450 us-gaap:CommonStockMember 2021-06-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001425450 us-gaap:RetainedEarningsMember 2021-06-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001425450 2021-06-30 0001425450 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001425450 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001425450 us-gaap:CommonStockMember 2021-09-30 0001425450 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001425450 us-gaap:RetainedEarningsMember 2021-09-30 0001425450 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001425450 2021-09-30 0001425450 kids:MDOrthopaedicsMember 2022-01-01 2022-09-30 0001425450 kids:MDOrthopaedicsMember 2021-01-01 2021-09-30 0001425450 kids:ApiFixLtdMember 2022-01-01 2022-09-30 0001425450 kids:ApiFixLtdMember 2021-01-01 2021-09-30 0001425450 country:US 2022-09-30 0001425450 us-gaap:CommonStockMember kids:PublicOfferingMember 2022-08-15 2022-08-15 0001425450 us-gaap:CommonStockMember us-gaap:IPOMember 2022-08-15 0001425450 us-gaap:CommonStockMember kids:PublicOfferingMember 2022-08-15 0001425450 kids:PublicOfferingMember 2022-08-15 2022-08-15 0001425450 us-gaap:CommonStockMember kids:PublicOfferingMember 2022-09-20 2022-09-20 0001425450 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-09-30 0001425450 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2022-01-01 2022-09-30 0001425450 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-09-30 0001425450 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-09-30 0001425450 srt:MinimumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-09-30 0001425450 srt:MaximumMember us-gaap:ComputerEquipmentMember 2022-01-01 2022-09-30 0001425450 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-09-30 0001425450 srt:MinimumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-09-30 0001425450 srt:MaximumMember us-gaap:OfficeEquipmentMember 2022-01-01 2022-09-30 0001425450 us-gaap:TechnologyEquipmentMember 2022-01-01 2022-09-30 0001425450 kids:SampleInventoryMember 2022-01-01 2022-09-30 0001425450 srt:MinimumMember 2022-01-01 2022-09-30 0001425450 srt:MaximumMember 2022-01-01 2022-09-30 0001425450 kids:New2017EquityIncentivePlanMember 2022-09-30 0001425450 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001425450 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001425450 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2022-01-01 2022-09-30 0001425450 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2022-01-01 2022-09-30 0001425450 kids:PegaMedicalMember 2022-07-01 2022-07-01 0001425450 kids:PegaMedicalMember 2022-07-01 0001425450 kids:PegaMedicalMember us-gaap:CommonStockMember 2022-07-01 2022-07-01 0001425450 kids:PegaMedicalMember us-gaap:CommonStockMember 2022-07-01 0001425450 us-gaap:RestrictedStockUnitsRSUMember kids:PegaMedicalMember 2022-07-01 0001425450 us-gaap:RestrictedStockUnitsRSUMember kids:PegaMedicalMember 2022-07-01 2022-07-01 0001425450 kids:PegaMedicalMember us-gaap:TrademarksAndTradeNamesMember 2022-07-01 2022-07-01 0001425450 kids:PegaMedicalMember us-gaap:PatentsMember 2022-07-01 2022-07-01 0001425450 kids:PegaMedicalMember us-gaap:CustomerRelationshipsMember 2022-04-01 2022-04-01 0001425450 kids:MDOrthopaedicsMember 2022-04-01 2022-04-01 0001425450 kids:MDOrthopaedicsMember 2022-04-01 0001425450 kids:MDOrthopaedicsMember us-gaap:TrademarksAndTradeNamesMember 2022-04-01 2022-04-01 0001425450 kids:MDOrthopaedicsMember us-gaap:PatentsMember 2022-04-01 2022-04-01 0001425450 kids:MDOrthopaedicsMember us-gaap:CustomerRelationshipsMember 2022-04-01 2022-04-01 0001425450 2022-04-01 2022-09-30 0001425450 kids:PegaMedicalMember 2022-01-01 2022-09-30 0001425450 us-gaap:PatentsMember 2022-01-01 2022-09-30 0001425450 us-gaap:PatentsMember 2022-09-30 0001425450 us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0001425450 us-gaap:LicensingAgreementsMember 2022-09-30 0001425450 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-09-30 0001425450 us-gaap:CustomerRelationshipsMember 2022-09-30 0001425450 us-gaap:IntellectualPropertyMember 2022-01-01 2022-09-30 0001425450 us-gaap:IntellectualPropertyMember 2022-09-30 0001425450 us-gaap:TrademarksMember 2022-09-30 0001425450 us-gaap:TrademarksMember 2022-01-01 2022-09-30 0001425450 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001425450 us-gaap:PatentsMember 2021-12-31 0001425450 us-gaap:IntellectualPropertyMember 2021-01-01 2021-12-31 0001425450 us-gaap:IntellectualPropertyMember 2021-12-31 0001425450 us-gaap:LicensingAgreementsMember 2021-01-01 2021-12-31 0001425450 us-gaap:LicensingAgreementsMember 2021-12-31 0001425450 us-gaap:TrademarksMember us-gaap:MeasurementInputDiscountRateMember 2022-09-30 0001425450 us-gaap:TrademarksMember kids:MeasurementInputEstimatedRoyaltyRateMember 2022-09-30 0001425450 us-gaap:TrademarksMember kids:MeasurementInputLongTermGrowthRateMember 2022-09-30 0001425450 us-gaap:TrademarksMember 2021-12-31 0001425450 kids:MDOrthopaedicsMember us-gaap:TrademarksMember 2022-01-01 2022-09-30 0001425450 kids:PegaMedicalMember us-gaap:TrademarksMember 2022-01-01 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001425450 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2022-09-30 0001425450 us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember kids:ExchangeTradeMutualFundsMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueMeasurementsRecurringMember us-gaap:OtherDebtSecuritiesMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member kids:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member kids:ContingentConsiderationLiabilityMember 2022-01-01 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member kids:ContingentConsiderationLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-01-01 2022-09-30 0001425450 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-01-01 2021-12-31 0001425450 us-gaap:MortgagesMember 2022-09-30 0001425450 us-gaap:MortgagesMember 2021-12-31 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember 2022-06-12 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember 2022-06-13 0001425450 us-gaap:RevolvingCreditFacilityMember 2022-08-15 2022-08-15 0001425450 us-gaap:RevolvingCreditFacilityMember 2022-06-01 2022-06-30 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-06-13 2022-06-13 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-06-13 2022-06-13 0001425450 us-gaap:RevolvingCreditFacilityMember kids:FourthAmendedLoanAgreementMember 2022-06-13 2022-06-13 0001425450 us-gaap:MortgagesMember 2022-01-01 2022-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2022-07-01 2022-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2021-07-01 2021-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2022-01-01 2022-09-30 0001425450 us-gaap:NotesPayableOtherPayablesMember 2021-01-01 2021-09-30 0001425450 kids:SquadronMember 2022-07-01 2022-09-30 0001425450 kids:SquadronMember 2021-07-01 2021-09-30 0001425450 kids:SquadronMember 2022-01-01 2022-09-30 0001425450 kids:SquadronMember 2021-01-01 2021-09-30 0001425450 us-gaap:DomesticCountryMember 2021-12-31 0001425450 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001425450 2014-05-30 0001425450 2018-12-11 0001425450 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2021-12-31 0001425450 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001425450 us-gaap:EmployeeStockOptionMember 2022-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001425450 us-gaap:RestrictedStockMember 2021-12-31 0001425450 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001425450 us-gaap:RestrictedStockMember 2022-09-30 0001425450 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001425450 kids:RestrictedStockAwardsAndRestrictedStockUnitsMember 2022-09-30 0001425450 kids:RestrictedStockAwardsAndRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001425450 kids:RestrictedStockAwardsAndRestrictedStockUnitsMember 2022-07-01 2022-09-30 0001425450 kids:RestrictedStockAwardsAndRestrictedStockUnitsMember 2021-07-01 2021-09-30 0001425450 kids:RestrictedStockAwardsAndRestrictedStockUnitsMember 2021-01-01 2021-09-30 0001425450 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001425450 kids:SquadronMember 2022-09-30 0001425450 us-gaap:RestrictedStockMember 2022-01-01 2022-09-30 0001425450 us-gaap:RestrictedStockMember 2021-01-01 2021-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001425450 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001425450 country:US 2022-07-01 2022-09-30 0001425450 country:US 2021-07-01 2021-09-30 0001425450 country:US 2022-01-01 2022-09-30 0001425450 country:US 2021-01-01 2021-09-30 0001425450 us-gaap:NonUsMember 2022-07-01 2022-09-30 0001425450 us-gaap:NonUsMember 2021-07-01 2021-09-30 0001425450 us-gaap:NonUsMember 2022-01-01 2022-09-30 0001425450 us-gaap:NonUsMember 2021-01-01 2021-09-30 0001425450 kids:TraumaAndDeformityMember 2022-07-01 2022-09-30 0001425450 kids:TraumaAndDeformityMember 2021-07-01 2021-09-30 0001425450 kids:TraumaAndDeformityMember 2022-01-01 2022-09-30 0001425450 kids:TraumaAndDeformityMember 2021-01-01 2021-09-30 0001425450 kids:SpineMember 2022-07-01 2022-09-30 0001425450 kids:SpineMember 2021-07-01 2021-09-30 0001425450 kids:SpineMember 2022-01-01 2022-09-30 0001425450 kids:SpineMember 2021-01-01 2021-09-30 0001425450 kids:SportsMedicineAndOtherMember 2022-07-01 2022-09-30 0001425450 kids:SportsMedicineAndOtherMember 2021-07-01 2021-09-30 0001425450 kids:SportsMedicineAndOtherMember 2022-01-01 2022-09-30 0001425450 kids:SportsMedicineAndOtherMember 2021-01-01 2021-09-30 0001425450 srt:AffiliatedEntityMember 2022-01-01 2022-09-30 0001425450 kids:StructureMedicalLLCMember srt:AffiliatedEntityMember 2022-07-01 2022-09-30 0001425450 kids:StructureMedicalLLCMember srt:AffiliatedEntityMember 2021-07-01 2021-09-30 0001425450 kids:StructureMedicalLLCMember srt:AffiliatedEntityMember 2022-01-01 2022-09-30 0001425450 kids:StructureMedicalLLCMember srt:AffiliatedEntityMember 2021-01-01 2021-09-30 0001425450 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember srt:AffiliatedEntityMember 2019-12-31 0001425450 kids:VilexMember srt:AffiliatedEntityMember 2022-07-01 2022-09-30 0001425450 kids:VilexMember srt:AffiliatedEntityMember 2022-01-01 2022-09-30 0001425450 kids:VilexMember srt:AffiliatedEntityMember 2021-07-01 2021-09-30 0001425450 kids:VilexMember srt:AffiliatedEntityMember 2021-01-01 2021-09-30 0001425450 kids:VilexAndOrthexMember 2019-06-01 2019-06-30 0001425450 kids:SquadronMember kids:TeamNoteBMember srt:AffiliatedEntityMember 2019-12-31 2019-12-31 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2021-07-20 2021-07-20 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-09-30 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2021-07-01 2021-09-30 0001425450 kids:FireflyTechnologyMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares kids:children iso4217:EUR pure kids:segment kids:supplier 2022 Q3 false 0001425450 --12-31 P18M http://www.orthopediatrics.com/20220930#AssetsNoncurrentExcludingPropertyPlantAndEquipment http://www.orthopediatrics.com/20220930#AssetsNoncurrentExcludingPropertyPlantAndEquipment http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 10-Q true 2022-09-30 false 001-38242 OrthoPediatrics Corp DE 26-1761833 2850 Frontier Drive Warsaw IN 46582 574 268-6379 Common Stock, $0.00025 par value per share KIDS NASDAQ Yes Yes Non-accelerated Filer true true true false 22891500 35423000 7641000 1449000 1365000 84710000 45902000 608000 347000 26184000 17942000 74041000 57569000 2751000 3229000 224558000 133648000 36313000 28515000 66285000 55494000 88044000 72349000 14854000 14268000 169183000 142111000 430054000 304274000 10881000 9325000 6323000 5351000 143000 137000 7630000 12862000 3769000 2040000 28746000 29715000 799000 907000 7822000 14309000 3460000 28910000 5457000 4771000 440000 293000 17978000 49190000 46724000 78905000 0.00025 0.00025 50000000 50000000 22896031 22896031 19677214 19677214 6000 5000 559339000 394899000 -168920000 -178026000 -7095000 8491000 383330000 225369000 430054000 304274000 34950000 25079000 91295000 73236000 9061000 6525000 21859000 17914000 25889000 18554000 69436000 55322000 11919000 9862000 34108000 29687000 15116000 11034000 42829000 34163000 3609000 0 3609000 0 2206000 1302000 5980000 3935000 32850000 22198000 86526000 67785000 -6961000 -3644000 -17090000 -12463000 -708000 -542000 -2485000 -1851000 -23010000 -1430000 -25450000 3710000 -945000 267000 -1668000 802000 21357000 1155000 21297000 -4759000 14396000 -2489000 4207000 -17222000 -4143000 -292000 -4899000 -890000 18539000 -2197000 9106000 -16332000 21150219 19291374 20703883 19256128 21295323 19291374 20958503 19256128 0.88 -0.11 0.44 -0.85 0.87 -0.11 0.43 -0.85 18539000 -2197000 9106000 -16332000 -4164000 288000 -15661000 -1343000 -452000 -88000 -1130000 -282000 1205000 0 1205000 0 -3411000 200000 -15586000 -1625000 15128000 -1997000 -6480000 -17957000 19677214 5000 394899000 -178026000 8491000 225369000 -9100000 -9100000 -2751000 -2751000 144084 1526000 1526000 19821298 5000 396425000 -187126000 5740000 215044000 -333000 -333000 -9424000 -9424000 1340 42000 42000 57180 1770000 1770000 173241 9707000 9707000 185811 10410000 10410000 20238870 5000 418354000 -187459000 -3684000 227216000 18539000 18539000 -3411000 -3411000 670 21000 21000 5342 1682000 1682000 2616250 1000 139282000 139283000 34899 22896031 6000 559339000 -168920000 -7095000 383330000 19560291 5000 388622000 -161766000 7907000 234768000 -10379000 -10379000 -3622000 -3622000 2010 62000 62000 97111 1316000 1316000 19659412 5000 390000000 -172145000 4285000 222145000 -3756000 -3756000 1797000 1797000 10632 1415000 1415000 19670044 5000 391415000 -175901000 6082000 221601000 -2197000 -2197000 200000 200000 2412 75000 75000 -294 1439000 1439000 19672162 5000 392929000 -178098000 6282000 221118000 9106000 -16332000 9579000 7870000 4978000 4170000 3609000 0 -25450000 3710000 1926000 1701000 4804000 890000 5567000 716000 14812000 3244000 -696000 138000 -389000 -956000 0 6342000 1800000 -168000 -903000 493000 -18425000 -11828000 8360000 0 31730000 0 45529000 4000000 0 7908000 85029000 0 10554000 6468000 -90144000 -10376000 31000000 0 31000000 0 3234000 0 139282000 0 63000 137000 102000 97000 136009000 40000 426000 -266000 27866000 -22430000 9006000 30132000 36872000 7702000 512000 43000 -193000 80000 9707000 0 10410000 0 BUSINESS<div style="padding-right:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediPlates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Cannulated Screws, PediFlex</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">nail, PediNail</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, PediLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Spine, BandLoc</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, Cerament</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;position:relative;top:-2.27pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> and ApiFix</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%"> Mid-C System, to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div style="padding-right:8pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">We are the only global medical device company focused exclusively on providing a comprehensive trauma and deformity correction, scoliosis and sports medicine product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. Since inception we have impacted the lives of over 613,000 children. We design, develop and commercialize innovative orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients, who we believe have been largely neglected by the orthopedic industry. We currently serve three of the largest categories in this market. We estimate that the portion of this market that we currently serve represents a $3,300,000 opportunity globally, including over $1,500,000 in the United States.</span></div><div style="padding-right:5pt"><span><br/></span></div><div style="padding-right:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%">Our largest investor is Squadron Capital LLC, or Squadron, a private investment firm based in Granby, Connecticut. </span></div>A novel strain of the coronavirus disease was first identified in Wuhan, China in December 2019, and the related outbreak was subsequently declared a pandemic by the World Health Organization and a national emergency by the President of the United States. Since then, the pandemic has presented a significant public health and economic challenge around the world and has adversely impacted our business. Specifically, we have seen surgeons and their patients deferring elective procedures in which our products would have otherwise been used. The volatility in COVID cases and hospitalizations, including the impacts of the Delta variant in the third quarter of 2021 and the current hospital support staffing shortages in certain geographies, continue to drive volatility into our business. We continue to closely monitor developments related to the pandemic and the related staffing shortages and our decisions will continue to focus on the safety and security of our employees, distributors, surgeons and their patients while maintaining operations to support our customers. The full extent of the impact of the pandemic on our business is uncertain and cannot be accurately predicted and will depend on future developments that are also uncertain and cannot be predicted. 613000 3300000 1500000 SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., Orthex, LLC, Telos Partners, LLC, ApiFix, Ltd., OrthoPediatrics Iowa Holdco, Inc., MD Orthopaedics, Inc., </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MD International Inc., OrthoPediatrics GMbH, OrthoPediatrics GP LLC, OrthoPediatrics US L.P. and OrthoPediatrics Canada ULC doing business as Pega Medical (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div><div style="padding-left:1pt;padding-right:1pt"><span><br/></span></div><div style="padding-left:1pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. We have experienced recurring losses from operations since our inception and had an accumulated deficit of $168,920 and $178,026 as of September 30, 2022 and December 31, 2021, respectively. Management continues to monitor cash flows and liquidity on a regular basis. We believe that our cash balance, including short term investments, at September 30, 2022 and expected cash flows from operations for the next twelve months subsequent to the issuance of the accompanying condensed consolidated financial statements, are sufficient to enable us to maintain current and essential planned operations for more than the next twelve months. </span></div><div style="padding-left:1pt;padding-right:1pt"><span><br/></span></div><div style="padding-left:1pt;padding-right:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, we completed a public offering of our common stock, in which we issued 1,091,250 shares of common stock at a public offering price of $55.00 per share and 1,525,000 pre-funded warrants to Squadron. The purchase price of each warrant was equal to the price per share at which the common shares were sold to the public, minus $0.00025, which was the exercise price of each warrant. The aggregate gross proceeds for both the warrants and common shares were $143,894. The total net proceeds from the offering were $139,282, after deducting $4,318 of underwriting discounts and commissions and paying $294 in offering costs. The Company has used $31,000 of the net proceeds to pay off the outstanding debt on the line of credit with Squadron. On September 20, 2022, the Company issued an aggregate of 1,525,000 shares of common stock to Squadron upon exercise of the pre-funded warrants. </span></div><div style="padding-left:1pt;padding-right:1pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in July 2022, we established an operating company in Germany and in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Contracts with Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – United States</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the customer for surgeries or other treatment on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – International</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns. </span><span style="color:#226600;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the hospital for surgeries on a case by case basis. On rare occasions, hospitals purchase products for their own inventory, and revenue is recognized when title passes upon shipment. Pricing for each customer is dictated by a unique pricing agreement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Short Term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the September 30, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 13 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 200 Euro at its Netherlands entity for potential Italian tenders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 5 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciable lives are generally as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 to 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sample inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortizable Intangible Assets, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amortizable intangible assets include fees necessary to secure various patents and licenses (including those acquired in the Band-Lok, MD Ortho and Pega transactions), the value of internally developed software (including by Orthex), and the value of acquired customer relationships and non-competition agreements (including in the Orthex, Telos, ApiFix, MD Ortho and Pega transactions, as applicable). Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges were recorded in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No goodwill impairment charges were recorded in any period presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022. No impairment charges were recorded in any other period presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Payable and Contingent Consideration</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. The amount of expense related to acquisition installment payables recorded in interest expense, net for the three and nine months ended September 30, 2022 were $381 and $1,926, respectively, and $489 and $1,701, respectively, for the same periods last year. The fair value adjustments of contingent consideration for the three and nine months ended September 30, 2022 were income adjustments of $23,010 and $25,450, respectively, and for the same periods last year, were an income adjustment of $1,430 and an expense adjustment of $3,710, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales and Marketing Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan"). The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, we would make an adjustment to the valuation allowance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers".</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments"</span>. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of OrthoPediatrics Corp. and its wholly-owned subsidiaries, OrthoPediatrics US Distribution Corp., OrthoPediatrics EU Limited, OrthoPediatrics AUS PTY LTD, OrthoPediatrics NZ Limited, OP EU B.V., OP Netherlands B.V., Orthex, LLC, Telos Partners, LLC, ApiFix, Ltd., OrthoPediatrics Iowa Holdco, Inc., MD Orthopaedics, Inc., </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MD International Inc., OrthoPediatrics GMbH, OrthoPediatrics GP LLC, OrthoPediatrics US L.P. and OrthoPediatrics Canada ULC doing business as Pega Medical (collectively, the “Company,” “we,” “our” or “us”). All intercompany balances and transactions have been eliminated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021, the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited and should be read in conjunction with the annual consolidated financial statements as of and for the year ended December 31, 2021 and related notes thereto contained in our Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 3, 2022. The financial data and other financial information disclosed in the notes to the accompanying condensed consolidated financial statements are also unaudited. As such, certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to applicable rules and regulations thereunder. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements as of and for the year ended December 31, 2021 and, in management’s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair presentation of the financial statements for the interim periods. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the full fiscal year or for any other period. </span></div>The accompanying condensed consolidated financial statements have been prepared assuming our Company will continue as a going concern. -168920000 -178026000 1091250 55 1525000 0.00025 143894000 139282000 4318000 294000 31000000 1525000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparation of our condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an </span></div>inherent degree of uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in our consolidated financial statements. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently bill our international stocking distributors in U.S. dollars, resulting in minimal foreign exchange transaction expense. </span></div>Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. The countries we serve under the agency model include the United Kingdom, Ireland, Australia, New Zealand, Canada, Belgium, the Netherlands, Poland, Italy, Israel, Germany, Switzerland, and Austria. Additionally, in July 2022, we established an operating company in Germany and in March 2019, we established an operating company in the Netherlands in order to enhance our operations in Europe. The financial statements of our foreign subsidiaries are accounted for in local functional currencies and have been translated into U.S. dollars using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations. Foreign currency translation adjustments have been recorded as a separate component of the consolidated statements of comprehensive loss. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Contracts with Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," revenue is recognized when our performance obligations under the terms of a contract with our customer are satisfied. This typically occurs when we transfer control of our products to the customers, generally upon implantation or when title passes upon shipment. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled to receive in exchange for these goods or services, and excludes any sales incentives or taxes collected from a customer which are subsequently remitted to government authorities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – United States</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in the United States is generated primarily from the sale of our implants and, to a much lesser extent, from the sale of our instruments. Sales in the United States are primarily to hospital accounts through independent sales agencies. We recognize revenue when our performance obligations under the terms of a contract with our customer are satisfied. The products are generally consigned to our independent sales agencies, and revenue is recognized when the products are used by or shipped to the customer for surgeries or other treatment on a case by case basis. On rare occasions, hospitals purchase product for their own inventory, and revenue is recognized when the products are shipped and the title and risk of loss passes to the customer. Pricing for each customer is dictated by a unique pricing agreement. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition – International</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the United States, we sell our products directly to hospitals through independent sales agencies or to independent stocking distributors. Generally, the distributors are allowed to return products, and some are thinly capitalized. Based on a history of reliable collections, we have concluded that a contract exists and revenue should be recognized when we transfer control of our products to the customer, generally when title passes upon shipment. Additionally, based on our history of immaterial returns from international customers, we have historically estimated no reserve for returns. </span><span style="color:#226600;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Beginning in early 2017 and continuing through 2022, we expanded operations and established legal entities outside the United States, permitting us to sell under an agency model direct to local hospitals internationally. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Short Term Investments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cash in bank deposit accounts which, at times, may exceed federally insured limits. To date, we have not experienced any loss in such accounts. We consider all highly liquid investments with original maturity of three months or less at inception to be cash equivalents. The carrying amounts reported in the balance sheets for cash are valued at cost, which approximates fair value. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in available-for-sale short term investments. The Company has the ability, if necessary, to liquidate without penalty any of its short term investments to meet its liquidity needs in the next twelve months. As such, those investments with contractual maturities greater than one year from the date of purchase are classified as short-term on the accompanying Consolidated Balance Sheets. The company includes unrealized gains or losses in stockholders' equity. If the adjustment to fair value reflects a decline in the value of the investment, the Company considers available information to determine whether the decline is "other than temporary" and, if so, reflects the change on the Consolidated Statements of Operations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div>In conjunction with the sale of Vilex, $1,250 was placed into a separate escrow account. This cash is reported as restricted cash on the September 30, 2022 and December 31, 2021 condensed consolidated balance sheets. These funds were to remain restricted until August 31, 2021, at which time, they were to be released to the Company subject to no claims related to the purchase being asserted; however, due to the pending IMED Surgical litigation, the cash remains reported as restricted until the conclusion of the legal matter (see “Legal Proceedings” under Note 13 – Commitments and Contingencies for additional information). The Company also maintains restricted cash of 200 Euro at its Netherlands entity for potential Italian tenders. 1250000 1250000 200000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are uncollateralized customer obligations due under normal trade terms, generally requiring payment within 30 days from the invoice date. Account balances with invoices over 30 days past due are considered delinquent. No interest is charged on past due accounts. Payments of accounts receivable are applied to the specific invoices identified on the customer's remittance advice or, if unspecified, to the customer's account as an unapplied credit.</span></div>The carrying amount of accounts receivable is reduced by an allowance that reflects management's best estimate of the amounts that will not be collected, determined principally on the basis of historical experience, management's assessment of the collectability of specific customer accounts and the aging of the accounts receivable. All accounts or portions thereof deemed to be uncollectible or to require an excessive collection cost are written off to the allowance for doubtful accounts. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature.  Valuation techniques are based on observable and unobservable inputs.  Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect market assumptions.  This guidance only applies when other </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standards require or permit the fair value measurement of assets and liabilities.  The guidance does not expand the use of fair value measurements.  A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.    </span></div>The Company's financial instruments include cash and cash equivalents, short-term investments, accounts receivable, accounts payable, acquisition installment payables, contingent consideration and long-term debt. The carrying amounts of accounts receivable, accounts payable, acquisition installment payables and long-term debt approximate the fair value due to the short-term nature or market rates of these instruments. The company bases the fair value of short-term investments on quoted market prices for identical or comparable assets except for investments classified as asset backed securities which we identify as Level 2. These securities are predominately priced by third parties, either a pricing vendor or dealer. When a quoted price in an active market for an identical security is not available these third parties will utilize an alternative market approach, such as a recent trade or matrix pricing, or an income approach, such as a discounted cash flow pricing model that calculates values from observable inputs such as quoted interest rates, yield curves and other observable market information. Contingent consideration represents the system sales payment the Company is obligated to make. The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date and as of the balance sheet date. See Note 5 for further discussion of financial instruments that carried a fair value on a recurring and nonrecurring basis. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in-first-out method. Inventories purchased from third parties, which consist of implants and instruments held in our warehouse or with third-party independent sales agencies or distributors, are considered finished goods. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of our inventories in relation to the estimated forecast of product demand, which takes into consideration the life cycle of the product. A significant decrease in demand could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. </span></div>In addition, we continue to introduce new products, which may require us to take additional charges for excess and obsolete inventory in the future. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of the assets. When assets are retired or otherwise disposed of, costs and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is recognized in operations for the period. Maintenance and repairs that prolong or extend the useful life are capitalized, whereas standard maintenance, replacements, and repair costs are expensed as incurred. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are hand-held devices, specifically designed for use with our implants and are used by surgeons during surgery. Instruments deployed within the United States, United Kingdom, Australia, New Zealand, Canada, Belgium, the Netherlands, Italy, Germany, Switzerland and Austria are carried at cost less accumulated depreciation and are recorded in property and equipment, net on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sample inventory consists of our implants and instruments, and is maintained to market and promote our products. Sample inventory is carried at cost less accumulated depreciation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciable lives are generally as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 to 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sample inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></div></td></tr></table></div> Sample inventory is carried at cost less accumulated depreciation. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciable lives are generally as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 to 30 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Business software</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 to 7 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instruments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sample inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 years</span></div></td></tr></table> P25Y P30Y P5Y P7Y P3Y P5Y P3Y P5Y P7Y P5Y P2Y <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortizable Intangible Assets, net</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amortizable intangible assets include fees necessary to secure various patents and licenses (including those acquired in the Band-Lok, MD Ortho and Pega transactions), the value of internally developed software (including by Orthex), and the value of acquired customer relationships and non-competition agreements (including in the Orthex, Telos, ApiFix, MD Ortho and Pega transactions, as applicable). Amortization is calculated on a straight-line basis over the estimated useful life of the asset. Amortization for patents and licenses commences at the time of patent approval, and for licenses upon market launch, respectively. Amortization for assets acquired commences upon acquisition. Intangible assets are amortized over a 3 to 20 year period. </span></div>Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If such assets are determined to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. P3Y P20Y 0 0 0 0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Other Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill represents the excess of the cost over the fair value of net assets acquired. The determination of the value of goodwill and intangible assets arising from acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of net tangible and intangible assets acquired. Goodwill is not amortized and is assessed for impairment using fair value measurement techniques on an annual basis or more frequently if facts and circumstances warrant such </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a review. The goodwill is considered to be impaired if we determine that the carrying value of our one reporting unit exceeds its respective fair value. No goodwill impairment charges were recorded in any period presented. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment by either performing a qualitative evaluation or a quantitative test. The quantitative assessment for goodwill requires us to estimate the fair value of our one reporting unit using either an income or market approach or a combination thereof. </span></div>We have indefinite lived trademark assets that are reviewed for impairment by performing a quantitative analysis, which occurs annually in the fourth quarter, utilizing balances as of October 1, or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net discounted cash flows expected to be generated by the associated asset. During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the ApiFix trademark asset was less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022. No impairment charges were recorded in any other period presented. 0 0 0 3609000 0 0 0 Acquisition Payable and Contingent ConsiderationUpon the completion of an acquisition, the Company may record an acquisition installment payable, contingent consideration or both. Acquisition installment payables, which are fixed future payments, are recorded at their net present value, and contingent consideration is recorded at fair value as determined by management with the assistance of an independent valuation specialist at the original issuance date and is marked to fair value on a recurring basis. Accretion of interest expense attributable to the acquisition installment payable is recorded as a component of interest expense, net. Changes in the fair value of the contingent consideration are included in fair value adjustments of contingent consideration on the condensed consolidated statement of operations. 381000 1926000 489000 1701000 -23010000 -25450000 -1430000 3710000 Cost of RevenueCost of revenue consists primarily of products purchased from third-party suppliers, excess and obsolete inventory adjustments, inbound freight, and royalties. Our implants and instruments are manufactured to our specifications by third-party suppliers who meet our manufacturer qualifications standards. Our third-party manufacturers are required to meet the standards of the Food and Drug Administration (the “FDA”), and the International Organization for Standardization, as well as other country-specific quality standards. The majority of our implants and instruments are produced in the United States. Sales and Marketing ExpensesSales and marketing expenses primarily consist of commissions to our domestic and select international independent sales agencies and consignment distributors, as well as compensation, commissions, benefits and other related costs for personnel we employ. Commissions and bonuses are generally based on a percentage of sales. Our international independent stocking distributors purchase instrument sets and replenishment stock for resale, and we do not pay commissions or any other sales related costs for international sales to distributors. Advertising Costs Advertising costs consist primarily of print advertising, trade shows, and other related expenses. Advertising costs are expensed as incurred and are recorded as a component of sales and marketing expense. Research and Development CostsResearch and development costs are expensed as incurred. Our research and development expenses primarily consist of costs associated with engineering, product development, consulting services, outside prototyping services, outside research activities, materials, development and protection of our intellectual property portfolio, as well as other costs associated with development of our products. Research and development costs also include related personnel and consultants’ compensation expense. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to our IPO, we adopted our 2017 Incentive Award Plan (the "2017 Plan"). The 2017 Plan provides for grants of options and restricted stock to officers, employees, consultants or directors of our Company. The 2017 Plan has authorized 1,832,460 shares for award. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options holders, upon vesting, may purchase common stock at the exercise price, which is the estimated fair value of our common stock on the date of grant. Option grants generally vest immediately or over three years. No stock options were granted in any of the periods presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock may not be transferred prior to the expiration of the restricted period, which is typically three years. The restricted stock that had been granted under the 2007 Plan had restriction periods that generally lasted until the earlier of six years from the date of grant, or an IPO or change in control, as defined in the 2007 Plan. All restricted stock granted prior to May 2014 vested upon our IPO and the remaining grants under the 2007 Plan vested six months after the IPO. We recognize the reversal of stock compensation expense when a restricted stock forfeiture occurs as opposed to estimating future forfeitures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the fair value of restricted stock at the grant date. Stock-based compensation is recognized ratably over the requisite service period, which is generally the restriction period for restricted stock.</span></div> 1832460 P3Y 0 0 0 0 P3Y P6Y P6M Litigation and ContingenciesAccruals for litigation and contingencies are reflected in the condensed consolidated financial statements based on management’s assessment, including advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount is reasonably estimable. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s results of operations in a given period. Comprehensive Income (Loss)Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes foreign currency translation adjustments and unrealized gain (loss) on our short term investments. ncome Taxes<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the condensed consolidated financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence. If we determine that we would be able to realize our deferred tax assets in the future in excess of the net recorded amount, we would make an adjustment to the valuation allowance. </span></div>We record uncertain tax positions on the bases of a two-step process in which (i) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the positions and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">“Emerging Growth Company” and "Smaller Reporting Company" Reporting Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We qualify as an “emerging growth company” as defined in the JOBS Act. "Emerging growth companies" may take advantage of specified reduced reporting and other regulatory requirements that are generally unavailable to other public companies. Among other things, we are not required to provide an auditor attestation report on the assessment of the internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act of 2002. Our status as an emerging growth company will remain until December 31, 2022. As such, our external auditors for the fiscal year ending December 31, 2022 will be required to provide an attestation over the operating effectiveness of our internal controls under Section 404(b) of the Sarbanes-Oxley Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 107 of the JOBS Act also provides that an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we have been and will continue to be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also qualify as a "smaller reporting company," as such term is defined in Rule 12b-2 under the Exchange Act. To the extent that we continue to qualify as a smaller reporting company, after we cease to </span></div>qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Business Combinations (Topic 805)-Accounting for Contract Assets and Contract Liabilities from Contracts with Customers".</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this Update address diversity and inconsistency related to the recognition and measurement of contract assets and contract liabilities acquired in a business combination. The amendments in this Update require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. For public business entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The amendments in this Update should be applied prospectively to business combinations occurring on or after the effective date of the amendments. Early adoption of the amendments is permitted, including adoption in an interim period. An entity that early adopts in an interim period should apply the amendments (1) retrospectively to all business combinations for which the acquisition date occurs on or after the beginning of the fiscal year that includes the interim period of early application and (2) prospectively to all business combinations that occur on or after the date of initial application. The Company is currently evaluating the impact of adopting ASU 2021-08 on its consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force)". </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ASU is intended to clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The guidance clarifies whether an issuer should account for a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU affect all entities that issue freestanding written call options that are classified in equity. The amendments do not apply to modifications or exchanges of financial instruments that are within the scope of another Topic and do not affect a holder’s accounting for freestanding call options. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company adopted this guidance effective January 1, 2022. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements and related disclosures. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13 "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments"</span>. The ASU is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financials assets including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. Financial institutions and other organizations will now use forward-looking information to better inform their credit loss estimates. Based on ASU 2019-10 and our status as a smaller reporting company, the Company will adopt ASU 2016-13 effective January 1, 2023. The adoption of this guidance is not expected to have a significant impact on the Company's consolidated financial statements and related disclosures. BUSINESS COMBINATIONS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Pega Medical </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 1, 2022, the Company, along with its newly-formed, indirect wholly-owned subsidiary OrthoPediatrics Canada ULC, purchased all of the issued and outstanding share capital of Pega Medical Inc., a corporation incorporated under the Canada Business Corporations Act (“Pega Medical”). Pega Medical has developed and sells a portfolio of trauma and deformity correction devices for children, including the Fassier-Duval Telescopic Intramedullary System, a well-recognized, innovative implant designed to treat bony deformities in children with osteogenesis imperfecta without disrupting their normal growth. Pega's product portfolio increases our total systems and increases the percentage of total trauma and deformity cases we can treat. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company acquired Pega Medical for approximately $32,045, comprised of $32,042 in cash and $3 in stock, representing the repurchase right price to be paid by the Company in the event a selling shareholder leaves employment with Pega Medical for certain reasons during the three-year period following the closing. Approximately $1,052 of the cash consideration was deposited into escrow and will be held for a period of up to eighteen (<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVhODliYjlmY2ZkYzQ2NmRiMjg5OWRiOTE3Y2RjOGQ2L3NlYzplYTg5YmI5ZmNmZGM0NjZkYjI4OTlkYjkxN2NkYzhkNl80Ni9mcmFnOjkzMzVlZTI5YWQ5MDRkOTY4ZjI5YmEwNGYzYjAzYTU0L3RleHRyZWdpb246OTMzNWVlMjlhZDkwNGQ5NjhmMjliYTA0ZjNiMDNhNTRfMTA5OTUxMTYzOTIxOQ_e0202dc2-595a-4c1c-9db4-80b7b28a08ff">18) months</span> to cover certain indemnification obligations of the selling shareholders of Pega Medical. Final purchase consideration is subject to certain working capital adjustments yet to be finalized. Additionally, 34,899 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $1,497 (based on the July 1, 2022 closing share price of $42.90) were issued to the selling shareholders. The common stock issued to the selling shareholders, excluding the value attributable to the repurchase right, is not considered part of the purchase consideration and is subject to a repurchase right previously mentioned. The Company will recognize expense over the three-year service period at which point the right to repurchase will expire. In the event the repurchase right is triggered, the Company will have the right to repurchase the shares of common stock issued to such selling shareholder at a price of $0.10 per share. Pursuant to the terms of the transaction, the Company also issued $499 in restricted stock units to employees of Pega Medical, which are subject to an approximate three-year vesting schedule. The restricted stock units are not considered part of the purchase consideration. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the total consideration paid for Pega Medical and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of estimated total acquisition consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable-trade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,654 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: total net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Economic Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks / Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,402 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value estimates and purchase price allocation included above are preliminary while the Company finalizes fair value estimates of the acquired intangible assets and related tax considerations. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">MD Orthopaedics</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2022, OrthoPediatrics Iowa Holdco, Inc., a newly-formed, wholly-owned subsidiary of the Company, merged with and into MD Orthopaedics, Inc., an Iowa corporation (“MD Ortho”). MD Ortho has developed and manufactures a portfolio of orthopedic clubfoot products. The acquisition expands our total addressable market, serving as a specialty bracing platform company within our Trauma and Deformity business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the related merger agreement, the Company paid to the indirect, sole shareholder of MD Ortho consideration of (a) $8,781 in cash, after adjusting for closing net working capital, and (b) 173,241 shares of unregistered common stock, $0.00025 par value per share, of the Company, representing approximately $9,707 (based on the April 1, 2022 closing share price of $56.03). The Company incurred approximately $381 of acquisition-related costs, that are included in general and administrative expenses on the consolidated statement of operations for the nine months ended September 30, 2022. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration paid for MD Ortho and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of estimated total acquisition consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable-trade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: total net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Economic Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks / Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value estimates and purchase price allocation included above are preliminary while the Company finalizes fair value estimates of the acquired intangible assets and related tax considerations. During the third quarter ended September 30, 2022, the Company increased the deferred tax liability recorded as a result of the acquisition of MD Ortho based on newly obtained prior year tax information. This resulted in an increase to goodwill. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the pro forma net revenue and net loss assuming the acquisitions of MD Ortho and Pega Medical occurred on January 1, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From the date of acquisition through September 30, 2022, combined revenue for the acquisitions was approximately $7,006 and combined net income was approximately $1,145. </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,680 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 32045000 32042000 3000 P3Y 1052000 34899000 0.00025 1497000 42.9 0.1 499000 P3Y The following table summarizes the total consideration paid for Pega Medical and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of estimated total acquisition consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,045 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable-trade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,362 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,654 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,527 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,992 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: total net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,662 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,383 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total consideration paid for MD Ortho and the preliminary allocation of purchase price to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of estimated total acquisition consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable-trade</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,444 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,682 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,645 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: total net assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,450 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 32045000 312000 2100000 4876000 360000 604000 10362000 3040000 21654000 2527000 160000 3305000 5992000 15662000 16383000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Economic Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks / Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,402 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of identifiable intangible assets was based on preliminary valuations using a combination of the income and cost approach, inputs which would be considered Level 3 under the fair value hierarchy. The estimated fair value and useful life of identifiable intangible assets are as follows: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Economic Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks / Names</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,460 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,530 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div> 3040000 3141000 P10Y 7221000 P15Y 13402000 8781000 173241 0.00025 9707000 56.03 381000 18487000 420000 1062000 1126000 100000 2444000 9120000 2410000 16682000 45000 586000 3014000 3645000 13037000 5450000 2410000 2660000 P10Y 6460000 P15Y 11530000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the pro forma net revenue and net loss assuming the acquisitions of MD Ortho and Pega Medical occurred on January 1, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From the date of acquisition through September 30, 2022, combined revenue for the acquisitions was approximately $7,006 and combined net income was approximately $1,145. </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.161%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.032%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,950 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,680 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,779 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 7006000 1145000 34950000 29680000 98779000 86544000 18539000 -1859000 10013000 -13576000 GOODWILL AND INTANGIBLE ASSETS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MD Ortho acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pega Medical acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,044 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the balances of intangible assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the balances of amortizable intangible assets were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,664)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,520)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licenses are tied to product launches and do not begin amortizing until the product is launched to the market. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks are non-amortizing intangible assets and are recorded in Other intangible assets on the condensed consolidated balance sheets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended September 30, 2022, management determined that a triggering event occurred, indicating that it was more likely than not the fair value of the trademark assets is less than the carrying value. As such, the company completed a quantitative analysis whereby we determined the fair value of the trademark asset associated with our ApiFix acquisition was below the carrying value. The primary reason for the impairment is the lower forecasted revenue of our ApiFix product than previously expected and the subsequent impact to the discounted cash flow model utilized to calculate the fair value. We recorded a $3,609 impairment charge in the three months ended September 30, 2022 to reduce the carrying amount of the intangible asset to its estimated fair value. Following the impairment, the newly calculated fair value becomes the new accounting basis and carrying value of the trademark. No impairment charges were recorded in any other period presented. The following table represents the significant unobservable inputs utilized in the calculation of estimated fair value associated with the ApiFix trademark asset:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated royalty rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of trademark assets for the nine months ended September 30, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark assets at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MD Ortho Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pega Medical Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark assets at September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of goodwill for the nine months ended September 30, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MD Ortho acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pega Medical acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill at September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,044 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 72349000 5450000 16383000 -6138000 88044000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the balances of intangible assets were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.774%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortizable intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,697 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer Relationships &amp; Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,170 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,899 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,489 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,204)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the balances of amortizable intangible assets were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Amortization Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Intangible Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,664)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,829 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intellectual Property</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License Agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total amortizable assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,014 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,520)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,494 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the carrying amount of trademark assets for the nine months ended September 30, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.387%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark assets at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MD Ortho Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pega Medical Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,040 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation impact</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademark assets at September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,854 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> P12Y2M12D 45763000 7334000 0 38429000 P4Y10M24D 10697000 3342000 0 7355000 P13Y7M6D 17170000 1271000 0 15899000 P10Y 5859000 1257000 0 4602000 79489000 13204000 0 66285000 18463000 3609000 14854000 P13Y8M12D 44493000 5664000 38829000 P10Y1M6D 9847000 1408000 8439000 P5Y6M 10674000 2448000 8226000 65014000 9520000 55494000 3609000 The following table represents the significant unobservable inputs utilized in the calculation of estimated fair value associated with the ApiFix trademark asset:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated royalty rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of September 30, 2022 and December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation techniques</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow, Monte Carlo</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value discount rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4 years</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The present value discount rate includes estimated risk premium.</span></div> 0.280 0.050 0.030 14268000 2410000 3040000 3609000 -1255000 14854000 FAIR VALUE OF FINANCIAL INSTRUMENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value. The accounting standards related to fair value measurements define fair value and provide a consistent framework for measuring fair value under the authoritative literature. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels.</span></div><div><span><br/></span></div><div style="text-indent:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices in active markets for identical assets or liabilities;</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Observable market-based inputs or unobservable inputs that are corroborated by market data; and</span></div><div style="padding-left:14pt"><span><br/></span></div><div style="padding-left:14pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Significant unobservable inputs that are not corroborated by market data.  Generally, these fair value measures are model-based valuation techniques such as discounted cash flows, and are based on the best information available, including our own data.</span></div><div style="padding-left:14pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange Trade Mutual Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange Trade Mutual Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's level 1 assets consist of short term investments which are comprised of exchange traded mutual funds and marketable securities with a maturity date greater than 3 months. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The fair value of the contingent consideration payment is considered a Level 3 fair value measurement and was determined with the assistance of an independent valuation specialist at the original issuance date using an option pricing model and a Monte Carlo simulation based on forecasted annual revenue, expected volatility and discount rates. The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of the acquisition and is determined using a discounted cash flow model or probability simulation model. The significant inputs of such models are not always observable in the market, such as certain financial metric growth rates, volatility rates, projections associated with the applicable milestone, the interest rate, and the related probabilities and payment structure in the contingent consideration arrangement. The adjustments in the fair value of the contingent consideration payments included an income adjustment of $23,010 and $1,430 for the three month periods ended September 30, 2022 and September 30, 2021, respectively, and an income adjustment of $25,450 and an expense adjustment of $3,710 for the nine month periods ended September 30, 2022 and September 30, 2021, respectively, in other expenses on the condensed consolidated statements of operations. For both the three and nine months ended September 30, 2022, the significant factor driving the reported fair value adjustment is the reduction in forecasted revenue which subsequently reduces the final expected payment. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The following table summarizes the change in fair value of Level 3 instruments in 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The recurring Level 3 fair value measurements of contingent consideration liabilities associated with commercial sales milestones include the following significant unobservable inputs as of September 30, 2022 and December 31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation techniques</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow, Monte Carlo</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value discount rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Volatility factor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4 years</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The present value discount rate includes estimated risk premium.</span></div>The estimated fair value reflects assumptions made by management as of September 30, 2022; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration. The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.428%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange Trade Mutual Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,680 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash Equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange Trade Mutual Funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate Bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,476 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset Backed Securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,272 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent Consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 0 0 0 42634000 0 42634000 9680000 0 0 9680000 32396000 0 0 32396000 0 0 0 0 0 0 0 0 0 0 3460000 3460000 0 0 0 0 0 0 0 0 22476000 0 0 22476000 14317000 0 0 14317000 0 8272000 0 8272000 837000 0 0 837000 0 0 28910000 28910000 -23010000 -1430000 -25450000 3710000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:123%">The following table summarizes the change in fair value of Level 3 instruments in 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.921%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,910 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,460 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 28910000 -25450000 3460000 0.162 0.184 0.465 0.503 P1Y7M6D P2Y4M24D DEBT AND CREDIT ARRANGEMENTS<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:57.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage payable to affiliate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt with affiliate, net of current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 13, 2022, the Company entered into a Fourth Amendment (the “Fourth Amendment”) to its Fourth Amended and Restated Loan and Security Agreement with Squadron Capital LLC, or Squadron (as so amended, the “Loan Agreement”). The Fourth Amendment increased the amount available under the revolving credit facility from $25,000 to $50,000 in anticipation of using the facility to fund the cash portion of the Company’s July 1, 2022 acquisition of Pega Medical Inc. After borrowing $31,000 under the Loan Agreement in June 2022 to fund such acquisition, the Company repaid the entire amount on August 15, 2022 with proceeds from a public offering of securities. See Note 3 – Business Combinations for information relating to the acquisition and Note 8 – Stockholders’ Equity for information relating to the public offering.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement provides a revolving credit facility, with interest only payments, at an annual interest rate equal to the greater of (a) six month SOFR plus 8.69% and (b) 10.0%. Prior to December 31, 2021, the interest rate on the facility had been equal to the greater of (a) three month LIBOR plus 8.61% and (b) 10.0%. The Company pays Squadron an unused commitment fee in an amount equal to the per annum rate of 0.50% (computed on the basis of a year of 360 days and the actual number of days elapsed) times the daily unused portion of the revolving credit commitment. The unused commitment fee is payable quarterly in arrears. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the revolving credit facility are made under a Second Amended and Restated Revolving Note, dated June 13, 2022 (the “Amended Revolving Note”), payable, jointly and severally, by the Company and each of its subsidiaries party thereto. The Amended Revolving Note will mature at the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier of: (i) the date on which any person or persons acquire (x) capital stock of the Company possessing the voting power to elect a majority of the Company’s Board of Directors (whether by merger, consolidation, reorganization, combination, sale or transfer), or (y) all or substantially all of the Company’s assets, determined on a consolidated basis; and (ii) January 1, 2024. </span></div><div><span><br/></span></div><div style="padding-right:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Loan Agreement are secured by substantially all of the Company's assets and are unconditionally guaranteed by each of its subsidiaries with the exception of Vilex. There are no traditional financial covenants associated with the Loan Agreement. However, there are negative covenants that prohibit us from, among other things, transferring any of our material assets, merging with or acquiring another entity, entering into a transaction that would result in a change of control, incurring additional indebtedness, creating any lien on our property, making investments in third parties and redeeming stock or paying dividends, in each case subject to certain exceptions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the purchase of our office and warehouse space in Warsaw, Indiana in August 2013, we entered into a mortgage note payable to Tawani Enterprises Inc., an affiliate of Squadron. Pursuant to the terms of the mortgage note, we pay Tawani Enterprises Inc. monthly principal and interest installments of $16 with interest compounded at 5% until maturity in 2028, at which time a final payment of remaining principal and interest is due. The mortgage is secured by the related real estate and building. At September 30, 2022 the mortgage balance was $942 of which current principal of $143 was included in the current portion of long-term debt. As of December 31, 2021, the mortgage balance was $1,044 of which current principal due of $137 was included in the current portion of long-term debt. </span></div>The aggregate interest expense relating to the notes payable to Squadron and the mortgage note payable to Tawani was $12 and $14 for the three months ended September 30, 2022 and 2021, respectively, and $512 and $42 for the nine months ended September 30, 2022 and 2021, respectively. The unused commitment fee paid to Squadron was $44 and $32 for the three months ended September 30, 2022 and 2021, respectively, and $111 and $95 for the nine months ended September 30, 2022 and 2021, respectively. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:57.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage payable to affiliate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt with affiliate, net of current maturities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">799 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">907 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 942000 1044000 143000 137000 799000 907000 25000000 50000000 31000000 31000000 0.0869 0.10 0.0861 0.10 0.005 16000 0.05 942000 143000 1044000 137000 -12000 -14000 -512000 -42000 44000 32000 111000 95000 INCOME TAXES <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes an estimated annual effective tax rate to determine its provision or benefit for income taxes for interim periods. The income tax provision or benefit is computed by multiplying the estimated annual effective tax rate by the year-to-date pre-tax book income (loss). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, the income tax benefit was $4,899 compared to $890 for the nine months ended September 30, 2021. Our effective income tax (benefit) rate was (116.5)% and 5.2% for the nine months ended September 30, 2022 and 2021, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets were fully offset by a valuation allowance at September 30, 2022 and December 31, 2021, with the exception of certain deferred tax liabilities recognized in a foreign jurisdiction as a result of fair value adjustments recorded upon the acquisition of ApiFix and Pega Medical. The company has recorded a tax benefit during the period ended September 30, 2022 for losses generated in the foreign jurisdiction. As of December 31, 2021, we had available federal, state and foreign tax loss carryforwards of $114,008, $73,997 and $22,671, respectively. We had available federal tax credits of $176. Net operating losses generated prior to December 31, 2017 will begin to expire in 2028. Federal net operating losses generated after January 1, 2018 will have an indefinite carryforward period. An ownership change under Section 382 of the Internal Revenue Code was deemed to occur on May 30, 2014. Given the limitation calculation, we anticipate approximately $23,920 in losses generated prior to the ownership change date will be subject to potential limitation. The estimated annual limitation is $1,062. A second ownership change under Section 382 was deemed to occur on December 11, 2018. The estimated annual limitation is $9,736, which is increased by $22,430 annually over the first five years as a result of an unrealized built in gain. NOLs sustained prior to May 30, 2014 will still be constrained by the lower limitation. </span></div>Management assesses the available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September 30, 2022. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. Management has reviewed the tax implications of the MD Ortho purchase accounting and recorded approximately $3,010 of deferred tax liabilities. This resulted in a decrease to the overall net US deferred tax assets, thereby causing a remeasurement of the valuation allowance during the quarter ended September 30, 2022, such that an approximately $3,010 of tax benefit was recorded for the reversal of the valuation allowance. -4899000 -890000 -1.165 0.052 114008000 73997000 22671000 176000 23920000 1062000 9736000 22430000 3010000 -3010000 STOCKHOLDERS’ EQUITY<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value for options granted at the time of issuance were estimated at the date of grant using a Black-Scholes options pricing model. Significant assumptions included in the option value model include the fair value of our common stock at the grant date, weighted average volatility, risk-free interest rate, dividend yield and the forfeiture rate. There were no stock options granted in any of the periods presented.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock option activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options generally include a time-based vesting schedule permitting the options to vest ratably over three years. At September 30, 2022 and December 31, 2021, all options were fully vested. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no stock-based compensation expense on stock options for the three and nine months ended September 30, 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards &amp; Restricted Stock Units</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">in Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216,631 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,634 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,067)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424,985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock exercisable at September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, there was $12,374 of unrecognized compensation expense remaining related to our service-based restricted stock awards and stock units. The unrecognized compensation cost was expected to be recognized over a weighted-average period of 1.7 years or earlier upon an elimination of the restriction period as a result of a change in control event. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense on restricted stock amounted to $1,682 and $1,440 for the three months ended September 30, 2022 and 2021, respectively, and $4,978 and $4,170 for the nine months ended September 30, 2022 and 2021, respectively. The increase in the stock compensation for the three and nine months ended September 30, 2022 is primarily due to increase in plan participants from acquired businesses and newly hired employees to support the continued expansion of our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2022 the Company purchased all of the issued and outstanding share capital of Pega Medical Inc. See Note 3 - Business Combinations for additional detail. As a component of that acquisition, the Company issued 34,899 shares of unregistered common stock. The Company determined that these shares were not part of the purchase consideration and would recognize expense over three years. During the three months ended September 30, 2022 the Company recognized expense of $133 associated with these shares. </span></div>During the three months ended September 30, 2022 the Company completed a following-on offering in which we issued 1,525,000 of pre-funded warrants to Squadron. The warrants had an exercise price of $0.00025. All warrants issued in the quarter were exercised and included in our outstanding common stock as of and during the three months ended September 30, 2022. As of September 30, 2022 and 2021 the Company had no warrants outstanding. 0 0 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock option activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.688%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.851%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,072)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,556 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9</span></td></tr></table> 6638 30.97 P1Y3M18D 2010 30.97 1072 0 3556 30.97 P0Y10M24D P3Y 0 0 0 0 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted stock activity and related information are summarized as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual Terms</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">in Years</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368,446 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216,631 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,634 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150,067)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424,985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,634 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock exercisable at September 30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table> 368446 P1Y1M6D 0 216631 11634 10025 0 150067 0 424985 P1Y8M12D 11634 P2Y9M18D 0 0 12374000 P1Y8M12D 1682000 1440000 4978000 4170000 34899000 133000 1525000 0.00025 NET LOSS PER SHARE<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted net loss per share:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.441%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator for basic and diluted net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,150,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,291,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,703,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,256,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding for diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,295,323 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,291,374 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,958,503 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,256,128 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.88 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our basic and diluted net loss per share is computed using the two-class method.  For purposes of our equity disclosures and calculation of weighted average shares for basic earnings per share calculations, the two-class method is an earnings allocation that determines net income per share for each class of common stock and participating securities according to their participation rights in dividends and undistributed earnings or losses.  Non-vested restricted stock that includes non-forfeitable rights to dividends are considered participating securities. For the periods presented with a net loss the weighted average shares outstanding remains consistent between basic and diluted as the effect would have been anti-dilutive. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the contingently issuable and convertible equity shares that were excluded from the calculation of diluted net earnings (loss) per share because their effect would have been anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382,553 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic and diluted net loss per share:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.441%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Earnings allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income available to common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,932 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,332)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denominator for basic and diluted net income (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,150,219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,291,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,703,883 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,256,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average shares outstanding for diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,295,323 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,291,374 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,958,503 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,256,128 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings (loss) per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.88 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.43 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 18539000 -2197000 9106000 -16332000 353000 353000 0 0 174000 174000 0 0 18186000 18186000 -2197000 -2197000 8932000 8932000 -16332000 -16332000 21150219 19291374 20703883 19256128 21295323 19291374 20958503 19256128 0.88 -0.11 0.44 -0.85 0.87 -0.11 0.43 -0.85 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the contingently issuable and convertible equity shares that were excluded from the calculation of diluted net earnings (loss) per share because their effect would have been anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382,553 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 375915 0 6638 0 382553 BUSINESS SEGMENT <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. We have one operating and reporting segment, OrthoPediatrics Corp., which designs, develops and markets anatomically appropriate implants and devices for children with orthopedic problems. Our chief operating decision-maker, our Chief Executive Officer, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance, accompanied by disaggregated revenue information by product category. We determined that disaggregating revenue into these categories achieves the disclosure objective of illustrating the differences in the nature, timing and uncertainty of our revenue streams. We do not assess the performance of our individual product categories on measures of profit or loss, or other asset-based metrics. Therefore, the information below is presented only for revenue by category and geography. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors and is based on the final destination where the products are sold. No customers accounted for more than 10% of total product sales for the three and nine months ended September 30, 2022 or 2021. No customer accounted for more than 10% of consolidated accounts receivable as of September 30, 2022 and December 31, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by source were as follows: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.325%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by geographic location:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,411 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,295 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,236 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.025%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by category:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trauma and deformity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scoliosis</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,979 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,383 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,874 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sports medicine/other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,950 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,079 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,295 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,236 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>No individual country with sales originating outside of the United States accounted for more than 10% of consolidated revenue for the three and nine months ended September 30, 2022 and 2021. 1 1 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales by source were as follows: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.325%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by geographic location:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,930 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,411 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,725 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,608 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,306 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,950 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,079 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,295 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,236 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 26539000 19354000 69687000 57930000 8411000 5725000 21608000 15306000 34950000 25079000 91295000 73236000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product sales by category:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trauma and deformity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,817 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,976 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Scoliosis</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,979 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,266 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,383 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,874 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sports medicine/other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,079 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,060 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,950 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,079 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,295 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,236 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 23892000 16817000 62976000 49302000 9979000 7266000 25383000 20874000 1079000 996000 2936000 3060000 34950000 25079000 91295000 73236000 RELATED PARTY TRANSACTIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the debt and credit agreements and mortgage with Squadron and its affiliate (see Note 6), we currently use Structure Medical, LLC (“Structure Medical”) as one of our suppliers. Structure Medical is affiliated with Squadron and a supplier with which we maintain certain long-term agreements. We made aggregate payments to Structure Medical for inventory purchases of $218 and $173 for the three months ended September 30, 2022 and 2021, respectively, and $768 and $441 for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2019, the Company divested Vilex for $25,000 to an affiliate of Squadron. In conjunction with the divestiture, the Company also entered into an exclusive perpetual license agreement to permit the purchasers of Vilex the ability to access intellectual property and sell products using the external fixation technology of Orthex, LLC to non-pediatric accounts. We had sales and payments related to inventory purchases to Squadron's affiliate, now known as Vilex, LLC, of $51 and $7, respectively, for the three months ended September 30, 2022, and sales and payments of $111 and $39, respectively, for the nine months ended September 30, 2022. We had sales and payments related to inventory purchases to Vilex, LLC of $45 and $150, respectively, for the three months ended September 30, 2021, and sales and payments of $200 and $675, respectively, for the nine months ended September 30, 2021.</span></div> 1 218000 173000 768000 441000 25000000 51000 7000 111000 39000 45000 150000 200000 675000 EMPLOYEE BENEFIT PLANWe have a defined-contribution plan, OrthoPediatrics 401(k) Retirement Plan (the “401(k) Plan”), which includes a cash or deferral (Section 401(k)) arrangement. The 401(k) Plan covers those employees who meet certain eligibility requirements and elect to participate. Employee contributions are limited to the annual amounts permitted under the Internal Revenue Code. The 401(k) Plan allows us to make a discretionary matching contribution. Discretionary matching contributions are determined annually by management. We have elected to match our employees' 401(k) contributions up to 4% of employees' salary. Additionally, employees of MD Ortho receive contribution matches up to 3% of their salary. 0.04 0.03 COMMITMENTS AND CONTINGENCIES<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Leases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September 30, 2022, the Company has recorded a lease liability of $303 and corresponding right-of-use-asset of $304 on its <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVhODliYjlmY2ZkYzQ2NmRiMjg5OWRiOTE3Y2RjOGQ2L3NlYzplYTg5YmI5ZmNmZGM0NjZkYjI4OTlkYjkxN2NkYzhkNl83Ni9mcmFnOjFjZGE3MGYzZTJlYzQ1OTc5NGYwMzQyMjNhYzE3MmEyL3RleHRyZWdpb246MWNkYTcwZjNlMmVjNDU5Nzk0ZjAzNDIyM2FjMTcyYTJfNzM4OA_43425c46-9145-4c87-b469-58dd3cbba87d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVhODliYjlmY2ZkYzQ2NmRiMjg5OWRiOTE3Y2RjOGQ2L3NlYzplYTg5YmI5ZmNmZGM0NjZkYjI4OTlkYjkxN2NkYzhkNl83Ni9mcmFnOjFjZGE3MGYzZTJlYzQ1OTc5NGYwMzQyMjNhYzE3MmEyL3RleHRyZWdpb246MWNkYTcwZjNlMmVjNDU5Nzk0ZjAzNDIyM2FjMTcyYTJfNzM4OA_53f54220-8006-4bd8-98b7-b785d2655752"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVhODliYjlmY2ZkYzQ2NmRiMjg5OWRiOTE3Y2RjOGQ2L3NlYzplYTg5YmI5ZmNmZGM0NjZkYjI4OTlkYjkxN2NkYzhkNl83Ni9mcmFnOjFjZGE3MGYzZTJlYzQ1OTc5NGYwMzQyMjNhYzE3MmEyL3RleHRyZWdpb246MWNkYTcwZjNlMmVjNDU5Nzk0ZjAzNDIyM2FjMTcyYTJfNzM4OA_dcba51bb-b4c6-4e0d-9dc4-e06ac961a2b9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmVhODliYjlmY2ZkYzQ2NmRiMjg5OWRiOTE3Y2RjOGQ2L3NlYzplYTg5YmI5ZmNmZGM0NjZkYjI4OTlkYjkxN2NkYzhkNl83Ni9mcmFnOjFjZGE3MGYzZTJlYzQ1OTc5NGYwMzQyMjNhYzE3MmEyL3RleHRyZWdpb246MWNkYTcwZjNlMmVjNDU5Nzk0ZjAzNDIyM2FjMTcyYTJfNzM4OA_e7989334-115a-4d03-a795-d92ce3e7eed1">condensed consolidated balance sheet</span></span></span></span>. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we are involved in various legal proceedings arising in the ordinary course of our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">IMED Surgical - Software Ownership Dispute</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, the Company, its wholly-owned subsidiary, Orthex, LLC (“Orthex”), the Company’s largest investor, Squadron Capital, LLC (“Squadron”), and certain other defendants, were named in a lawsuit filed by IMED Surgical, LLC, a New Jersey company (the “Plaintiff”), in Broward County, Florida Circuit Court. In the lawsuit, the Plaintiff claims, among other things, that it is the rightful owner of certain patented point-and-click planning software being used by the Company, Orthex and Squadron (specifically, U.S. Patent No. 10,258,377 (titled “Point and click alignment method for orthopedic </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surgeons, and surgical and clinical accessories and devices,” issued on April 16, 2019) (hereinafter, the “’377 Patent”).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company purchased all the issued and outstanding units of membership interests in Orthex, and all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. for $60,000 in total consideration. Vilex and Orthex are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as the Orthex Hexapod technology, a system of rings, struts, implants, hardware accessories, and the Point &amp; Click Software used to treat congenital deformities and limb length discrepancies. On December 31, 2019, the Company divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron, in exchange for a $25,000 reduction in a term note owed to Squadron in connection with the initial acquisition. As part of the sale, the Company also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property, including the ‘377 Patent.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the lawsuit, the other defendants, who are unrelated to the Company, assigned the ‘377 Patent to Orthex in violation of certain agreements with the Plaintiff.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plaintiff, among other things, requests that the defendants be ordered to convey and assign to Plaintiff all of their rights, title and interests in and to the ’377 Patent and seeks certain compensatory, consequential and unjust enrichment damages from Orthex and the unrelated defendants. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2021, the Court ordered the lawsuit stayed pending arbitration. To the extent the Plaintiff desires to further pursue the matter, it must first do so through a separate arbitration proceeding. In mid-November 2021, the Plaintiff initiated an arbitration proceeding; however, the Plaintiff failed to pay the fees it was required to pay for the arbitration to continue, resulting in the arbitration panel terminating the arbitration proceedings in mid-October 2022. In connection with the stay order, the Court also ordered the Company, Orthex and Squadron to give notice to the Plaintiff before any attempt to dispose, assign, sell or otherwise encumber the ‘377 Patent. The Company, Orthex and Squadron filed an appeal of this component of the order, but the appellate court affirmed the lower court’s decision. The Company, Orthex and Squadron have not sought to further pursue an appeal of the subject order. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the IMED lawsuit is without merit and will vigorously defend the claims asserted against us, arbitration and litigation can involve complex factual and legal questions, and an adverse resolution of such proceedings could have a material adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Wishbone Medical, Inc. – Patent Infringement Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 30, 2020, OrthoPediatrics, along with its wholly-owned subsidiary, Orthex, LLC, filed a lawsuit in federal district court (N.D. Indiana, South Bend Division, Case No. 3:20-cv-00929) against Wishbone Medical, Inc. and Nick A. Deeter (collectively “Wishbone”), claiming infringement of ’377 Patent, unfair competition, false advertising, breach of contract, defamation per se, tortious interference with contractual relationships, and tortious interference with prospective contractual relationships. In early January 2021, OrthoPediatrics amended its lawsuit by adding a declaratory judgment claim of infringement of the ‘377 Patent against Wishbone. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter, in January 2021, Wishbone filed a motion to dismiss all OrthoPediatrics’ causes of action. In late August 2021, the Court denied Wishbone's motion to dismiss with respect to OrthoPediatrics’ infringement and breach of contract claims and dismissed OrthoPediatrics' remaining causes of action. In late September 2021, Wishbone filed its answer and counterclaims, in part, seeking declaratory judgment of non-infringement and invalidity of the ‘377 Patent, and alleging OrthoPediatrics patent infringement claim(s) against Wishbone was made in bad faith. In mid-October 2021, OrthoPediatrics filed its answer to Wishbone’s counterclaims, denying all of them. Although we believe Wishbone’s counterclaims are </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without merit and will vigorously defend the claims asserted against us, litigation can involve complex factual and legal questions, and an adverse resolution of this proceeding could have an adverse effect on our business, operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are not presently a party to any other legal proceedings the outcome of which, if determined adversely to us, would individually or in the aggregate materially affect our financial position or results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Purchase Obligations and Performance Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of entering into a license agreement for the exclusive distribution of the 7D Surgical FLASH</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Navigation platform, the Company has agreed to a minimum purchase commitment for the first twelve months of that agreement. As of September 30, 2022, the remaining purchase commitment under the agreement was $0.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 20, 2021, we entered into an amended license agreement, resulting in a five-year extension of our exclusive distribution rights of the FIREFLY Technology. As a component of the agreement the Company is required to meet minimum performance metrics, measured by the number of spine procedures in the fiscal year which used the FIREFLY products against the annual requirement in the agreement. This includes any scheduled surgeries whereby the Company has committed to payment of the product. The number of required surgeries varies each year of the agreement. The Company analyzes its projected achievement of these performance metrics and accrues for any estimated shortfall. During the three and nine months ended September 30, 2022, the Company recorded an expense of $101 and $442, respectively. No expense was recorded for either the three or nine months ended September 30, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we are contracted to pay royalties to individuals and entities that provide research and development services, which range from 0.5% to 20% of sales. </span></div>We have products in development that have milestone payments and royalty commitments. In any development project, there are significant variables that will affect the amount and timing of these payments and as of September 30, 2022, we have not been able to determine the amount and timing of payments. We do not anticipate these future payments will have a material impact on our financial results. 303000 304000 60000000 25000000 0 P5Y 101000 442000 0 0 0.005 0.20 EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

89/4M MFRU__05&P5M;E"_D["A6/,2*?=Z7EU1N;0'VHZ)N5%L1;IL*;_%@"S<-_K!U$I47.F*U/% ME$U>;-PX)L'!1.WEF59A'$:I75XRR$N\\C[7;$=Y#MB]!K!DLDNJ4%M6ZRI_ M6&=LNA,SK7$XE6T:880I5_54H6CQ#8&H*1"0,DXE$TPQBS97$+A(& M(\.")Y*KVYI:/71)9?\U?-KGSJ MGKJ'*OOQ+X25E_)V'.T(4>CEUO*BU+62_^C*#Z\4K6YX^[$/W_V(D)'[*-+9 MGSXBTRP,24H%%9IV*SI24"F1SHPV'K8@W<1!\,DF0*2(M9BI&KG(^(A'Y&:J5UTW:I MHFS13OO=J0;1FE5LPQV3RD1AA(V^VF(5XM QX]&(2^3'Y>.$VK6568O5?5XA MJIO3KJ'-V5KI/:C: KK9Z.E&E37GR(0C)%/]-B,<.^2/_$1>8MGDTTQ#7_+N MDE=2+^BB[$SZR6,- )KU.<+3SMQB!5$2.7I5=+"U]%/QTU'G=["RK5)-RN$X MFFYT+%8H((%#Z8A"Y$?A<0OXE%(3>BB)2325:C%+8U=GA48V(N*ME!^&6?Q4 MK41>R/[TSOV%O!V'/8(6^4'[P;=XNQ:K72/9\;*Q9L5D;)P:\\PT2@/7HAXI MC)[:K7I7\$]%88(X3A":AF'9A6JN._HS--(:^?>AEZ)2O+II-6:BDCQG-74J M-;>:F$1*M4))"U\H>$8O\B+UB&Z:3F>M\:W8QH.B]8U6;X Q)&$]EFE8D MCEVP&O&*_'CM*V5A6]E6K28R"3$R:MFOIMBN%(]8Q7ZL]I7RV4JQ!8YQ&D_W MS!8SDL+4\?3Q2%'LI^A>[1,:3?R1*$;3UM=B%B=IX*CG>*0D]I_ KI3(OF]% MH=>0_*W;V*L':SG'+WH0^U+>CJ,^.(I]XBQ6E*6N@K(-?@Y.@M=!$*!05\(: MW-*B86]!&,SU=^T_(+>T;D^3&K45-?_!\K< H7F21O, P^%7W8W"=![%\1Q! M\O@ME[+M6VEWT+=B.\7*-:O[0(93^5=-19N<*Y;_WKFY8MFAV?[4_>F306PB M?]H56$Q<,VCL"+!_MWR1YQU3]%1OC]].>04RNN-ZZEM%FCOA,$PQGB+08H=3 MDJ0.>."1Y-A/O3_L+)7;=&\BU4$J4W<BA +?S(3,J<:NG+NJE$!3"\JY&WA> MZ.:4%4[V[#DK(<"L5$023,>D[?/QU$)MX&?&>P5&MM8IQ,A7@PGIE3!0/ ?+-59SSEV2 HS6G%] M*Y87L/+3,7R)X,K^DV4=&YTX)*F4%OD*C IR5M1/^KC*PQK ;^\ !"M \%Y M:P5H6:.U,FMK2#6-NU(LB331R&8:-C<6C6Y8859QHB6^98C3\>#F>CBZGHR& M!%N3FZO+8?\..V?]J_[U8$0F%Z/1W83LCZF$0F>@64+Y ?E"[B=#LK]W0/8( M*\A=)BI%BU1U78V:#+.;K.8_J^!T^A 3AOH7[ MFW 7,]&D(VC2$5B^UBXYFFK 3:J)F)%S5M B8923L5#,[KJ?_:G2$O?>KVU6 M:^[V=FYS'D]521/H.7C@%,@%./'G3W[H?=UF_#^1;:2AU:2A]1I[W.=XNM$[ M$+PG2"JJJ9Y5',]<(JI";UWFFC"TA.;J6,2A=]QU%^N67L:TVE$3LZ&TW2AM MOZIT(/(4>> MYP6=9^+?CMLPT&D,=#Y@P,I4A%8Z$Y+]A=0:J4>WJJ_).VNJ.E[]>R;_'8$; M^L-&?_AQ_4RIZFWMX0M)07!\$GHM_YGVEX'^21A%@=_>KCUJM$%(AQF"/6.(N20=66J.UJ4]G*?"HVE MPC8S+.8@30"^GPFAGSJF7C2?!_$_4$L#!!0 ( *&8560)Y"WT 8 'T@ M 8 >&PO=V]R:W-H965T&ULK5I=;]LV%/TKA%<,+5#' M(JG/+#&06.H68$V".%T?ACTH-A-KE45/I)WLWX^2',DFK[ATTTLM*8>'/+R7 MO(=2SYYY^4VL&)/H99T7XGRTDG)S.IF(Q8JM4W'"-ZQ0?WGDY3J5ZK9\FHA- MR=)EW6B=3XCC^)-UFA6CZ5G][+:3*9GF_2)S9G\LKDMU=VD95EF:U:(C!>H9(_GHPM\FI"@:E C?LO8 MLSBX1I64!\Z_53=7R_.14XV(Y6PA*XI4_>S8C.5YQ:3&\=>>=-3V634\O'YE M_U2+5V(>4L%F//^:+>7J?!2.T)(]IMMD%?Q+7@NZG_1H MI4\:[?7$Q:E,IVSF^LXN9XG M,5)7\YM?K^*+>W4SOU<_GY/K^SFZ^81N;I.[B_LK!4!C]&4>H_?O/J!W*"O0 M_8IO15HLQ=E$JM%4G)/%ON?+IF?2TS-%GWDA5P(EQ9(M@?:QO7UD:3]1L]!. M!7F=BDMB)9RSS0FBSD=$'$* \WAQ#JVJ1LEVK-@R* )-8[]N7%6'W92ZD>>< M37:'4VNBB.<$T3$J-E$1)I%WC$I,5$ )]5O4D4JO5>E95E;=?Y<1FP\I49L438B_* MVP@F3B&UP9#;QY!D\9!DR4!D1Y$(VTB$UH2;ISD32)5JY1[*;ZR*"12)T,PH M'&$][TQ4%/I$2SL31%WLA%K:F2@2^6$ IUW4BHWLJXL5*N_R6FZZ5+8IJVI7 M94DAS9&IV<-86Q\S (4=JJ\U$^62D.A;BHE24^-36#1V.B_G6&7?E^F25>%% MV7J39F55N$%CYIC]^XX>9 "EE9/X342)E>A8ZH%MQ5:I=VJ!I.5B58=XJ8I% MSC>]"HHDY M!!(:A@" $8*C4)=MPD)54/4: L#\( C[A'=F%%N=U4$9R579!.52H^>Q'QFV M ()1W]57,03#@1,9<89PQ.U=R9W7PZZ];LH5*]OXHO=9;<<_@,436WWC]U;/ M0=GB0=F2H=B.@])94VSWIE>%9(I7OL;E(RH8O.&8EC'0"]\, 'FNL=T %M4- M=2<.H)0/Q#U)V%E4;/>HGU0)0;LTWS)51/_<"ED?!)4Y7ZB#MUJ,U9VZ%-FR M7IV\ .?"])5C0AUL;$0 #KO4J#@0G>?J^UH"X&B ^\I.9V>QU:,=K\MV68*Z M ],CN9XNV@2-B1_HFDT4]GW=2$%SI9S28CD2!+M_$N<'!6>Y8?F MO62'B0#JQ<;[$+4)4]U5 S"5SWHZQP LPKIG32 R=8Z@?4'OG"8A5O_QM7[! MSM3I::?V]B>&Q"I5I0_QK1126>Z>TR.Q^M?OM2*#LL6#LB5#L1W'IS/$Q&Z( M+U.1+:IM>!\8."--=TK4#NL0XSP/('%$(DP#W1E#G$[@T#"D>FZ"G)Z/2=B3 MG9T[)O97H7&6;ZOD_#?]+J"?1!XEQB9D(OOT YQ.Y*F#E:$?Y+3I[XPH\:RK MT]B/D#H?-3,!SH/5UG[WJAR2+1Z4+1F*[3@NG6$F=L/(#2+SN$@$4 M*!XBT[U& I,9XB<'GU/7K'RJOV,+==39%K+Y@M8^;;^57]1?B+7GE_ATAH'G M,3Y-FB_A'7WS8?YS6CYEA4 Y>U1=.2>!2NBR^=;=W$B^J3_F/G I^;J^7+%4 M'< J@/K[(^?R]:;JH/T?!]-_ %!+ P04 " "AF%5B@'26_4# "+#@ M& 'AL+W=O MS_! V3<>$R+0:Y;F?*3%0FP'NLZ7,I9E.3:>%C,/;#QD.Y$FN3D@2&^R[*(_;@C*3V,-*R]33PFFUC("7T\ MW$8;$A+QO'U@,-)KEE62D9PG-$>,K$?:! \";$B# O$U(0=^](ZD*R^4?I.# MV6JD&7)')"5+(2DB>.S)E*2I9()]?*](M7I-:7C\_L;^J7 >G'F).)G2]/=D M)>*1YFEH1=;1+A6/]/"95 XYDF])4U[\HD.%-32TW'%!L\H8=I E>?F,7BLA MC@R 1VU@5@9FT\ ^8V!5!M9[5[ K _N]*SB50>&Z7OI>".='(AH/&3T@)M' M)E\*]0MKT"O)9:*$@L'7!.S$>+J8^\$\#'P$;^'BR\R?/,$@?(+'?3!_"M'B M$WRZ?W@,/@-N]C5 LSF, W3U91&&U^@&/8<^NOIPC3Z@)$=/,=WQ*%_QH2Y@ M>W(1?5EMY:[ M(LOXB$S#-!7[F;[?'*O<^7^K!_]Y]1,QK#I1K(+/.L5\)ZDI2QN$HIY]>J.)04;D$AJ\A^C#W' MZ@_U_;' ;=2-B?N]4Y3?1O6QX9Z" @45=BW+K&$GOCJUKTYG.BY$3!A:GN3A MB>\#E?/.)9/PDF3^)*C5V[D9IME.EYC<14,&''=7$C-54PR[;4F=FK!>AU M"O"I_^3.L8([K&H+0:!U$A$0I0">*T=8=-P&@*T00W'_/?0 M!%TT)Z[W:]?[G:[_ZZ'T$>6D** B>E5YWV_'P[)Q(VVG;12T!0T!%$S8<;SF MX:R"N::CE@$;/R^51J<0T_,2*.^%1KLH.=ALY/14 ;O!_5954L%?UH\MU1MBFZ&HX1'F7B_+Z5,_6G=.DZ!<:\W=X,,6*>5]V6L5E_B=] MV:;=1VR3Y!RE9 U+&;<]"!0K.Y]R(.BVN-J_4 &-0O$:0[=(F 3 ]S6EXFT@ M%ZC[S_$_4$L#!!0 ( *&856K%^YDE T .V% 8 >&PO=V]R:W-H M965T&ULM5U_<]LV$OTJ'+73:V;JB #X,[4]DXC -+TFSL7I MW=R?K$1;G$BB2M)Q\NT/E!5! %8@J5LW,[5D+]^2> 2)]Q8@+Q^K^G.S+(K6 M^[I>;9JKR;)MMZ^FTV:^+-9Y\[+:%AOYE[NJ7N>M_%K?3YMM7>2+W4;KU93Z M?C1=Y^5FFA7Y:;X4'O-PWJ=U]_>%*OJ\6I")M]_\;&\7[;= M+Z;7E]O\OK@MVC^W'VKY;7I 693K8M.4U<:KB[NKR6OR2B2[#781_RZ+Q^;H ML]<=RE]5];G[\G9Q-?&[/2I6Q;SM('+YXTLQ*U:K#DGNQ]][T,DA9[?A\>?O MZ&)W\/)@_LJ;8E:M_E,NVN75))EXB^(N?UBU'ZO'WXK] 84=WKQ:-;O_>X_[ M6'_BS1^:MEKO-Y9[L"XW3S_SK_N&.-J L!,;T/T&=.@&;+\!,S:@\8D-@OT& M@;G!J6,(]QN$Q@9!=&*#:+]!M&O[I\;:M726M_GU95T]>G47+=&Z#SNZ=EO+ M!BXWW9EUV];RKZ7W;S/^/M;GGGRT^W-'V^SUY_DE]M/\L<[_OZ3=R/D MEYO9/W^[^2/C'V]_^B&A)/[5X__Z\^VG_WH7WI^WF??SCR^\'[URXWU:5@]- MOEDTE]-6[ER78CK?[\B;IQVA)W;D4]7F*V"SF7NS6;5>RQ/TMJWFGX&M,_?6 MKQ>+LCO!\Y7W(2\7%_(09OFVA/>$]V#-YP_KAU7>%@LO*^[*>=D"(&(XR$V[ M+&I/'J"\9"R[OORE\-YNYM6Z\'[^HVJ:%SK\5#)_H)\>Z*>[?,&)?&_R5;Z9 M%U[>RGV>O_08^<6C/O4A_IZ0HAU2=\'Z5TT+P:UD1.UNTN\ M:K;YO+B:2$Z;HOY23*Y_^H%$_J_0F?\$%AX=&$G#R*/SOA[+]!E$98%*) M"99A@G%,,($$IM$='N@.G5WVO1R&E?O+X\J^/#Z1&EI=ZH+X+$Z-:Y@STUBZ M,,'XL ,02#DU(J(#$9&3B*?[UER[;_42$]G'Q:Q;PLR9>"POF& <$TST-89& M2WR@)7;2LKON>=5V-Z OOA;UO&P*B(K8RAZ9/#@SC>6A/Q_'S">0P#02D@,) MR7@2CD<9$"%.R+%WHL1J;>H3WQA08&;DF& ""4PC+SV0ESK)^U@T;5W.N[%Y M .-A@ 0)/.RQ$R7/B ME(-G>RQNV-%G>C#494'-RU'1!!::3J62WB1\3JN%8$KD&2I:AHK&4=$$%IK. MNM+YQ"WT!SDN!!"S)&+,E)3N7*-90Q7WJ&@""TUG3=D Q.T#G&7/$%ND2Q:I M-0Y#-090T3@JFL!"TTE4-@)Q^PA'0XO;8BOOE[YC9 A(?BHEBS6T2/J'%C84 M2ZG\9PXM[#@YB$[\-#&'%G9@1),33A=10IVXE?J)H45_4V'JY!D!I'D:22UA M^EL9:EZ.BB:PT/3ZI)+[U"WWQ\A%:HMS4"[NXYPU2AL*E(M '"P7@<#3FQ52*I\\YB*:H!@ J6H:*QE'1 M!!::SKHR":C;)!@TB*: 5&=Q:/K*[E2C24.=5C#L$ 164IT-Y4E0MR=QUN"8 M A9"G,8F.:AS %#1."J:Z&L/G1ME,E!W@7](^87:]7$2$.O^C^H0#,K)47,* M+#2="J7\J5OYCZW!N.%&WYML2X'XD>DH9*A).2J:P$+3^5,> '5[ $>#ZM\? M-FY-1&WI+\?4D4_,3A7W#ZIM*)9"?05R&^(P-7,*(##R3\E'JM0U'::NC4%U M?U.A5NJIK8T[^>C[06"V*VJ]'A5-8*'I5"HG@*;/.JA&-010T3)4-(Z*)K#0 M],F[RC1@;M-@T*": =*=$FO$X@L^<#Q.:HVIUK-!G]&3EJ1H&% MIG-QM.+ ;02<-370C3EZP0$P"<&V\%!SCM2:AS$!@P3Y^FYK@=-2='11-8:#I] MRF%@;H=A3(&3V7X 6.#+G R)>#9, $_ML#IAAU] MEMOR^T2!$S4O1T436&@ZE8T: [$79 D)M:8&0@,X^"$K1LH\1P,$\^.28%P4Z&6Z0.@3)\FE%!3)&>H M>3DJFL!"TZE40C\87*GOE3R!78$'U2$09YWI4*4>4(= '*P.@<#3ZC!0XCDX MJU+?WU1P;1U0AX,C,_>NCCZ+4:OP6&@Z34K$!\]:A0]0J_"H:!DJ&D=%$UAH M^O-XE"<0(E3A0WLNOE16YI#7G6DL9ZAH'!5-8*'IG"E%'SY#K3Z$ULR'86*Q MB"KQ4=$X*IK 0M-95$Y Z'8"9I5D3EY5\UTQ^:ZJO7>9=U.WR\K+-POO0W&? M>^^*13G/5UX^E]?=9O<8Q#X=Y,XZ]CH4J MA(.?,7!<_ &']Z'][ "6,,9,)PZ(BTQ&;-,@#%-FE92!N L2)2DUK3,H,/;3 M$^NC0B7U0[?4'U H@]O*%NF4)FGD,],9&QR9N7=U]&F,*NBQT'2:CI[=AR?H M0UNH@X(>B#-E3CA0T -QL* ' D\+^E )^O!Y!+T;=O0%>["@1\W+4=$$%II. MI1+T8?R<4BA$+>"CHF6H:!P536"AZ:PKGR)T^Q3#I!!0:I>W9_.RAFD,9*AH M?- 1"*R<.A?*C C=,PK.DSCV)(&+-*#6/0?56T!%XZAHHK=!]&?'*M,@O-YL:BVP8",'#6CP$+3N5!F0.0V \Z:DNS&''N'BH G"[# %(BH M.3DJFL!"TSE45D#DM@*&E)TCX&E_<6S*0G>BT9UI2$Z.FE-@H>E4**T>C9L! MT-N34"?W1X!DCTEB=274V?VH: (+3>=/>0F1VTMPN6K*1 .9M#V"-/;-E6;N M]*,[V)"<'#6GP$+3"5(N0N1V$9[)]G1G'=T/@<<%Q(P&IEN$FI6CH@DL-)WG MHQ<,N.V0IW')MJIW[%5WWNMM*H;^MD*= Q'9ZETF9DEBCL SU+P<%4U@ MH>GO4U%61?RL:QYBU#4/J&@9*AI'11-8:#KKRA2)$=8\Q(!MD836*E]WJM&D MH;H@PPY!8"75V5#V1OP,:QYB8(H_"\R[_,R=>C0[J),84-%$;X/H["C'(S[C MF08@(\"3!RPZ4)<]#,C(43,*+#2="^5>Q&[WXBPSUXTY^AYE6Q*1->! 3N;.)O:0#G&<,Q)GSC($0 M<)XQ$ ?/,X8"3\\S3I0KD)SU'H;^MH+>< C.,QXQIC(HFL-">:)HV MRZ)HL[S-KR^W^7WQ+J_ORTWCK8H[">^_[ :)=7F_/'QIJ^W51.["7U7;5NO= MQV61+XJZ"Y!_OZNJ]ON7J<1_K.K/NQS7_P-02P,$% @ H9A50C=XKJR M" T2< !@ !X;"]W;W)KS+IY+_$BM*)7A>YX6X:JVDW%QT.B)=T3417\L-+=1_EB5?$ZE^ M\H>.V'!*LJK1.N^@(.AUUH05K?YE=6W&^Y?E5N:LH#,.Q':])OSE&\W+IZL6 M;+U>N&,/*ZDO=/J7&_) YU3^V,RX^M4Y>,G8FA:"E07@='G5&L"+89CH!I7% M3T:?Q-%WH$.Y+\M?^L!7-/!!V6^9\LDZNK5MP"&5V2;2[ORJ<_Z#Z@KO:7EKFH_H*GO6W0 M NE6R'*];ZP4K%FQ^R3/^XXX:J#\V!N@?0/4;! Z&N!] UP%NE-6A34BDO0O M>?D$N+96WO27JF^JUBH:5NAAG$NN_LM4.]D?WDY'X^E\/ +JV_SV9C(:+-2/ M^4)]?!]/%W-P>PV&@_D?X/KF]L\Y:(,?\Q'X]-MG\!M@!5BLRJT@128N.U*I MT3X[Z?[.WW9W1HX[)^![6@WE&_(ZG-/-5X"#+P % M"%GT#-_?''KDX$//XLH?=OB[G8WO!HO)]'+R7ANZZ6=E]#N1:_B M"[$A*;UJJ64J*'^DK?Z__P5[P7]L(9[)V4G X2'@T.>]/U5)AQ5IN:;@4UX* M\=D6[!R%:=2&/8S1P>Q$7_>@K^L=D$'V7[6>5 J2 M LA2Y:"T+%*64U TA>M_ZXLI$2NP%3334UUE3DXD*QYVJ8=)1L6%+<3N.0?T M3,Y..JQWZ+">=T!'5#E-&=GEVR(#9%URR?Y77;!%OG/7/1[<;I0T!M97.99G^:NMTG@$UCHIQPBDR,NX?)E'<$&DQ@BZ1\4%D[!6YX"13 M#.:_ %MO".-Z)MH$QL:]<2]H]J)IY%"7'-0E7G772A%X)/F6 G)8**!" ;I7ULF6#5;62$D MR?,JA@UY(?:9VCD*S M6\,X")LR+69QXNI65,M$WK0Y7!$U^D*GP)1R2?3G5NE6/4N$H"J9ZM20,W+/ M6.:6<5W#5&]Q%B^IE$;XM@AO(8C]-/Q, GV^<4[ M TSHM7'K6)1B;KVC .4;>AVVH'8^3H3E13$4$O;B;3 MG^/Y.[9-R O7CP+E7-Y.@ZX9B[S .BE=5,GU?01NN5R57ZI=B*[!]% 2;<2; M6^5];R +^U79V!PUT\Q1'Z :AN@M&)YHGZDL\P'=%N9A&&%#N&GG$EZ#$?G! M."F*Z!2IY.7S7^[1ZVP##N!F87FW:N M_JV)B?S$/.G?#=>Y4[Y4.*)J*F]<&S=D 2,,NMUFH6ZSZX4N$J$:H,@/4"/I M,U7ZB?+!F-/8S>L;+E-),@"4OUX )L25%6JV7C-Y+\,2DRIW+I:I[B+16E=AD,(:! M4?=8S!PK!->4QOZ]ZXR\[ [25-)_KUK+]M0JU[1SR:WYBOU\G9P>!U2?RY*# MP89=LV>K6@M0,<+-%6$QQH,?:8\97LHZ"A47:H+![ML$YZ]9OELL8$XRF>JPZN &CR7QX MTT\)J_H9^_U8A5QWR:NJQ06P$U=-:P3:!VC;-(BU'H M.#():^R&?NPN."G$DO**J:I>X-L= RIPV33L- MO"X!0G\),+$4B"O"=T]L2'TX8^T(RQ/;*&@^F+!8N:9GC?_PC4/IJO(&-]*> MIKV-/SQ 9_)V&FI=,H3Q^6:FM_KX<.!G\G8:>%UDA/XBXQ_-S)WKXW= 8!#" MYF;18M:"]M4+V-U;C^#5X,=V^7U6YV M+[M])UP530+D=*E(NO_W]02P,$% @ H9A55:"3Q^0!0 ,PP !@ !X;"]W M;W)K^(@IB M6VOCSWM5",V[P<#G%=72]VU#!B.9!&5:CT8#8=O!K54IC](0,B37E@"Q(_ M:YJ1UFP(,/[9V^P=7++B\7=G_2K&CEB6TM/,ZJ^J"-5Y[]>>*&@E6QWN[.8/ MVL?SFNWE5OOX5VSVLL.>R%L?;+U7!H):F?0KM_L\_(C":*\PBKB3HXCR@PQR M<)LW1 M=S1_$S?6A,J+2U-0\5A_ !0'**,.RG3THL$%-7TQ'F9B-!R-7K W/H0VCO;& MW[%WZTIIU#?)U<_$S!IOM2ID(H,IQ-R1)Q/2AEV)*V6DR9748H%- O."%W]= M+'UPX,[?SV4H 3A]'@#WTSO?R)S.>PW[3-\/T+X9T>PCM]R?J+ ME7M1\WE0EI)$)Y-Z9V03>-L MXX"#A*H;+5$/^#.H1YN*P\I+%(>\P'@2>:5TX3QK2\5XA%[C##DMB5IJWX?".,5#KM?,(7[V1/ M[7Y62R4S<3&[%G>$U'&^TPA=[#SZ(A,0OF= 1[ZF6A;T<#)W=JMJ,.**ZM9E M8M$@&^*S7&H"H+O+Q?SVT^*2W>/$0'&*E#.& Z!4' 89[<$+WT#BW\[B!U#- MD[B+\3!G:8O@R4FF1A<*U_&B45=JV^WT!"XGG 'FW!.@_Z0P.5!QW7*I)01E%'%5_,:]AULJUEQ(++ M$"7B)L&$<.G:S83'%:6L5PFOQ^0 ].@=A>]XCKA6% /D_@+49_LSY1(A8K,@ MQ[)(!J"E\#3P>,[0#PR"OEB@L8B[BYI([@V)2J[CJ$&VN5^/3<*'$V].QMEP M.#S8C\E-_7T8:FEV8/"1VS8^$T_GF M_SX=->F^YOOFU3@;#X>Q%K9A0ZUAVB5JZ]WQT(R%>W62O=[+1VQ/VK8ND//<$&!P]Y$"@,CY7/>C4FI#>=(?=PXOX(CT$'\33 M<_H&T8!50M,*JL/^V]<]X=(3-2V";>*S<&D#[MSX6>%53XX%<+ZR-G0+=G#X M/V'R'U!+ P04 " "AF%5^@0F6S4J !=A0 & 'AL+W=O^E7R8FTJ6]15TIC%ST?GIS^^?(3G^8&_%V9K MHW\G.,FLKK_@C\O\YZ,) #*EF;=8(:/_W)@+4Y98B,#X7=<\\EOBQ?C?;O4W M?'8ZRRRSYJ(N?RWR=O7ST=.C)#>+K"O;C_7V;T;/\QCKS>O2\O\G6WGV;'J4 MS#O;UFM]F2!8%Y7\-_NJ>(A>>#HY\,)47Y@RW+(10_DJ:[,7SYMZFS1XFE;# M/_BH_#8!5U2XE.NVH6\+>J]]<7WYR_O+-Y<7Y^\_)><7%Q\^O_]T^?Z7Y.K# MV\N+R]?7SQ^VM D>?3C7!5_*@M,#"SY+WM55N[+)ZRHW>?_]AP2WK'?F3WS&ZYT=6.]\/J^[JBVJ97)5E\6\,#;YO^^_E3"R8O,UO8I%XD5SA,U6;,/)]6AAAH7J\W6;4#ZN8U76]E38Y_6<)C MGK7TQZ*HLFI>9&5BZ4U#W-O:I*CF99>;I-5%.GQ(.WQHVE5]9?(B:YMB;I.+ MNJ&KSJH\*>B![:HNR]UQO:UH7=O-;$$/-G1;Z=Z+GZ^35P5=8#'K&%I>:/^Q MUY^3M\6Z(#CWOSNG-:X^_9_D[:=7^U^^_\_HQ2NL\_+D[R?\[_>&3M64!+1U M']++YFN:O'U[D2:?2.K9Y"IKVLHT5C\\WQ1O"CS1YB-07M;;+/E;7>;S.DTN MJSD]\NZ5/+7)Z+&YC3Z^K%K35'Q'A'/Y>+C@+^]F?QOY]$J &<'EVY,KN8:] M"\JJ+,^2SV\ODKP&%EL2T.4E!%G MX'NSP8+T+O;^7/%9&$3FK_,U'6J>)?<5>;^L8OFE:^AH[ MKV>F\9*9D?[*S/734_[T5*[^P,K1\6E)LC.:3*Z+T,#OM:O&&%ZX(C)+UJ)8 M#!3+(0B^<5,FV2^\2S]L'_(!2DY>=?2-SE)"-P0:<__)28 MWSM0PI\$0ECASMC(["I9D)T6KN ;=VM,TGFNPL=V575'80[DS4*VA[Y\8.-*7F]J@9?0%R;ML96+=FLPCXD M:Y)S >&CV=1-FQ!PL/J2T\GQOQ,D)3WG@;TV\ZXIVD(ES>NO\U56+0W)C/6Z ML&RNWC^Z?GUQ] #+O,N:^2HY$U0)VX63T4DS7J0&7-$7124&-Q;+"SLGD@R< MKB>I_YS(P65EI:W#C9%,M:1JYZLTF9L&Z.G!(5BO6VSO@.K(2B!XZ!&()-7T M#.CHGEY8%A4#WN0L6QBU$$^1I Y'H8NN22SB()NNL5U6M3A\MMF0^9;-2J*M MKM3+:,RR*U6,\%5WM$HC: ^4^2UH"A!YX&NY!IN1L)BQO919N8NP_E].QREP MMB8-O.0E5$[0,INBHN.FWLRBFTBR_#?R'7BKE*$A\PCT 3E;T47)C1&VB)(; M?-%[H:+]K24?S0.WR(HFV<06(:W4]D@Y.IQ[JU"U2I*]J',KMT"+D,?T5XG\ MAKG!0UPP$<(&@>GA@'1;$M&0(#)?-V29F(#Y14<86Q ]TRGX%NAS? >;0OA2 M#G!WG7E70LHL.<-\+R2 U#(B9BA9$M*%=0:$DB7+6CQ$W+)IZ'6.8+#7B-&R$?VP\1Z\R2&H9H^ MFT[XT7NG/SQ-)],GWVP$T 5LG#5X0A+1$;$_)M\-77;1$MXC-83URH)480YE M"(B5PQMA/,;%C(PZ

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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 279 304 1 false 71 0 false 8 false false R1.htm 0000001 - Document - Cover Sheet http://www.orthopediatrics.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS??? EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - BUSINESS Sheet http://www.orthopediatrics.com/role/BUSINESS BUSINESS Notes 8 false false R9.htm 0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 0000010 - Disclosure - BUSINESS COMBINATIONS Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONS BUSINESS COMBINATIONS Notes 10 false false R11.htm 0000011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 11 false false R12.htm 0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS FAIR VALUE OF FINANCIAL INSTRUMENTS Notes 12 false false R13.htm 0000013 - Disclosure - DEBT AND CREDIT ARRANGEMENTS Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS DEBT AND CREDIT ARRANGEMENTS Notes 13 false false R14.htm 0000014 - Disclosure - INCOME TAXES Sheet http://www.orthopediatrics.com/role/INCOMETAXES INCOME TAXES Notes 14 false false R15.htm 0000015 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 0000016 - Disclosure - NET LOSS PER SHARE Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 16 false false R17.htm 0000017 - Disclosure - BUSINESS SEGMENT Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENT BUSINESS SEGMENT Notes 17 false false R18.htm 0000018 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS Notes 18 false false R19.htm 0000019 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 19 false false R20.htm 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 0000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 21 false false R22.htm 0000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES 22 false false R23.htm 0000023 - Disclosure - BUSINESS COMBINATIONS (Tables) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSTables BUSINESS COMBINATIONS (Tables) Tables http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONS 23 false false R24.htm 0000024 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS 24 false false R25.htm 0000025 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables) Tables http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS 25 false false R26.htm 0000026 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables DEBT AND CREDIT ARRANGEMENTS (Tables) Tables http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS 26 false false R27.htm 0000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY 27 false false R28.htm 0000028 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.orthopediatrics.com/role/NETLOSSPERSHARE 28 false false R29.htm 0000029 - Disclosure - BUSINESS SEGMENT (Tables) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables BUSINESS SEGMENT (Tables) Tables http://www.orthopediatrics.com/role/BUSINESSSEGMENT 29 false false R30.htm 0000030 - Disclosure - BUSINESS (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSDetails BUSINESS (Details) Details http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSTables 30 false false R31.htm 0000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details) Details 31 false false R32.htm 0000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details) Details 32 false false R33.htm 0000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details) Details 33 false false R34.htm 0000034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details) Details 34 false false R35.htm 0000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details) Details 35 false false R36.htm 0000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details) Details 36 false false R37.htm 0000037 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) Sheet http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details) Details 37 false false R38.htm 0000038 - Disclosure - BUSINESS COMBINATIONS - Pega Medical and MD Orthopaedics (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails BUSINESS COMBINATIONS - Pega Medical and MD Orthopaedics (Details) Details 38 false false R39.htm 0000039 - Disclosure - BUSINESS COMBINATIONS - Assets acquired and liabilities assumed (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails BUSINESS COMBINATIONS - Assets acquired and liabilities assumed (Details) Details 39 false false R40.htm 0000040 - Disclosure - BUSINESS COMBINATIONS - Estimated fair value and useful life of identifiable intangible assets (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails BUSINESS COMBINATIONS - Estimated fair value and useful life of identifiable intangible assets (Details) Details 40 false false R41.htm 0000041 - Disclosure - BUSINESS COMBINATIONS - Schedule of pro forma net revenue and net loss (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSScheduleofproformanetrevenueandnetlossDetails BUSINESS COMBINATIONS - Schedule of pro forma net revenue and net loss (Details) Details 41 false false R42.htm 0000042 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details) Details 42 false false R43.htm 0000043 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Details 43 false false R44.htm 0000044 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Estimated Fair Value (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails GOODWILL AND INTANGIBLE ASSETS - Estimated Fair Value (Details) Details 44 false false R45.htm 0000045 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 45 false false R46.htm 0000046 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Trademark Assets (Details) Sheet http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Trademark Assets (Details) Details 46 false false R47.htm 0000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details) Details 47 false false R48.htm 0000048 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables 48 false false R49.htm 0000049 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details) Details 49 false false R50.htm 0000050 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) Sheet http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details) Details 50 false false R51.htm 0000051 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details) Details 51 false false R52.htm 0000052 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Sheet http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails DEBT AND CREDIT ARRANGEMENTS - Narrative (Details) Details 52 false false R53.htm 0000053 - Disclosure - INCOME TAXES (Details) Sheet http://www.orthopediatrics.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://www.orthopediatrics.com/role/INCOMETAXES 53 false false R54.htm 0000054 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails STOCKHOLDERS' EQUITY - Stock Options (Details) Details 54 false false R55.htm 0000055 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details) Sheet http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails STOCKHOLDERS' EQUITY - Restricted Stock (Details) Details 55 false false R56.htm 0000056 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details) Details 56 false false R57.htm 0000057 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details) Sheet http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails NET LOSS PER SHARE - Antidilutive Securities (Details) Details 57 false false R58.htm 0000058 - Disclosure - BUSINESS SEGMENT - Narrative (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails BUSINESS SEGMENT - Narrative (Details) Details 58 false false R59.htm 0000059 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details) Details 59 false false R60.htm 0000060 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Sheet http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails BUSINESS SEGMENT - Schedule of Revenue by Category (Details) Details 60 false false R61.htm 0000061 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED PARTY TRANSACTIONS (Details) Details http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS 61 false false R62.htm 0000062 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details) Sheet http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails EMPLOYEE BENEFIT PLAN - Narrative (Details) Details 62 false false R63.htm 0000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES 63 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: kids:BusinessCombinationContingentConsiderationLiabilityTerm - kids-20220930.htm 4 kids-20220930.htm exhibit311-ceocertificatio.htm exhibit312-cfocertificatio.htm exhibit321-ceocertificatio.htm exhibit322-cfocertificatio.htm kids-20220930.xsd kids-20220930_cal.xml kids-20220930_def.xml kids-20220930_lab.xml kids-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kids-20220930.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 279, "dts": { "calculationLink": { "local": [ "kids-20220930_cal.xml" ] }, "definitionLink": { "local": [ "kids-20220930_def.xml" ] }, "inline": { "local": [ "kids-20220930.htm" ] }, "labelLink": { "local": [ "kids-20220930_lab.xml" ] }, "presentationLink": { "local": [ "kids-20220930_pre.xml" ] }, "schema": { "local": [ "kids-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 512, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 4, "http://www.orthopediatrics.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 10 }, "keyCustom": 31, "keyStandard": 273, "memberCustom": 21, "memberStandard": 46, "nsprefix": "kids", "nsuri": "http://www.orthopediatrics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "role": "http://www.orthopediatrics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - BUSINESS COMBINATIONS", "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONS", "shortName": "BUSINESS COMBINATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - DEBT AND CREDIT ARRANGEMENTS", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS", "shortName": "DEBT AND CREDIT ARRANGEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - INCOME TAXES", "role": "http://www.orthopediatrics.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - NET LOSS PER SHARE", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARE", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - BUSINESS SEGMENT", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENT", "shortName": "BUSINESS SEGMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - EMPLOYEE BENEFIT PLAN", "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - BUSINESS COMBINATIONS (Tables)", "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSTables", "shortName": "BUSINESS COMBINATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - DEBT AND CREDIT ARRANGEMENTS (Tables)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables", "shortName": "DEBT AND CREDIT ARRANGEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - NET LOSS PER SHARE (Tables)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - BUSINESS SEGMENT (Tables)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables", "shortName": "BUSINESS SEGMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:CumulativeChildrenImpactedCount", "reportCount": 1, "unique": true, "unitRef": "children", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - BUSINESS (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSDetails", "shortName": "BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:CumulativeChildrenImpactedCount", "reportCount": 1, "unique": true, "unitRef": "children", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i8a7bb9544d7640bc811768b37af7482b_D20220815-20220815", "decimals": "-3", "lang": "en-US", "name": "kids:SaleOfStockConsiderationReceivedOnTransactionGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:EscrowDeposit", "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EscrowDeposit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EscrowDeposit", "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EscrowDeposit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "ib01a9d719a874081abeac96bd1f4831e_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Assets Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "ib01a9d719a874081abeac96bd1f4831e_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Amortization Intangible Assets, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsFiniteLivedPolicy", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i959877bd3f8b446e944a8d185b84e279_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Goodwill and Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Acquisition Payable and Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "ib524ca4b26c94caea88c3969a0d708a7_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - BUSINESS COMBINATIONS - Pega Medical and MD Orthopaedics (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "shortName": "BUSINESS COMBINATIONS - Pega Medical and MD Orthopaedics (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i990b77df38b04c5ea7f607147bd02b2d_D20220401-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - BUSINESS COMBINATIONS - Assets acquired and liabilities assumed (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "shortName": "BUSINESS COMBINATIONS - Assets acquired and liabilities assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i8ef501d64fbf4c0b8f87bb51a8b8d41e_I20220701", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i7db46c98274d461fae4a33e62f0e9b18_D20220401-20220401", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:IntangibleAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - BUSINESS COMBINATIONS - Estimated fair value and useful life of identifiable intangible assets (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "shortName": "BUSINESS COMBINATIONS - Estimated fair value and useful life of identifiable intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i7db46c98274d461fae4a33e62f0e9b18_D20220401-20220401", "decimals": "-3", "first": true, "lang": "en-US", "name": "kids:IntangibleAssetsAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - BUSINESS COMBINATIONS - Schedule of pro forma net revenue and net loss (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSScheduleofproformanetrevenueandnetlossDetails", "shortName": "BUSINESS COMBINATIONS - Schedule of pro forma net revenue and net loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i36afa377f68847b3ba83120734a27761_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Changes in Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i36afa377f68847b3ba83120734a27761_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i844cd28b898f4963b7ab5562be37604e_I20220930", "decimals": "3", "first": true, "lang": "en-US", "name": "kids:IndefiniteLivedIntangibleAssetMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Estimated Fair Value (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Estimated Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i844cd28b898f4963b7ab5562be37604e_I20220930", "decimals": "3", "first": true, "lang": "en-US", "name": "kids:IndefiniteLivedIntangibleAssetMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i36afa377f68847b3ba83120734a27761_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Trademark Assets (Details)", "role": "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Trademark Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i496b4670971c467ea5359f60cc86169c_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "iaea7bc8a8a9b4d8fa31adb8394fb06fe_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "iaea7bc8a8a9b4d8fa31adb8394fb06fe_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i072f203905ad4757a3ff95afb51ad41a_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Change in Fair Value of Level 3 Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i072f203905ad4757a3ff95afb51ad41a_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i94ecf67edc694aa8a94ac690c09f8d6f_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "kids:ContingentConsiderationMeasurementInputPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details)", "role": "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "shortName": "FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurements of Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i94ecf67edc694aa8a94ac690c09f8d6f_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "kids:ContingentConsiderationMeasurementInputPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i77a8c7ff33f645218e42203300b512f4_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i77a8c7ff33f645218e42203300b512f4_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "shortName": "DEBT AND CREDIT ARRANGEMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i1103edbe85d7483895c75edc40ca0cc5_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LineOfCreditFacilityCommitmentFeeAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - INCOME TAXES (Details)", "role": "http://www.orthopediatrics.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - STOCKHOLDERS' EQUITY - Stock Options (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails", "shortName": "STOCKHOLDERS' EQUITY - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "role": "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Restricted Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "ib524ca4b26c94caea88c3969a0d708a7_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails", "shortName": "NET LOSS PER SHARE - Reconciliation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities (Details)", "role": "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "shortName": "NET LOSS PER SHARE - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - BUSINESS SEGMENT - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails", "shortName": "BUSINESS SEGMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:NumberOfReportableSegments", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Geographical Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if33cd25914874fbf99e9d52006e172fa_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i78dffa59fade4e67a0776da1d2097023_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "ibac847abd6c54fbf94e7093eab4fa36c_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "icc2167c57686478fac72d513606eb75d_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "role": "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "shortName": "BUSINESS SEGMENT - Schedule of Revenue by Category (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "ia29e27ce53f44e7fa9612cd9d90d2db3_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i95f07ca7275242e0a170809a1091b0e8_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "kids:NumberOfRelatedPartyEntitiesSuppliers", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i95f07ca7275242e0a170809a1091b0e8_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "kids:NumberOfRelatedPartyEntitiesSuppliers", "reportCount": 1, "unique": true, "unitRef": "supplier", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - EMPLOYEE BENEFIT PLAN - Narrative (Details)", "role": "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "shortName": "EMPLOYEE BENEFIT PLAN - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "if7c4bf988a9342da9c0a7eac5dc4e2a1_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "role": "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i959877bd3f8b446e944a8d185b84e279_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "kids:ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - BUSINESS", "role": "http://www.orthopediatrics.com/role/BUSINESS", "shortName": "BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "kids-20220930.htm", "contextRef": "i289e26f95b5549cdad3a2b6b23c68157_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r647" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r648" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r657" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r656" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r645" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r644" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of Each Class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r646" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol(s)" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.orthopediatrics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "kids_ApiFixLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ApiFix Ltd.", "label": "ApiFix Ltd. [Member]", "terseLabel": "ApiFix Ltd" } } }, "localname": "ApiFixLtdMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "domainItemType" }, "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets, Noncurrent, Excluding Property, Plant and Equipment", "label": "Assets, Noncurrent, Excluding Property, Plant and Equipment", "totalLabel": "Total other assets" } } }, "localname": "AssetsNoncurrentExcludingPropertyPlantAndEquipment", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_BusinessAcquisitionSharePriceTradingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition Share Price Trading Period", "label": "Business Acquisition Share Price Trading Period", "terseLabel": "Business acquisition share price trading period" } } }, "localname": "BusinessAcquisitionSharePriceTradingPeriod", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "durationItemType" }, "kids_BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Current", "label": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Current", "verboseLabel": "Current portion of acquisition installment payable" } } }, "localname": "BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableCurrent", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent", "label": "Business Combination, Contingent Consideration, Acquisition Installment Payable, Noncurrent", "verboseLabel": "Acquisition installment payable, net of current portion" } } }, "localname": "BusinessCombinationContingentConsiderationAcquisitionInstallmentPayableNoncurrent", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable", "label": "Business Combination, Contingent Consideration, Change in Fair Value, Acquisition Installment Payable", "terseLabel": "Acquisition installment payable" } } }, "localname": "BusinessCombinationContingentConsiderationChangeInFairValueAcquisitionInstallmentPayable", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "kids_BusinessCombinationContingentConsiderationLiabilityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Term", "label": "Business Combination, Contingent Consideration, Liability, Term", "terseLabel": "Contingent consideration liability term" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityTerm", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "durationItemType" }, "kids_BusinessCombinationContingentRepurchasePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Repurchase Price, Per Share", "label": "Business Combination, Contingent Repurchase Price, Per Share", "terseLabel": "Contingent repurchase price, per share (in dollars per share)" } } }, "localname": "BusinessCombinationContingentRepurchasePricePerShare", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "perShareItemType" }, "kids_ClassOfWarrantOrRightDiscountOnExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Discount On Exercise Price Of Warrants Or Rights", "label": "Class Of Warrant Or Right, Discount On Exercise Price Of Warrants Or Rights", "terseLabel": "Warrants exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightDiscountOnExercisePriceOfWarrantsOrRights", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "perShareItemType" }, "kids_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration Liability", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liability" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "domainItemType" }, "kids_ContingentConsiderationMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Measurement Input", "label": "Contingent Consideration, Measurement Input", "terseLabel": "Contingent consideration, measurement input" } } }, "localname": "ContingentConsiderationMeasurementInput", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "kids_ContingentConsiderationMeasurementInputPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent Consideration, Measurement Input, Period", "label": "Contingent Consideration, Measurement Input, Period", "terseLabel": "Expected years" } } }, "localname": "ContingentConsiderationMeasurementInputPeriod", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "durationItemType" }, "kids_CumulativeChildrenImpactedCount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative Children Impacted, Count", "label": "Cumulative Children Impacted, Count", "terseLabel": "Impacted children" } } }, "localname": "CumulativeChildrenImpactedCount", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails" ], "xbrltype": "integerItemType" }, "kids_EmergingGrowthCompanyAndSmallerReportingCompanyReportingRequirementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy", "label": "Emerging Growth Company and Smaller Reporting Company Reporting Requirements, Policy [Policy Text Block]", "terseLabel": "\"Emerging Growth Company\" and \"Smaller Reporting Company\" Reporting Requirements" } } }, "localname": "EmergingGrowthCompanyAndSmallerReportingCompanyReportingRequirementsPolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_EquityIssuanceCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Issuance Cost", "label": "Equity Issuance Cost", "terseLabel": "Equity issuance cost" } } }, "localname": "EquityIssuanceCost", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "kids_EstimatedMarketPortionOpportunities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Market Portion Opportunities", "label": "Estimated Market Portion Opportunities", "terseLabel": "Estimated market portion opportunities" } } }, "localname": "EstimatedMarketPortionOpportunities", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails" ], "xbrltype": "monetaryItemType" }, "kids_ExchangeTradeMutualFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Trade Mutual Funds", "label": "Exchange Trade Mutual Funds [Member]", "terseLabel": "Exchange Trade Mutual Funds" } } }, "localname": "ExchangeTradeMutualFundsMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "kids_FiniteLivedIntangibleAssetUsefulLifeExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Useful Life Extension Period", "label": "Finite-Lived Intangible Asset, Useful Life Extension Period", "terseLabel": "Finite lived intangible asset useful life extension period (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLifeExtensionPeriod", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "durationItemType" }, "kids_FireflyTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Firefly Technology", "label": "Firefly Technology [Member]", "terseLabel": "Firefly Technology" } } }, "localname": "FireflyTechnologyMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_FourthAmendedLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fourth Amended Loan Agreement", "label": "Fourth Amended Loan Agreement [Member]", "terseLabel": "Fourth Amended Loan Agreement" } } }, "localname": "FourthAmendedLoanAgreementMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "kids_IncreaseDecreaseInSettlementLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Settlement Liabilities, Current", "label": "Increase (Decrease) In Settlement Liabilities, Current", "negatedTerseLabel": "Accrued legal settlements" } } }, "localname": "IncreaseDecreaseInSettlementLiabilitiesCurrent", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "kids_IndefiniteLivedIntangibleAssetMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indefinite Lived Intangible Asset, Measurement Input", "label": "Indefinite Lived Intangible Asset, Measurement Input", "terseLabel": "Indefinite lived intangible asset, measurement input (percent)" } } }, "localname": "IndefiniteLivedIntangibleAssetMeasurementInput", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails" ], "xbrltype": "decimalItemType" }, "kids_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Gross", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill), Gross", "terseLabel": "Gross Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillGross", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "kids_IntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intangible Assets Acquired", "label": "Intangible Assets Acquired", "totalLabel": "Fair value of identifiable intangible assets" } } }, "localname": "IntangibleAssetsAcquired", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "kids_LongTermDebtCurrentMaturitiesRelatedParty": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Current Maturities, Related Party", "label": "Long-term Debt, Current Maturities, Related Party", "terseLabel": "Current portion of long-term debt with affiliate" } } }, "localname": "LongTermDebtCurrentMaturitiesRelatedParty", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "kids_MDOrthopaedicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MD Orthopaedics", "label": "MD Orthopaedics [Member]", "terseLabel": "MD Orthopaedics" } } }, "localname": "MDOrthopaedicsMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "domainItemType" }, "kids_MeasurementInputEstimatedRoyaltyRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Estimated Royalty Rate", "label": "Measurement Input, Estimated Royalty Rate [Member]", "terseLabel": "Estimated royalty rate" } } }, "localname": "MeasurementInputEstimatedRoyaltyRateMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "kids_MeasurementInputLongTermGrowthRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input, Long Term Growth Rate", "label": "Measurement Input, Long Term Growth Rate [Member]", "terseLabel": "Long term growth rate" } } }, "localname": "MeasurementInputLongTermGrowthRateMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "kids_New2017EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New 2017 Equity Incentive Plan [Member]", "terseLabel": "2017 Plan" } } }, "localname": "New2017EquityIncentivePlanMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "kids_NumberOfRelatedPartyEntitiesSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Related Party Entities Suppliers", "label": "Number Of Related Party Entities Suppliers", "terseLabel": "Number of related party suppliers" } } }, "localname": "NumberOfRelatedPartyEntitiesSuppliers", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "integerItemType" }, "kids_OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation", "label": "Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation", "terseLabel": "Estimated limitation on losses generated prior to ownership change date" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitation", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards Limitations on Use Estimated Amount Subject to Limitation Annual Limit", "terseLabel": "Estimated annual limitation of losses" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimit", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards Limitations On Use Estimated Amount Subject to Limitation Annual Limit Increase", "terseLabel": "Increase of estimated annual limitation of first five years" } } }, "localname": "OperatingLossCarryforwardsLimitationsOnUseEstimatedAmountSubjectToLimitationAnnualLimitIncrease", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "kids_PegaMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pega Medical", "label": "Pega Medical [Member]", "terseLabel": "Pega Medical" } } }, "localname": "PegaMedicalMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "domainItemType" }, "kids_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Offering", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "kids_ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement Contract to Perform for Others Royalty Agreement Percent", "terseLabel": "Royalty agreement percentage (as a percent)" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltyAgreementPercent", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "percentItemType" }, "kids_RestrictedStockAwardsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Awards And Restricted Stock Units", "label": "Restricted Stock Awards And Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Awards And Restricted Stock Units" } } }, "localname": "RestrictedStockAwardsAndRestrictedStockUnitsMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "kids_SaleOfStockConsiderationReceivedOnTransactionGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross", "label": "Sale Of Stock, Consideration Received On Transaction, Gross", "terseLabel": "Sale of stock, consideration received on transaction, gross" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "kids_SalesAndMarketingExpensePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sales And Marketing Expense Policy [Policy Text Block]", "terseLabel": "Sales and Marketing Expenses" } } }, "localname": "SalesAndMarketingExpensePolicyPolicyTextBlock", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "kids_SampleInventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sample Inventory [Member]", "terseLabel": "Sample inventory" } } }, "localname": "SampleInventoryMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "kids_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award Equity Instruments Other than Options Exercisable Number", "terseLabel": "Restricted stock exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "kids_SpineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spine [Member]", "label": "Spine [Member]", "terseLabel": "Scoliosis" } } }, "localname": "SpineMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_SportsMedicineAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sports Medicine And Other [Member]", "label": "Sports Medicine And Other [Member]", "terseLabel": "Sports medicine/other" } } }, "localname": "SportsMedicineAndOtherMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_SquadronMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Squadron", "label": "Squadron [Member]", "terseLabel": "Squadron" } } }, "localname": "SquadronMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "kids_StockIssuedDuringPeriodSharesAnniversaryInstallmentPayment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Anniversary Installment Payment", "label": "Stock Issued During Period, Shares, Anniversary Installment Payment", "terseLabel": "Stock portion of ApiFix anniversary installment payment (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAnniversaryInstallmentPayment", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "kids_StockIssuedDuringPeriodValueAnniversaryInstallmentPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Anniversary Installment Payment", "label": "Stock Issued During Period, Value, Anniversary Installment Payment", "terseLabel": "Stock portion of ApiFix anniversary installment payment" } } }, "localname": "StockIssuedDuringPeriodValueAnniversaryInstallmentPayment", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "kids_StructureMedicalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure Medical, LLC", "label": "Structure Medical, LLC [Member]", "terseLabel": "Structure Medical, LLC" } } }, "localname": "StructureMedicalLLCMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "kids_TeamNoteBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Team Note B", "label": "Team Note B [Member]", "terseLabel": "Team Note B" } } }, "localname": "TeamNoteBMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_TransferOfPropertyAndEquipmentToInventory": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Transfer Of Property And Equipment To Inventory", "terseLabel": "Transfer of instruments from property and equipment to inventory" } } }, "localname": "TransferOfPropertyAndEquipmentToInventory", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "kids_TraumaAndDeformityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trauma And Deformity [Member]", "terseLabel": "Trauma and deformity" } } }, "localname": "TraumaAndDeformityMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "kids_VilexAndOrthexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vilex and Orthex", "label": "Vilex and Orthex [Member]", "terseLabel": "Vilex and Orthex" } } }, "localname": "VilexAndOrthexMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "kids_VilexMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vilex", "label": "Vilex [Member]", "terseLabel": "Vilex" } } }, "localname": "VilexMember", "nsuri": "http://www.orthopediatrics.com/20220930", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r353", "r516", "r517", "r519", "r640" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r45", "r47", "r109", "r110", "r281", "r317" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r257", "r258", "r259", "r260", "r280", "r316", "r364", "r366", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r611", "r614", "r641", "r642" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r257", "r258", "r259", "r260", "r280", "r316", "r364", "r366", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r611", "r614", "r641", "r642" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r186", "r258", "r259", "r338", "r339", "r561", "r610", "r612" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r186", "r258", "r259", "r338", "r339", "r561", "r610", "r612" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r253", "r257", "r258", "r259", "r260", "r280", "r316", "r343", "r364", "r366", "r399", "r400", "r401", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r611", "r614", "r641", "r642" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r253", "r257", "r258", "r259", "r260", "r280", "r316", "r343", "r364", "r366", "r399", "r400", "r401", "r531", "r532", "r533", "r534", "r535", "r536", "r555", "r611", "r614", "r641", "r642" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r46", "r47", "r109", "r110", "r281", "r317" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r187", "r188", "r338", "r340", "r613", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r187", "r188", "r338", "r340", "r613", "r625", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r35", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable - trade" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r192", "r193" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable - trade, less allowance for doubtful accounts of $608 and $347, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r51", "r52", "r53", "r601", "r619", "r620" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r50", "r53", "r61", "r62", "r63", "r113", "r114", "r115", "r475", "r513", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Remaining economic useful life (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r113", "r114", "r115", "r409", "r410", "r411", "r481" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r30", "r198", "r211" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r203", "r344" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset Backed Securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r105", "r170", "r175", "r182", "r209", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r472", "r476", "r496", "r522", "r524", "r578", "r598" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r34", "r105", "r209", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r472", "r476", "r496", "r522", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Consolidated Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and building improvements" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r363", "r365", "r452" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r363", "r365", "r446", "r447", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Issuance of common stock" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Consideration for acquisition (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/BUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of Pro Forma Net Revenue and Net Loss" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Common stock (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r444", "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Pro forma net income (loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSScheduleofproformanetrevenueandnetlossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r444", "r445" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Pro forma net revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSScheduleofproformanetrevenueandnetlossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r442" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition related costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r460", "r461", "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Fair value of estimated total acquisition consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r460", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Amount of Stock as consideration (in shares)" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r89", "r467" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Fair value adjustment of contingent consideration", "verboseLabel": "Fair value adjustment of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAcquisitionPayableandContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r459", "r462", "r466" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent Consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r459", "r463" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "verboseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r453", "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS COMBINATIONS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "terseLabel": "Actual net income from acquired entities" } } }, "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r443" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Actual revenue from acquired entities" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable-trade" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other", "terseLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "verboseLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Other intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r448", "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Amortizable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r448", "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r448", "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Less: total net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r448", "r449" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisition Payable and Contingent Consideration" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r12", "r524", "r622", "r623" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents and Short Term Investments" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r86", "r92", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and restricted cash, end of period", "periodStartLabel": "Cash and restricted cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r497" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND RESTRICTED CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r21", "r22", "r23", "r103", "r105", "r129", "r130", "r135", "r139", "r141", "r150", "r151", "r152", "r209", "r264", "r269", "r270", "r271", "r275", "r276", "r314", "r315", "r318", "r319", "r321", "r496", "r649" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r254", "r255", "r256", "r261", "r626" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r262", "r628" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Litigation and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r113", "r114", "r481" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r23", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r23", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00025 par value; 50,000,000 shares authorized; 22,896,031 shares and 19,677,214 shares issued as of September\u00a030, 2022 (unaudited) and December\u00a031, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r56", "r58", "r59", "r67", "r588", "r606" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r344", "r359", "r621" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r72", "r561" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships", "verboseLabel": "Customer Relationships & Other" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r102", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r294", "r301", "r302", "r304", "r310" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "DEBT AND CREDIT ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r104", "r111", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r306", "r307", "r308", "r309", "r507", "r579", "r580", "r596" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate (as a percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r41", "r278" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r42", "r104", "r111", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r306", "r307", "r308", "r309", "r507" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r42", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Monthly interest and principal installments" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r42", "r104", "r111", "r277", "r278", "r279", "r280", "r281", "r282", "r284", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r300", "r303", "r306", "r307", "r308", "r309", "r322", "r325", "r326", "r327", "r505", "r506", "r507", "r508", "r595" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r418", "r419" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r419", "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsAllocationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan, Plan Assets, Allocation [Line Items]", "terseLabel": "Benefit Plan, Plan" } } }, "localname": "DefinedBenefitPlanPlanAssetsAllocationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsAllocationTable": { "auth_ref": [ "r343", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment allocation of defined benefit plan assets. Includes, but is not limited to, investment allocation percentage or range of percentages.", "label": "Defined Benefit Plan, Plan Assets, Allocation [Table]", "terseLabel": "Defined Benefit Plan, Plan Assets, Allocation [Table]" } } }, "localname": "DefinedBenefitPlanPlanAssetsAllocationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer contribution as a percentage of employees' salary (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLANNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r168" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r370", "r371", "r404", "r405", "r407", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.", "label": "Discontinued Operations, Disposed of by Sale [Member]", "terseLabel": "Discontinued Operations, Disposed of by Sale" } } }, "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Divestiture purchase price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal and State" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r68", "r118", "r119", "r120", "r121", "r122", "r126", "r129", "r139", "r140", "r141", "r145", "r146", "r482", "r483", "r589", "r607" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r68", "r118", "r119", "r120", "r121", "r122", "r129", "r139", "r140", "r141", "r145", "r146", "r482", "r483", "r589", "r607" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r142", "r143", "r144", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r497" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount [Abstract]", "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense, weighted average period of recognition (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock Option", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r61", "r62", "r63", "r113", "r114", "r115", "r117", "r123", "r125", "r149", "r210", "r321", "r328", "r409", "r410", "r411", "r432", "r433", "r481", "r498", "r499", "r500", "r501", "r502", "r503", "r513", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r585", "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of debt, amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r484", "r485", "r492" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r292", "r306", "r307", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r359", "r485", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r484", "r485", "r487", "r488", "r493" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r292", "r344", "r346", "r351", "r359", "r485", "r528" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r292", "r306", "r307", "r344", "r346", "r351", "r359", "r485", "r529" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r292", "r306", "r307", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r359", "r485", "r530" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r489", "r492" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r489" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Contingent consideration, ending balance", "periodStartLabel": "Contingent consideration, beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r292", "r306", "r307", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r359", "r528", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r491", "r493" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSChangeinFairValueofLevel3InstrumentsDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r494", "r495" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r203", "r204", "r206", "r207", "r208", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r220", "r221", "r303", "r320", "r480", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r649", "r650", "r651", "r652", "r653", "r654", "r655" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "verboseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Intangible asset, useful life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r14", "r245" ], "calculation": { "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r238", "r242", "r245", "r247", "r562", "r563" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r245", "r563" ], "calculation": { "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r238", "r244" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r245", "r562" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0 }, "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Amortizable intangible assets, net", "totalLabel": "Net Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Finite-Lived Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Weighted-Average Amortization Period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r239" ], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails": { "order": 2.0, "parentTag": "kids_IntangibleAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Finite-lived intangible assets acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r13", "r225", "r226", "r233", "r237", "r524", "r577" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r227", "r237" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill acquired" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r234", "r243" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r231" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation impact" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r71", "r105", "r170", "r174", "r178", "r181", "r184", "r209", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r496" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r90", "r248" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Trademark impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r90", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r90", "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "negatedTerseLabel": "Impairment", "terseLabel": "Impairment of indefinitely-lived tradename assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESGoodwillandIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r65", "r170", "r174", "r178", "r181", "r184", "r576", "r586", "r591", "r608" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r106", "r422", "r425", "r429", "r434", "r436", "r438", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r124", "r125", "r169", "r420", "r435", "r437", "r609" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Provision for income taxes (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r60", "r416", "r417", "r425", "r426", "r428", "r431" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndNotesReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans.", "label": "Increase (Decrease) in Accounts and Notes Receivable", "negatedTerseLabel": "Accounts receivable - trade" } } }, "localname": "IncreaseDecreaseInAccountsAndNotesReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable - trade" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedTerseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in certain current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedTerseLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r241", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Schedule of Finite-Lived Intangible Assets", "verboseLabel": "Indefinite-Lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r246" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "kids_AssetsNoncurrentExcludingPropertyPlantAndEquipment", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Other intangible assets", "verboseLabel": "Non-amortizing intangible assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation impact" } } }, "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r241", "r246" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Indefinite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Indefinite-Lived Intangible Assets" } } }, "localname": "IndefiniteLivedIntangibleAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails": { "order": 1.0, "parentTag": "kids_IntangibleAssetsAcquired", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-Lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived intangible assets acquired" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r99", "r244", "r558", "r559", "r560", "r562" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Amortizable Intangible Assets, net" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]", "terseLabel": "Other intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntellectualPropertyMember": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.", "label": "Intellectual Property [Member]", "terseLabel": "Intellectual Property" } } }, "localname": "IntellectualPropertyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r590" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedTerseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r85", "r87", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r32", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r8", "r31", "r100", "r148", "r222", "r223", "r224", "r556" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories, net" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Short term investments" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r105", "r176", "r209", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r473", "r476", "r477", "r496", "r522", "r523" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r105", "r209", "r496", "r524", "r582", "r603" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r7", "r40", "r105", "r209", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r473", "r476", "r477", "r496", "r522", "r523", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r9", "r10", "r11", "r18", "r19", "r105", "r209", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r473", "r476", "r477", "r496", "r522", "r523" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "License Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r36" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Commitment fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Unused commitment fee percentage (as a percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Revolving credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Trademark impairment" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "Three Month LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r18", "r291", "r305", "r306", "r307", "r580", "r599" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt with affiliate", "verboseLabel": "Less: current maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt with affiliate, net of current maturities" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesAndLoans": { "auth_ref": [ "r42" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes and Loans, Noncurrent", "terseLabel": "Long-term debt with affiliate, net of current portion" } } }, "localname": "LongTermNotesAndLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Long-Term Purchase Commitment [Line Items]", "terseLabel": "Long-term Purchase Commitment" } } }, "localname": "LongTermPurchaseCommitmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.", "label": "Long-Term Purchase Commitment [Table]", "terseLabel": "Long-term Purchase Commitment [Table]" } } }, "localname": "LongTermPurchaseCommitmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r42", "r263" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Present Value Discount Rate", "verboseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility factor" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MortgagesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan.", "label": "Mortgages [Member]", "terseLabel": "Mortgage payable to affiliate" } } }, "localname": "MortgagesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r153", "r161" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r88", "r91" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r54", "r57", "r63", "r66", "r91", "r105", "r116", "r118", "r119", "r120", "r121", "r124", "r125", "r137", "r170", "r174", "r178", "r181", "r184", "r209", "r264", "r265", "r266", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r483", "r496", "r587", "r605" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r118", "r119", "r120", "r121", "r126", "r127", "r138", "r141", "r170", "r174", "r178", "r181", "r184" ], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income (loss)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r128", "r131", "r132", "r133", "r134", "r138", "r141" ], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income available to common stockholders, diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expenses (income)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Note payable to Squadron" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office and other equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r170", "r174", "r178", "r181", "r184" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r509" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r430" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r4", "r112", "r161", "r478" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other assets:" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r470", "r471", "r474" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Adjustment for realized loss on securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r470", "r471", "r474" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r48", "r49" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized loss on short-term investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r55", "r58", "r470", "r471", "r474" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDebtSecuritiesMember": { "auth_ref": [ "r205", "r217", "r344", "r491" ], "lang": { "en-us": { "role": { "documentation": "Investments in debt securities classified as other.", "label": "Other Debt Obligations [Member]", "terseLabel": "Other" } } }, "localname": "OtherDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r39", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other expense (income)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expenses (income):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": { "auth_ref": [ "r136", "r138" ], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic", "terseLabel": "Earning allocated to participation securities, basic" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": { "auth_ref": [ "r138" ], "calculation": { "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.", "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted", "terseLabel": "Earning allocated to participation securities, diluted" } } }, "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r84" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r80" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Pega, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r78" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of MD Ortho, net of cash acquired", "verboseLabel": "Cash paid to acquire" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r79" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of licenses" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r202" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Purchase of short-term marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r343", "r345", "r351", "r352", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r367" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/EMPLOYEEBENEFITPLAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r81" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r82" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of debt with affiliate" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r76", "r77", "r202" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Sale of short-term marketable securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r81", "r408" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r252", "r524", "r593", "r604" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r252", "r629", "r630" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment, Depreciable Lives" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Depreciable lives (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "auth_ref": [ "r20", "r581", "r600" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.", "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Purchase commitment, remaining minimum amount committed" } } }, "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r353", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r353", "r516", "r517", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r353", "r516", "r519", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r514", "r515", "r517", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r83" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Payments on mortgage notes" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r83" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "negatedTerseLabel": "Installment payment for ApiFix" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r83" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedTerseLabel": "Payments on debt with affiliate", "terseLabel": "Payments on note with affiliate" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r415", "r557", "r643" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r12", "r98" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted stock", "verboseLabel": "Restricted Stock Awards" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "verboseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r328", "r524", "r602", "r618", "r620" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r113", "r114", "r115", "r117", "r123", "r125", "r210", "r409", "r410", "r411", "r432", "r433", "r481", "r615", "r617" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r166", "r167", "r173", "r179", "r180", "r186", "r187", "r190", "r337", "r338", "r561" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails", "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r101", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r341" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition - United States and International" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r69", "r267", "r269", "r270", "r274", "r275", "r276", "r624" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Sales to related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock issued and sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Public offering price (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r446", "r447", "r452" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSAssetsacquiredandliabilitiesassumedDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails", "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/BUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r42", "r111", "r306", "r308", "r322", "r325", "r326", "r327", "r505", "r506", "r508", "r595" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r238", "r244", "r562" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSChangesinGoodwillDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAmortizationIntangibleAssetsnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r238", "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r241", "r451" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of characteristics and cost, by total and major class, of indefinite-lived intangible assets acquired as part of a business combination. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. The future benefit is not expected to diminish over a stated period of time. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.", "label": "Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets Acquired as Part of Business Combinations" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r246", "r249" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r70", "r189" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Schedule of Product Sales by Geographic Location" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r64", "r189" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyGeographicalLocationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r170", "r171", "r177", "r234" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r170", "r171", "r177", "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Product Sales by Category" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r368", "r369", "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r375", "r390", "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Awards & Restricted Stock Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r21", "r22", "r23", "r103", "r150", "r151", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r162", "r164", "r165", "r170", "r172", "r178", "r182", "r183", "r184", "r185", "r186", "r189", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "BUSINESS SEGMENT" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSSEGMENTScheduleofRevenuebyCategoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at period end (in shares)", "periodStartLabel": "Outstanding at period start (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted-average remaining contractual terms (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Shares available for award (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited or expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited or expired, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, granted (in shares)", "verboseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at period end (in shares)", "periodStartLabel": "Outstanding at period start (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r376", "r377" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at period end, weighted-average exercise price (in dollars per share)", "periodStartLabel": "Outstanding at period start, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised, weighted-average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vesting Period One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Vesting Period Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r374", "r396", "r397", "r398", "r399", "r402", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Contractual terms (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r33", "r583", "r584", "r597" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Business software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r21", "r22", "r23", "r103", "r105", "r129", "r130", "r135", "r139", "r141", "r150", "r151", "r152", "r209", "r264", "r269", "r270", "r271", "r275", "r276", "r314", "r315", "r318", "r319", "r321", "r496", "r649" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSPegaMedicalandMDOrthopaedicsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r44", "r61", "r62", "r63", "r113", "r114", "r115", "r117", "r123", "r125", "r149", "r210", "r321", "r328", "r409", "r410", "r411", "r432", "r433", "r481", "r498", "r499", "r500", "r501", "r502", "r503", "r513", "r615", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r113", "r114", "r115", "r149", "r561" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of common shares in acquisition" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r22", "r23", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Consideration for MD Ortho and Pega Medical acquisition (in shares)", "verboseLabel": "Stock issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r22", "r23", "r321", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance cost (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Issuance of unregistered shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r22", "r23", "r321", "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r22", "r23", "r321", "r328", "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Stock option exercise (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r44", "r321", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Consideration for MD Ortho acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r22", "r23", "r321", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance cost" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r321", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r44", "r321", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercise" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r23", "r27", "r28", "r105", "r200", "r209", "r496", "r524" ], "calculation": { "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r430" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Instruments" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESAssetsUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r194", "r195", "r196", "r197", "r199", "r201" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "terseLabel": "Trademarks / Names" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/BUSINESSCOMBINATIONSEstimatedfairvalueandusefullifeofidentifiableintangibleassetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks", "verboseLabel": "Trademarks Assets" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSEstimatedFairValueDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.orthopediatrics.com/role/GOODWILLANDINTANGIBLEASSETSTrademarkAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r203", "r204", "r206", "r207", "r208", "r303", "r320", "r480", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r649", "r650", "r651", "r652", "r653", "r654", "r655" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "verboseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r108", "r344", "r359", "r592" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "Treasury Bonds" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSScheduleofAssetsandLiabilitiesMeasuredatFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r154", "r155", "r156", "r157", "r158", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r427" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "negatedTerseLabel": "Reversal of valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/INCOMETAXESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Discounted cash flow, Monte Carlo" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/FAIRVALUEOFFINANCIALINSTRUMENTSFairValueMeasurementsofContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/DEBTANDCREDITARRANGEMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r371", "r372", "r373", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r391", "r392", "r394", "r395", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants and rights outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/SIGNIFICANTACCOUNTINGPOLICIESBasisofPresentationDetails", "http://www.orthopediatrics.com/role/STOCKHOLDERSEQUITYRestrictedStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r128", "r141" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "verboseLabel": "Weighted average shares outstanding for diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding", "verboseLabel": "Denominator for basic and diluted net income (loss) per share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r126", "r141" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares outstanding for basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.orthopediatrics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.orthopediatrics.com/role/NETLOSSPERSHAREReconciliationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2740-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r161": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "https://asc.fasb.org/topic&trid=2122478" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r4": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4922-128472" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "44", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r469": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r504": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r521": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(17))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r644": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r645": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r646": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r647": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r648": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r649": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r650": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r651": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r652": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r653": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r654": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r655": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r656": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r657": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 82 0001425450-22-000107-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001425450-22-000107-xbrl.zip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e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ý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�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end